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Summary 
The correct function of the immune system is based on its ability to distinguish self-
antigens from those that are part of pathogens. For this reason, redundant mechanisms have 
evolved to avoid an inflammatory response against antigens of the own organism. When these 
mechanisms fail, autoimmunity occurs. 
In recent years, the interaction of the leukocyte receptor PSGL-1 with its ligand in 
endothelial cells, P-selectin, has been shown to be necessary for the maintenance of peripheral 
tolerance and immune system homeostasis. 
In the present thesis, it is detailed how female PSGL-1 deficient mice are prone to develop 
pulmonary arterial hypertension as a part of an autoimmune syndrome similar to scleroderma. 
Using the reduction of blood flow acceleration time in the pulmonary artery as a marker of 
pulmonary hypertension, we described that PSGL-1-deficient females progressively increase 
their pulmonary pressure, reaching significant differences at 15 months of age. With aging, and 
associated with an increase in Th1 response, there is an increase in the pulmonary 
concentration of angiotensin II together with a decrease in the vasodilator receptor AT2R, 
observed from the young age. In this context, isolated arteries of PSGL-1-deficient female mice 
exhibited a higher KCL-dependent vasoconstriction, and a lower nitric oxide-dependent 
vasodilator response. Accordingly, lung endothelial cells from PSGL-1 deficient females 
exhibited reduced amounts of nitric oxide. Importantly, we have found that P-selectin deficient 
female mice also develop PAH with ageing. 
This thesis also describes that P-selectin deficiency leads to the appearance of an 
autoimmune syndrome similar to human systemic lupus erythematosus in mice. This syndrome 
is characterized by the presence of circulating autoantibodies, including anti-double-stranded 
DNA antibodies, and the deposition of immune complexes in skin and glomeruli. P-selectin 
deficient mice present a reduced naïve T cell population and elevated effector subsets with 
reduced IL-10 producing leukocytes. Mice deficient in P-selectin exhibit dermatitis and lupus 
nephritis, which become more severe with aging, coinciding with the increase in the circulating 
and dermal Th17 populations. Lupus dermatitis developed by P-selectin deficient mice is 
characterized by an increase in plasmacytoid dendritic cells, T lymphocytes, and by an 
alteration in the balance between effector and regulatory T lymphocytes. Finally, the study of 
skin biopsies of patients with cutaneous lupus erythematosus and healthy controls revealed that 
P-selectin expression was reduced in the skin vessels of cutaneous lupus patients. 
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Resumen 
El correcto funcionamiento del sistema inmune se basa en su capacidad para distinguir los 
antígenos propios de aquellos que forman parte de patógenos. Para ello, ha desarrollado 
mecanismos redundantes que evitan una respuesta inflamatoria frente a antígenos propios. 
Cuando estos mecanismos fallan se produce autoinmunidad. En los últimos años, en nuestro 
laboratorio se ha puesto de manifiesto que la interacción del receptor leucocitario PSGL-1 con 
su ligando en células endoteliales, P-selectina, es necesaria para el mantenimiento de la 
tolerancia periférica y la homeostasis del sistema inmune.  
En esta tesis, se detalla cómo los ratones hembra deficientes en PSGL-1 son proclives a 
desarrollar hipertensión arterial pulmonar como una parte del síndrome autoinmune similar a la 
esclerodermia. Utilizando como marcador de hipertensión pulmonar la reducción del tiempo de 
aceleración del flujo sanguíneo en la arteria pulmonar, describimos que las hembras deficientes 
en PSGL-1 aumentan progresivamente su presión pulmonar, alcanzando diferencias 
significativas a los 15 meses de edad. Asociado a un incremento de la respuesta Th1, se 
produce un aumento en la concentración pulmonar de angiotensina II y una disminución del 
receptor vasodilatador AT2R. En este contexto, las arterias aisladas de ratones hembra 
deficientes en PSGL-1 presentan una mayor vasoconstricción dependiente de KCL, y una 
menor respuesta vasodilatadora dependiente de óxido nítrico. En concordancia, las células 
endoteliales de pulmón de hembras deficientes en PSGL-1 presentan una cantidad reducida de 
óxido nítrico. De la misma manera, los ratones hembra deficientes en P-selectina desarrollan 
hipertensión arterial pulmonar con el envejecimiento. 
La deficiencia en P-selectina provoca la aparición en ratones de un síndrome autoinmune 
similar al lupus eritematoso humano, caracterizado por la presencia de autoanticuerpos 
circulantes, incluidos los anticuerpos anti-ADN de doble cadena, y por los depósitos de 
inmunocomplejos en la piel y los glomérulos. Los ratones deficientes en P-selectina presentan 
menos linfocitos T naïve, más T efectores y una reducción en las poblaciones de leucocitos 
productores de IL-10. Los ratones deficientes en P-selectina presentan dermatitis y nefritis 
lúpica, que se vuelven más severas con el envejecimiento. La dermatitis lúpica de los ratones 
deficientes en P-selectina se caracteriza por un aumento de las células dendríticas 
plasmacitoides, los linfocitos T, y por una alteración del balance entre linfocitos T efectores y 
reguladores. Por último, el estudio de biopsias de piel de pacientes con lupus eritematoso 
cutáneo y controles sanos reveló que la expresión de P-selectina estaba reducida en los vasos de 
la piel de los pacientes de lupus cutáneo. 
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Introduction 
 
1. PSGL-1 and P-selectin 
1.1 Chromosomic location, structure and expression of PSGL-1 
Selplg is the gene coding for P-Selectin Glycoprotein ligand-1 (PSGL-1). It is located at 
chromosome 12 in humans, and at chromosome 5 in mice. The human and mice genes  have the same 
structure, with two exons and the coding region corresponding to the second one (1, 2). Mice and human 
PSGL-1 proteins also have high degree of homology both in structure and aminoacid sequence (2). 
PSGL-1 is a type I transmembrane protein of 120 kDa that dimerizes through a disulfide bridge. 
The core protein is formed by an extended mucin ectodomain composed of serine, threonine, and 
proline-rich decameric repeats (3, 4)  bearing sites for potential O-glycan modification (14-16 repeats in 
humans and 15 in mice) (2, 5) (Figure I1). Several post-translational modifications are needed for the 
correct recognition by P-selectin (P-sel), E-selectin (E-sel) and L-selectin (L-sel), such as O- and N-
glycosylations, sialylation, fucosylation or tyrosyl sulfation. (6, 7). The region participating in selectin 
recognition is disialylated and monofucosylated with a terminal sialyl Lewis X (sLe
X
; 
NeuAcα2,3Galβ1,4[Fucα1,3]GlcNAcβ1-R) (8, 9) (Figure I1). Sulfation of tyrosine residues near the N-
terminus is necessary to produce high-affinity P-sel/PSGL-1 interaction (10). However, PSGL-1 
recognition by E-sel is tyrosine sulfation-independent but requires O-glycan modifications in decameric 
repeats proximal to membrane (11). The aminoacid sequences of human and mouse PSGL-1 
cytoplasmic domains are highly conserved, and have been implicated in PSGL-1 intracellular signaling 
(12) and re-distribution to the uropod in activated cells (13). 
PSGL-1 is expressed in all leukocyte lineages and also in platelets (4). PSGL-1 is also expressed on 
certain endothelial cells, such as mesenteric lymph node venules in the context of an ileitis murine 
model (14), human umbilical vein endothelial cells (HUVEC),  foreskin microvascular cells and in 
atherosclerotic coronary arteries (15). 
The expression of PSGL-1 can be modulated by different stimuli. Activation of monocyte-derived 
dendritic cells (moDCs) and langerhans cells raises the expression levels of PSGL-1 (16) and activation 
of platelets with thrombin also leads to an increase in surface PSGL-1 (17). One mechanism for altering 
PSGL-1 expression and function includes proteolytic processing of PSGL-1 extracellular domains. 
Several proteases have been reported to act as PSGL-1 sheddases (4), such as the snake venom 
metalloproteases Mocarhagin and Triflamp, or endogenous enzymes such as cathepsin G, neutrophil 
elastase, β secretase BACE1, and members of the α-disintegrin-and-metalloprotease (ADAM) family of 
metalloproteases.  Indeed, ADAM8 can cleave PSGL-1 in vitro with the subsequent impairment of 
THP1 cell rolling over HUVEC monolayers (18). In fact, apoptosis, in vitro activation with phorbol 
myristate acetate or in vivo treatment with lipopolisaccharide (LPS), granulocyte-colony stimulating 
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factor (G-CSF) or granulocyte monocyte-colony stimulating factor (GM-CSF) leads to reduced PSGL-1 
expression in neutrophils and increased levels of extracellular soluble PSGL-1 (19-21). In addition to 
protease cleavage, the expression of glycosyltransferases that regulate the addition of carbohydrate 
groups rises as the dominant way of regulating PSGL-1 function. Glycosyltransferases relevant for 
modification of P-sel binding are constitutively expressed in neutrophils and monocytes (22). 
Megakaryocytes also appear to express a full contingent of glycosyltransferases,  and as a result 
platelets express functional PSGL-1 (17, 23). However, naïve T cells are not able to bind to P- and E-sel 
even though PSGL-1 is expressed on their surface because α1,3fucosyltransferases IV and VII (FucT-IV 
and FucT-VII) are upregulated upon activation (24, 25). Likewise, Th1 but not Th2 cells are able to bind 
P- and E-sel (25, 26). 
1.2 Chromosomic location, structure and expression of P-selectin  
The gene coding for P-selectin (Selp) is located at chromosome 1 in both humans and mice (27). In 
humans, the gene spans over >50 kb, including 17 exons (16 coding exons), and is translated into a 140 
kDa protein (830aa) (27-29). In mice, 15 out 16 exons code for the P-sel protein, resulting in a transcript 
of 3,438 bp that can be translated into a 768 aa polypeptide (30, 31).   
Selectins (P-, E- and L-selectin) are type I transmembrane proteins that mediate adhesion of 
leukocytes and platelets to endothelial cells and to each other. The extracellular rod of selectins contains 
a N-terminal C-type lectin domain, an epidermal growth factor-like domain and a series of consensus 
repeats (CR) that is different among the three selectins, with 9, 2 and 6 repeats for P-, E- and L-sel, 
respectively  (3, 32) (Figure I1). The lectin domain contains a Ca
2+
-binding site, which is critical for the 
interaction with the fucose moiety of sLe
X
 (33, 34). The lectin domains of the three selectins share about 
60% homology, with subtle differences in carbohydrate binding and that conferr selectin specificity 
(24).  
L-sel (CD62L) is constitutively expressed on all leukocyte populations, mediating homing to 
secondary lymphoid organs and leukocyte-leukocyte interactions. PSGL-1 modifications needed for the 
interaction with L- and P-sel are the same (3, 4). E-sel (CD62E) is expressed on endothelial cells. Its 
expression is regulated at transcriptional level by inflammatory mediators, and is constitutively 
expressed in adult skin and bone marrow (35). 
P-sel (CD62P) is stored in α-granules of platelets and in Weibel–Palade bodies of endothelial cells, 
and is translocated to the cell surface of endothelial cells and platelets upon activation (3, 32) by 
different mediators such as thrombin, histamine, or complement (36). Tumor necrosis factor alpha 
(TNF-α), interleukin 1 beta (IL-1β), or LPS increase transcription of P-sel mRNA in most mammals, 
including mice, but not in primates, including humans (37, 38). In addition, constitutive expression of P-
sel has been reported on lung and choroids plexus microvessel endothelium, and on peritoneal 
macrophages (32, 39). 
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1.3. PSGL-1/P-selectin signaling and adhesion  
The interaction of PSGL-1 with its ligands is relevant for multiple physiologic and 
physiopathologic processes. Binding under flow of PSGL-1 on circulating leukocytes to P- and E-sel on 
the vessel wall mediates inflammatory and surveillance functions of the immune system. During 
immune surveillance, lymphoid cells continuously recirculate between blood and lymphoid organs to 
search for their cognate antigens. Although the role of L-sel mediating homing to secondary lymphoid 
organs is well established (40, 41), PSGL-1 participates in the homing of leukocytes to both lymphoid 
and non-lymphoid tissues such lymph nodes (42), colonic lamina propria (43), lung (44) or bone 
marrow (35). The homing of early T lymphocyte progenitors to thymus is also mediated by PSGL-1/P-
sel interaction (45).  
 
 
 
 
 
 
Leukocyte extravasation starts with the tethering and rolling of leukocytes on activated 
endothelium. As the longest protein of the selectin family, P-sel transiently binds to PSGL-1 on the 
Figure I1. Structure of the human PSGL-1 homodimer and P-selectin. (A) PSGL-1: N-terminal 
tyrosine sulfates (purple) are followed by a long, extended glycoprotein backbone (light green) with many 
O-linked carbohydrates (dark green) and some N-linked carbohydrates (yellow). A stabilizing disulfide 
bond (S–S) (orange line) is located near the plasma membrane, and the transmembrane domain (red) and the 
short cytoplasmic tail are also shown. (B) P-selectin binding site. Tyrosine sulfates (purple) and the crucial 
O-glycan at T57 (dark green) are represented. Typical carbohydrate side-chains are shown, with the 
responsible enzymes indicated next to the respective linkage. The sLe
x
 (minimal selectin recognition) motif 
is highlighted by a red box. (C) P-selectin: the cytoplasmic and transmembrane domain is represented in 
black. The 9 consensus repeats (CR) ar represented as purple ovals. The EGF-like domain is represented in 
blue. The lectin domain, which binds PSGL-1, is highlighted in pink. Adapted from Trends Mol Med. 2003; 
9 (6): 263-8. 
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surface of leukocytes, establishing the initial contacts with endothelial cells. This transient interaction 
slows down leukocytes, resulting in a rolling movement on the vessel wall (40), that is essential for the 
subsequent firm adhesion (Figure I2). PSGL-1/P-sel interaction mediates the capture and fast rolling 
(20– 40 μm/s) of leukocytes on the endothelium whereas E-sel mediates leukocyte slow rolling (3–7 
μm/s) (46). During the rolling process, engagement of PSGL-1 by selectins activates β1 (47, 48) and β2 
(49-51) leukocyte integrins whose affinity for their vascular ligands aids in 
inducing leukocyte adhesion under flow (52). Integrin activation by E-sel is mediated by the adaptor 
protein ADAP12 and Fcγ receptors, Src kinases and Spleen tyrosine kinase (Syk) that phosphorylate the 
Bruton tyrosine kinase (BTK) followed by an activation of Phospholipase Cγ2 (PLCγ2)- or 
Phosphatidylinositol-4,5-bisphosphate 3-Kinase (PI3K)-dependent pathways (36, 40, 53). 
 
 
 
In addition, Syk phosphorylation induced by PSGL-1 interaction with P-sel is required for optimal 
rolling on P-sel (54)  as well as for E-sel-dependent slow rolling of neutrophils and for integrin 
activation and leukocyte adhesion (55).  
1.4 PSGL-1/P-selectin interaction in immune system homeostasis and tolerance 
As described above, PSGL-1 engagement activates Syk, triggering an intracellular signaling 
cascade that permits leukocyte rolling and activation of integrins. In addition, the interaction of PSGL-1 
with the three selectins induces its association with Syk through the actin-linking proteins of the ezrin-
radixin-moesin (ERM) family, in an ITAM-dependent manner that leads to the activation of the 
transcription factor cFos, implicated in the gene expression of different interleukins and cytokines, 
including IL-10 or  transforming growth factor beta (TGF-β) (12, 16). In this sense, the intracellular 
signals elicited by PSGL-1/P-sel interaction trigger a tolerogenic program in human moDCs 
characterized by the upregulation of IL-10, IDO and TGF-β, and the downregulation of MHC-II and 
costimulatory molecules such as CD86 and CD40 (16). These tolerogenic DCs promote naïve T cell 
Figure I2. The multistep cascade of leukocyte extravasation. A range of cell adhesion receptors on 
endothelial cells (green squares) mediates the capture, rolling, arrest and crawling of leukocytes on the 
luminal endothelial cell surface, prior to the transmigration through the endothelial barrier. Adapted from 
Nat Rev Immunol. 2015; 15: 692-704.  
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differentiation to regulatory T cells (Tregs) in human allogeneic moDC/T cell recognition assays (16). 
Accordingly, it was demonstrated that mice lacking PSGL-1 have a 33% reduction of the natural Treg 
population in the thymus (16). A consequence of Treg reduction in PSGL-1 deficient mice would be the 
disease exacerbation found in these mice under different experimental mouse models of inflammatory 
disease such as dextrane sodium sulfate (DSS)-induced colitis, scleroderma or lupus-prone Mrl/lpr 
mouse model (43, 56, 57). More importantly, an autoimmune syndrome which shares multiple 
characteristics with human systemic sclerosis (SSc) progressively develops in the total absence of 
PSGL-1(58). Likewise, P-sel absence has also been related to increased inflammation in mice (56, 59), 
resulting in more severe gromerulonephritis, what could be explained by the lack of tolerance signals 
elicited by PSGL-1 in leukocytes. PSGL-1 controls proliferation of human hematopoietic progenitors 
(60, 61) as well as T cell proliferation and exhaustion (39). As a consequence, T cells isolated from 
PSGL-1
 
deficient mice show enhanced adhesion and increased proliferation rates and are more effective 
in clearing viral infections, due to reduced exhaustion of CD8
+
 T lymphocytes in a CD4
+
 T lymphocyte-
dependent manner (62, 63). 
1.5 Other ligands of PSGL-1 and P-selectin 
PSGL-1 binds to several chemokines such as CCL19, CCL21 and CCL27, suggesting that PSGL-1 
could also regulate chemokine-mediated responses (4, 42, 64). CCL27, a selective chemoattractant for 
memory T cells to cutaneous sites requires PSGL-1 aminoterminal tyrosine sulfation but not O-
glycosilation or N-Glycosilation. (64). CCL19 and CCL21 are constitutively expressed in lymph nodes 
and their interaction with PSGL-1 contributes to naïve and memory T cells homing to these organs. As 
in the case of CCL27, O-glycosylation is not necessary for CCL21 binding, but it is not clear whether 
tyrosine sulfation is required, although  the existence of a common binding site for CCL19 shared by 
PSGL-1 and CCR7 was identified (65).  The capability of PSGL-1 to interact with these chemokines has 
been proposed to synergize with CCR7 signaling in the homing of naïve T lymphocytes to secondary 
lymphoid organs , provided that activated T cells are less efficient in binding CCL21 and CCL27 (42). 
PSGL-1 can also bind to pathogens. PSGL-1 can bind to human enterovirus 71 (66) and it has been 
described that aminoterminal tyrosine sulfation is necessary for viral infection (67). Moreover, PSGL-1 
binds to pneumococcal capsular polysaccharide and amidase LytA, playing a critical role in the 
recognition, uptake and killing of Streptococcus pneumoniae by neutrophils (68). Staphylococcus 
aureus has been proposed to bind PSGL-1, since recombinant SSL5 and SSL11 bind sLe
X
 moieties of 
PSGL-1 on leukocytes and, when assayed in vitro, interfere with the binding of neutrophils to P-sel and 
neutrophil adhesion and rolling (69, 70).  
Finally, it has been recently described that soluble Siglec-5, a member of the sialic acid-binding 
immunoglobulin-like lectin family, is able to bind to PSGL-1 in a Ca
2+
 dependent manner, and can 
interfere with the rolling of leukocytes on P-sel in vitro and preventing the recruitment of leukocytes to 
sites of inflammation in vivo (71). 
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Regarding P-sel, in addition to PSGL-1, CD24 and Pentraxin-3 (PTX-3) have been found to bind P-
sel (72, 73). 
2. Pulmonary Arterial Hypertension 
2.1 Defintion, epidemiology and symptoms 
Pulmonary arterial hypertension (PAH) is a rare, progressive and severe disease affecting 
pulmonary vasculature and heart. The prevalence in the population is around 1.1-2.4 cases per 1 million 
inhabitants per year (74-76),  being women more frequently affected by PAH (2:1) (75, 76). PAH is 
internationally defined by right-heart catheterization showing precapillary pulmonary hypertension with 
a mean pulmonary artery pressure (mPAP) of >25 mmHg (77).  
Persistent dyspnea on exertion is present in almost all patients even in the presence of mild 
hemodynamic abnormalities (77, 78), constituting the most frequent symptom of PAH.  Fatigue, 
weakness and worsening dyspnea are associated with disease progression. In the most severe form of 
PAH, chest pain, syncope, jugular vein extension, and edema are considered signs of right heart failure 
(77, 78). 
2.2 Classification of Pulmonary Hypertension (PH) 
In the 2
nd
 World Symposium on PH, held in 1998, a clinical classification was established with the 
objective of individualizing different categories of PH sharing similar pathological findings, similar 
hemodynamic characteristics and, similar management (79). This classification is currently used by the 
United States FDA (Food and Drug Administration) and the European Agency for Drug Evaluation for 
the labeling of new drugs approved for PH (Table I1). 
Group 1 (PAH) agglutinates different forms of precapillary PH with diverse etiologies. First, 
idiopathic PAH (iPAH) is defined as sporadic disease with neither a family history of PAH nor an 
identified risk factor (77). Heritable PAH includes all the cases with an identified genetic origin that are 
associated with a familial history. In Group 1 are also classified PAH variants induced by drug and 
toxins, as well as PAH cases associated with other syndromes and diseases, such as infectious agents, 
congenital heart disease and connective tissue diseases. 
Groups 2 and 3 comprise postcapillary PH caused by left heart or lung diseases, respectively. Group 
4 includes chronic thromboembolic pulmonary hypertension, whereas Group 5 agglutinates other forms 
of PH with multifactorial mechanisms that are not yet completely understood. 
2.3 Pathophysiology 
PAH is characterized by distal pulmonary vascular remodeling resulting from endothelial 
dysfunction, uncontrolled vascular smooth muscle and endothelial cell proliferation, and inflammation 
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that promotes hypertrophy of pulmonary arteries and luminal obliteration (80) (Figure I3). To 
reestablish functional blood flow, plexiform structures consisting of microvessels are formed in the 
lumen of obliterated lung vessels. These pathologic events increase pulmonary vascular resistance and 
augment pulmonary artery pressure leading to an increment in the hemodynamic load on the right 
ventricle (RV). To compensate, the RV adapts with an increment in its wall thickness and contractility 
(81). When the RV is no longer able to adapt its function to the increasing load, death ensues from right 
heart failure. 
1. Pulmonary arterial hypertension (PAH) 1.1 Idiopathic PAH  
1.2 Heritable PAH 
      1.2.1 BMPR2 
      1.2.2 ALK-1, ENG, SMAD9, CAV1,  KCNK3  
      1.2.3 Unknown  
1.3 Drug and toxin induced  
1.4 Associated with:  
      1.4.1 Connective tissue disease  
      1.4.2 HIV infection  
      1.4.3 Portal hypertension 
      1.4.4 Congenital heart diseases  
      1.4.5 Schistosomiasis 
1’. Pulmonary veno-occlusive disease and/or pulmonary capillary hemangiomatosis  
1’’. Persistent pulmonary hypertension of the newborn (PPHN) 
2. Pulmonary hypertension due to left heart disease  
3. Pulmonary hypertension due to lung diseases and/or hypoxia  
4. Chronic thromboembolic pulmonary hypertension (CTEPH)  
5. Pulmonary hypertension with unclear 
multifactorial mechanisms 
5.1 Hematologic disorders 
5.2 Systemic disorders: sarcoidosis, pulmonary 
histiocytosis  
5.3 Metabolic disorders  
5.4 Others: tumoral obstruction, fibrosing 
mediastinitis, chronic renal failure, segmental PH 
 
 
2.4 Etiopathogenesis of PAH 
a. Genetic factors 
 Germline mutations in the bone morphogenetic protein receptor 2 (BMPR2) gene, a member of the 
TGF-β signaling family, can be detected in up to 70% of patients with heritable PAH (82-85). 
Moreover, mutations in BMPR2 have also been found in 5-40% of patients previously diagnosed of 
Table I1. Pulmonary hypertension classification.  Summarised PH classification according to the 
2
nd
 World Symposium on pulmonary hypertension (1998). 
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Figure I.3. The pathophysiology of 
PAH. Cellular changes in PAH. Healthy 
endothelium regulates the vascular tone 
to maintain a low-resistance pulmonary 
vasculature. 1) In PAH, dysfunctional 
endothelium alters 
vasodilator/vasoconstrictor balance to 
increase contractility of pulmonary 
arteries. 2) Abnormal proliferation of 
smooth muscle cells leads to 
muscularization of peripheral 
pulmonary arteries and medial 
hypertrophy. Increased proliferation and 
progressive migration of smooth muscle 
cells further results in intimal fibrosis. 
3)  Formation of plexiform lesions and 
in situ thrombus occlude the vessel 
lumen. These dysregulated events lead 
to progressive reduction of the blood 
flow, thus causing PAH. ET-1 indicates 
endothelin-1; NO, nitric oxide; PGI2, 
prostacyclin; and TXA2, thromboxane 
A2. Adapted from Circulation 
Research. 2014; 115: 115-130 and the 
National Center for Chronic Disease 
Prevention and Health Promotion.  
iPAH (82, 86, 87). However, only 20% of family members carrying BMPR2 mutations develop PAH, 
indicating low levels of penetrance of heritable PAH (75, 88).   
Apart from BMPR2, mutations in other members of the TGF-β signaling pathway have been 
associated with the development of PAH. Thus, several studies have demonstrated allele variants of 
ACVRL1 (89), ENG (90), Smad1, Smad4, Smad5, Smad8, Smad9 (91, 92) and CAV-1(93) in patients 
with idiopathic or heritable PAH.  
 
b. Drugs and toxins 
Exposure to certain drugs or substances has explained several cases of primary PAH. Aminorex and 
fenfluramine are anorexigen drugs that promote the release of catecholamines, and both drugs were 
withdrawn from markets by FDA because of their association with PAH in 1968 (94) and 1997 (95), 
respectively. Ingestion of toxic rapeseed oil, as the colza oil commercialized in 1981 in Spain, also 
triggered the development of an aggressive PAH (96).  To a lesser extent, benfluorex (95), 
amphetamines, metamphetamine (97) and the tyrosine kinase inhibitor dasatinib used for the treatment 
of chronic myelogenous leukaemia (98) have been associated with PAH.  
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c. Cellular and molecular factors 
A number of molecular mechanisms have been shown to play a role in the control of pulmonary 
pressure and to be deregulated in PAH patients. 
Nitric oxide (NO) 
NO is a lipophilic gas generated by three different isoforms of nitric oxide synthases (NOS): 
neuronal (nNOS), inducible (iNOS) and endothelial NOS (eNOS). NOS catalyzes the reaction of L-
arginine, NADPH and oxygen which requires iron protoporphyrin IX (haem), tetrahydrobiopterin, FAD, 
and FMN as cofactors (99) (100): 
L-arginine + 2O2 + 3/2(NADPH + H
+
 )  NO + L-citrulline + 3/2NADP+ + 2H2O 
NO released by endothelial cells binds its G-protein coupled receptors on the surface of vascular 
smooth muscle cells (VSMC), activating the cyclic guanosin monophosphate (cGMP) signaling 
pathway which leads to the increase in intracellular Ca
2+
 levels, Akt phosphorylation and calcineurin 
activation.  In this context, NO is probably the most important endothelium-derived vasodilator, and a 
key regulator of vascular tone (101). NO also inhibits leukocyte adhesion (102, 103) and platelet 
aggregation (104), as well as VSMC proliferation and migration (105-108). 
In fact, decreased pulmonary vascular eNOS expression/activity has been described in numerous 
animal models of PH in vivo and in humans with this disease (109). Pulmonary artery endothelial cells 
from patients with iPAH produce decreased amounts of NO (110) and lungs from patients with PAH 
have been reported to express reduced levels of eNOS (111). In addition, eNOS knockout mice showed 
enhanced leukocyte adhesion to vascular endothelium associated with increased expression of P-sel 
(112), and showed increased RV systolic pressure when exposed to hypoxia (113). Moreover, reduced 
NO bioavailability has been linked to impaired endothelium-dependent vasodilation and VSMC 
proliferation (114). In PAH, the reduced NO bioavailability may be explained by eNOS uncoupling, low 
L-arginine intracellular concentration, increased reactive oxygen species levels or endogenous 
competitive inhibitors of eNOS (such as asymmetric dimethylarginine) (115). 
Phosphodiesterase-5 (PDE-5) inhibitors enhance the antiproliferative and vasodilating effects of 
endogenous NO by preventing cGMP inactivation by PDE-5 (115, 116). 
Prostacyclin (PGI2) 
PGI2 is an araquidonic acid metabolite vasodilator that is produced by endothelial cells and acts via 
the cyclic adenosine monophosphate (cAMP) pathway (117).  
The expression of the key enzyme for PGI2 synthesis, PGI2 synthase, is reduced in pulmonary 
arteries of patients with PAH, hepato-pulmonary PH, and human immunodeficiency virus (HIV)-
associated PH (118). Moreover, production of prostacyclin is reduced in endothelial cells of patients 
with PAH (119). Furthermore, administration of prostacylcin or its analogs in experimental PH models 
leads to decreased PAP and RV pressure (120, 121).  
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Serotonin (5-HT) 
Serotonin has been described as an important mediator of PAH, inducing vasoconstriction and 
VSMC proliferation (122, 123). Indeed, treatment of rats or BMPR2
-/-
 mice with serotonin potentiates 
the effects of hypoxia on mPAP, RV hypertrophy and pulmonary vascular remodeling (122, 124). On 
the other hand, mice lacking the 5-HT transporter, where platelets (the main reservoir of systemic 5-HT) 
are depleted of 5-HT, the development pulmonary vascular remodeling in response to chronic hypoxia 
is reduced (125). 
Endothelin-1 (ET-1) 
ET-1 is a 21 aa peptide that is produced by cleavage of a larger precursor in endothelial cells, and in 
smaller amounts in  pulmonary artery smooth muscle cells (PASMC) (126) and lung fibroblasts (127). 
ET-1 biosynthesis is induced by different stimuli, including hypoxia, growth factors, cytokines, shear 
stress, and thrombin in endothelial cells (128-131). ET-1 binds to two different seven-transmembrane G 
protein-coupled receptors: endothelin receptor type A (ETA) and type B (ETB) (132, 133). Activation 
of ETA and/or ETB on vascular smooth muscle cells (134) and fibroblasts (127) mediates 
vasoconstriction and proliferation (135, 136). On the other hand, activation of ETB receptors on 
endothelial cells enhances the clearance of circulating ET-1 (up to 80% of circulating ET-1 in lung 
circulation) (137) and increases their production of PGI2 and NO (132, 138). 
Elevated concentrations of ET-1 in the lung and plasma of human patients and experimental animal 
models of PAH have been described (135, 139, 140). Both selective and non selective ET receptor 
antagonists (ERAs) can prevent or attenuate experimental PAH by increasing vasodilation and 
preventing vascular and right heart hypertrophy (141, 142). In fact, bosentan (a non selective ERA that 
antagonizes ET-1 binding to both ETA and ETB, blocking irreversibly their activity (143)) was 
approved by the FDA in 2001 for the treatment of PAH.  Selective ETA receptors antagonists, like 
ambrisentan (144), have been developed because of their potential benefits based on the preservation of 
the vasodilator and clearance functions specific to ETB receptors, and the prevention of vasoconstriction 
and cellular proliferation mediated by ETA receptors (144, 145). 
Immune system and autoimmunity 
There is increasing evidence for the important role of the immune system in the pathogenesis of 
PAH. For example, circulating levels of several cytokines and chemokines (such as IL-6, IL-1β, TNF-α 
and MCP-1) are elevated in patients with iPAH and may be associated with a worse clinical outcome 
(146-148). 
In addition, pathogen infections such as schistosomiasis (149), Human Herpes Virus 8 (HHV-8) 
(150), and HIV (151) have also been associated with higher prevalence of PAH.   
 Systemic sclerosis (SSc) represents the major cause of connective tissue disease (CTD)-associated  
PAH (77). The prevalence of PAH among SSc patients has been estimated in several studies, ranging 
from 2% (152) to more than 25% (153), although the majority of reports established a prevalence of 5-
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15% (78, 154-156). With the improvement of renal care, PAH has emerged as the major cause of 
mortality of SSc patients (77, 157, 158). Interestingly, autoantibodies against  the angiotensin II receptor 
1 (AT1R) and ETA have been found in patients with SSc-PAH and CTD-associated PAH (159), that 
could account for the increased activation of these pathways in PAH. 
The renin-angiotensin-aldosterone system (RAAS) and PAH 
The RAAS plays a pivotal role in maintaining an adequate blood pressure, by regulating sodium 
and water balance in the kidney, and by increasing systemic vascular resistance on peripheral blood 
vessels (160).  
In the canonic pathway, when blood pressure falls, due to blood loss, dehydration or ventricular 
pump failure, the juxtaglomerular cells, located next to the afferent arterioles of the renal glomeruli, 
release renin into the bloodstream. Renin cleaves angiotensinogen, which is secreted by the liver, to 
angiotensin I (AngI). Once in the circulation, AngI is hydrolyzed to angiotensin II (AngII) by 
angiotensin converting enzyme (ACE), which is located primarily in the pulmonary and renal 
endothelium (160) (Figure I4). AngII activates AT1R on endothelial and VSMC to initiate a 
vasoconstrictor response and stimulate aldosterone synthesis by the adrenal gland (160). In contrast, 
angiotensin type 2 receptor (AT2R) mediates vasodilation, reduced proliferation, apoptosis and 
decreased inflammation (161). Aldosterone then binds to its receptors on the renal tubules to initiate 
sodium and water retention to increase circulating blood volume and, then recovering blood pressure 
(162). 
In addition to the canonical pathway, other vasoactive peptides, receptors and enzymes have been 
identified to play a role in the physiological functions of the RAAS. Angiotensinogen and 
angiotensin(1-12) can be cleaved into AngII by some peptidases such as chymase, that is expressed in 
mast cells, skeletal muscle and endothelial cells (163-166). ACE2, a homologue of ACE, catalyzes the 
conversion of AngI and AngII to Ang(1-7), an heptapeptide that binds to the Mas receptor and 
counteracts the vasoconstrictor effects of AngII, without stimulating aldosterone secretion (167).  
There is clear evidence that the renin-angiotensin signaling system contributes to the disease 
pathology. In patients with iPAH, increased levels of renin, AngI, and AngII were observed in 
association with disease progression and mortality (168). Moreover, ACE expression and activity and 
increased AT1R signaling have been reported to be elevated in the lung arteries of rats exposed to 
hypoxia (169, 170) and patients lung tissue (168, 171).  
Treatment with ACE inhibitors (enalapril or captopril) or an AT1R antagonist (losartan) delayed 
disease progression, reduced pulmonary artery pressure, RV hypertrophy and pulmonary vascular 
remodeling in rats with monocrotaline-induced PAH (168, 169, 172, 173). On the other hand, 
overexpression or external activation of ACE2 in a monocrotaline (MCT) mouse model was able to 
prevent the increase in RV pressure and remodeling, as well as pulmonary vessel muscularization (174, 
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175) and MCT-induced inflammation (176), in an ang(1-7)-Mas receptor interaction-dependent manner 
(175).  
 
Angiotensin II and inflammation 
AngII has also been described as a pro-inflammatory molecule by regulating the expression of 
cytokines such as IL-12 or TNF-α in monocytes and macrophages as well as the production of NO 
through the activation of AT1R (177). AngII also promotes the expression of endothelial adhesion 
molecules such as E-sel, P-sel, Vascular cell  adhesion molecule 1 (VCAM-1) and Intercellular adhesion 
molecule 1 (ICAM-1), facilitating leukocyte rolling and extravasation, increasing inflammation (178). 
In addition, in inflammatory conditions, local macrophage chemoattractant protein-1 (MCP-1) augments 
AngII synthesis (179). 
 
 
 
 
 
 
 
 
 
 
 
3. Systemic lupus erythematosus (SLE) 
 
3.1 Definition, epidemiology, symptoms and treatment 
Systemic lupus erythematosus (SLE) is a chronic, inflammatory autoimmune disease characterized 
by the production of autoantibodies against double stranded DNA (dsDNA) and nuclear antigens, 
immune complex deposition, complement activation and polyclonal expansion of auto-reactive 
lymphocytes (180-183).  
 
Figure I4. The renin angiotensin system. 
Angiotensin II may be generated from 
angiotensin I by the actions of angiotensin-
converting enzyme (ACE) or chymase. 
Angiotensin I may also be cleaved by 
angiotensin-converting enzyme 2 (ACE2) 
to yield angiotensin-(1–7). Angiotensin II 
binds to the angiotensin type 1 receptor 
(AT1R) and the angiotensin type 2 receptor 
(AT2R), which have opposing effects on 
vascular structure and function. 
Angiotensin-(1–7), which binds to the Mas 
receptor, is considered vasculoprotective. 
Adapted from Pulm Circ. 2014; 4 (2): 200-
10. 
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Interestingly, the incidence of lupus has nearly tripled in the last 40 years, mainly due to improved 
diagnosis of mild disease (183). The prevalence of lupus ranges from approximately 40 cases per 
100,000 persons among Northern Europeans (181) to 73 cases per 100,000 persons in the USA (184). 
Higher prevalence has been found among black and Asian (185, 186) population in both USA (2.3-fold 
higher in black persons than in white persons) (184) and Europe (206 per 100,000 persons) (186, 187).   
Apart from race, SLE is a strongly gender-biased disease. SLE predominantly affects women (6-10:1 
ratio of women to men) in the childbearing years (181, 182, 184, 188, 189).  
In the last 50-60 years, the life expectancy of SLE patients has improved from an approximate 4-
year survival rate of 50% in the 1950s to a 15-year survival rate of 80% today (181), even though since 
1959, only one agent (belimumab) has been approved by the FDA for use in SLE (189). 
Criteria for SLE classification were developed in 1971 (190), and revised in 1982 (191) and 1997 
(192). Further revision was accomplished by the Systemic Lupus International Collaborating Clinics 
(SLICC) in 2012 (193) (Table I.2). These criteria distinguish patients with the disease in question from 
those without the disease. The American College of Rheumatology (ACR) classification criteria were 
developed for clinical studies of lupus to ensure that cases reported in the literature do in fact have the 
disease. In addition to the wide variety of manifestations, SLE runs an unpredictable course. Clinical 
manifestations of SLE include inflammation of the skin and internal organs, which are translated into 
non-specific symptoms like fever, arthralgia, skin rashes and anemia (183, 188). The ACR Criteria are 
summarized in Table I2. To describe disease activity of SLE patients, a SLE disease activity index 
(SLEDAI) score has been stablished (194). 
Mild lupus treatment includes non steroid anti-inflammatory drugs (NSAIDs), anti-malarial drugs 
(hydroxychloroquine) and low-dose corticosteroids, whereas more severe forms of SLE are managed 
with higher doses of corticosteroids and other immunosuppressive agents, such as tacrolimus, 
azathioprine, methotrexate, cyclophosphamide and mycophenolate mofetil (189, 195). Clinical trials of 
anti-CD20 antibody (rituximab) have failed to show significant effects, although this therapy has been 
used off-label to treat refractory cases with success (195). Promising results of a couple of studies 
targeting the IFN-α pathway have been published. Both sifalimumab (196), a monoclonal antibody that 
neutralizes IFN-α (Phase IIb) and anifrolumab (197), a type I IFN receptor antagonist (Phase II) were 
effective in reducing disease activity in association with a reduction in the expression of IFN-regulated 
genes (195-197). Nevertheless, to date there is not curative treatment for SLE. 
3.2 Etiopathogenesis of SLE 
SLE etiology is complex and not fully understood nowadays, with intertwined genetic, hormonal 
and environmental factors contributing to the pathology of this syndrome. These factors lead to an 
irreversible break in immunological tolerance manifested by immune responses against endogenous 
nuclear antigens. 
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a. Gender and sexual hormones 
Since the majority of SLE patients are female, a strong influence of sexual hormones has been 
postulated as a pivotal component in SLE development. Regarding epidemiologic data, the incidence 
rates decline to 3:1 in the pre-adolescent population and to 5:1 after menopause, compared with women 
in the childbearing age (10:1) (198, 199). The X chromosome encodes several immune-related genes, 
such as CD40L, CXCR3, O-linked N-acetylglucosamine transferase, FOXP3, Toll like receptor (TLR) 
7, TLR8, IL-2R-γ, tyrosine-protein kinase BTK, and IL-9R (199, 200). Chromosome abnormalities have 
also highlighted an important role for X chromosome, which is randomly inactivated in early stages of 
embryogenesis. For example, the prevalence of SLE among Turner syndrome patients (women who 
bear only one copy of X chromosome) is lower (201). However, among Klinefelter syndrome patients 
(XXY), the prevalence is 14-fold higher than for age-matched men (202).  At the molecular level, 17-β 
Criteria Definition 
Malar rash 
Fixed erythema, flat or raised, over the malar eminences, tending to spare the 
nasolabial folds 
Discoid rash 
Erythematous raised patches with adherent keratotic scaling and follicular 
plugging; atrophic scarring occurs in older lesions 
Photosensitivity 
Skin rash as a result of unusual reaction to sunlight, by patient history or 
physician observation 
Oral ulcers Oral or nasopharyngeal ulceration, usually painless, observed by a physician 
Arthritis 
Non-erosive arthritis involving two or more peripheral joints, characterized by 
tenderness, swelling or effusion 
Serositis 
a. Pleuritis: convincing history of pleuritic pain or rub heard by a physician or 
evidence of pleural effusion or 
b. Pericarditis: documented by ECG or rub or evidence of pericardial effusion 
Renal disorder 
a. Persistent proteinuria >0.5 g per day or >3+ if quantification is not performed  
b. Cellular casts: may be red cell, hemoglobin, granular tubular, or mixed 
Neurological disorder 
a. Seizures*, or 
b. Psychosis* 
*in the absence of off ending drugs or known metabolic derangements  
Haematologic 
disorder 
a. Hemolytic anaemia with reticulocytosis, or 
b. Leucopenia: <4000/mm3, or 
c. Lymphopenia: <1500/mm3, or 
d. Thrombocytopenia: <100 000/mm3 in the absence of off ending drugs 
Immunologic 
disorder 
a. Anti-DNA: antibody to native DNA in abnormal titre, or 
b. Anti-Sm: presence of antibody to Sm nuclear antigen, or 
c. Positive finding of antiphospholipid antibodies  
Antinuclear antibody 
An abnormal titre of antinuclear antibody by immunofluorescence or an 
equivalent assay at any point in time and in the absence of drugs known to be 
associated with ‘drug-induced lupus’ syndrome 
Table I2. The American College of Rheumatology revised classification criteria for systemic lupus 
erythematosus 
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estradiol acts mainly as an enhancer of humoral immunity, promoting IL-4 and IL-10 secretion (203). 
Prolactin increases antibody production as well as B cell survival, and triggers IFN-γ and IL-6 secretion 
(204). On the other hand, testosterone inhibits Th1 and B cell differentiation, antibody production, and 
NK cytotoxicity (205).  
b. Genetic factors 
The concordance rate for lupus is 25-70% between monozygotic twins and approximately 1-2% 
between dizygotic twins (181, 183, 206, 207), indicating that genetic factors are relevant, but not 
sufficient for the development of SLE. 
Genome-wide association studies (GWAS) have confirmed the importance for SLE susceptibility of 
different genes associated with the immune response and inflammation (HLA-DR, PTPN22, STAT4, 
IRF5, BLK, OX40L, FCGR2A, BANK1, SPP1, IRAK1, TNFAIP3, C2, C4, CIq, PXK), DNA repair 
(TREX1), adherence of leukocyte to the endothelium (ITGAM), and tissue response to injury (KLK1, 
KLK3) (180, 183). Among Major Histocompatibility Complex (MHC) genes, HLA-A1, B8, DR2 and 
DR3, have been linked to lupus (181, 208).  
c. Epigenetics 
Demethylation or hypomethylation of immune response-related genes in T cells or B cells may 
contribute to T and B cell hyperreactivity in SLE (209). Aberrant methylation patterns have been found 
in Gadd45a, CD11a, CD70, perforin and CD40L among other genes, leading to the overexpression of 
these molecules in T cells and promoting autoantibody production by B cells (180, 209). Regarding 
drug-induced lupus, it has been associated with inhibition of DNA methyltransferase 1  (Dnmt1) and 
activation of T cell genes, such as CD11a and CD70 (180).  
Some studies in lupus-prone mice suggest that increased activity of histone deacetylases is involved 
in T cell hyperreactivity in murine lupus (210). Epigenetic mechanisms affecting activation-induced 
deaminase (AID) may directly contribute to the production of pathogenic anti-dsDNA IgG 
autoantibodies by B cells (211). 
Differences in the methylation status of genes may explain, at least in part, why some identical 
twins are discordant for SLE. Taking into account that drugs known to induce lupus, such as 
procainamide and hydralazine may downregulate Dnmt1 levels by inhibiting ERK phosphorilation, 
epigenetic mechanisms may also represent the missing link between genetic and environmental risk 
factors (180, 183). Finally, 17β-estradiol downregulates Dnmt1 activity and enhances global DNA 
hypomethylation in female SLE CD4
+
 T cells, partially explaining the gender differences in SLE 
prevalence (212).  
d. Environmental factors: infections and drugs 
Elevated IFN-α production, mainly by plasmacytoid dendritic cells (pDCs), is a common factor 
shared by SLE and viral infections (182, 183). The strongest candidate to be involved in SLE 
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etiopathogenesis is Epstein-Barr virus (EBV) (183, 213), due to its marked lymphotropism and the fact 
that 100% of multiple sclerosis patients are seropositive for EBV (214). Parvovirus B19, 
Cytomegalovirus (CMV), HHV-6, HHV-7, HHV-8, Human Papilloma Virus (HPV), among others, 
have also been associated with SLE (213, 215-220). In general, serological and molecular studies have 
found antibodies and PCR products related to these viruses at higher levels in SLE patients as compared 
to controls together with increased viral loads. In some cases, these phenomena have been correlated 
with disease activity (213).  
In the case of EBV, the mechanisms proposed to participate in loss of tolerance and development of 
autoimmunity are some viral proteins involved in immune evasion and suppression of apoptosis of 
transformed infected lymphocytes, and molecular mimicry of viral antigens with self antigens (221). 
It is well established that certain drugs induce autoantibodies in a significant number of patients, 
most of whom do not present previous signs of an autoantibody associated disease. Over 100 drugs have 
been reported to cause drug-induced lupus, including a number of the new biologics and antiviral agents 
(183). 
e. Immune factors 
 Probably, the main characteristic of SLE is the aberrant immune response against endogenous 
nuclear antigens. The proposed mechanism regulating the loss of tolerance in SLE is the release of 
autoantigens by apoptotic cells, which are not successfully cleared and are captured and presented by 
DCs to T cells, leading to their activation (180, 181, 183) (Figure I5). T cell activation promotes 
antinuclear antibodies (ANAs) secretion by B cells. ANAs form complexes with nuclear antigens 
released from apoptotic cells, and deposition of such immune complexes in the capillary bed followed 
by local complement and leukocyte activation results in destructive tissue inflammation (222). 
Autoantibodies 
Antibodies directed against dsDNA are highly specific for lupus; constituting a hallmark in the 
diagnosis of this disease. They are present in 70-96% of patients with lupus but in less than 0.5% of 
healthy people or patients with other autoimmune diseases such as rheumatoid arthritis (183, 223), and 
levels of anti-dsDNA antibodies in serum have been correlated with disease activity (224). 
Other autoantibodies that are frequently found in blood serum of SLE patients are anti-Sm and anti-
RNP. Anti-Sm antibodies, directed against 7 proteins  that constitute the common core of U1, U2, U4 
and U5 small nuclear ribonucleoprotein (snRNP) particles, are detectable in a percentage of SLE 
patients ranging between 5 and 30%, or even higher frequencies (225, 226). Studies in North America 
generally cite a prevalence of around 30% (191), but European studies report lower frequencies of 
approximately 5% (225, 227). Anti-RNP antibodies react with proteins that are associated with U1 RNA 
and form U1snRNP. Anti-RNP antibodies are detectable in 13–47% of SLE patients (183, 226). 
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Additionally to  anti-Sm and anti-RNP, other antibodies are commonly found in SLE patients sera, 
such as anti-Ro, anti-La, anti-phospholipid, anti-α-actinin, anti-NMDA and anti-C1q (181, 183, 228).  
Cells and cytokines 
The hallmark of SLE is the overproduction of IFN-α by pDCs, and it is considered to play a central 
role in the initiation and perpetuation of lupus (222). In fact, serologic levels of IFN-α are elevated in 
SLE patients and correlate with disease activity (229). TLR7 and TLR9, which are two innate 
endosomal sensors that are specialized in detecting single-stranded RNA and unmethylated CpG DNA, 
respectively (230); as well as some members of the IRF family (IRF7) are required for IFN-α synthesis 
by pDCs. Binding of IFN-α to its receptor leads to the upregulation of a  large group of genes (more 
than 300):  the α-interferon signature or interferon-stimulated genes (231, 232).  
Thus, type I IFNs cause DC maturation and activation, with increased expression of major MHC 
class I and II molecules and co-stimulatory molecules such as CD80 and CD86 (233). Furthermore, type 
I IFN stimulates the production of several cytokines by natural killer (NK) cells and 
monocytes/macrophages/DCs, such as IFN-γ, IL-6, IL-10 and IL-15 (231). Type I IFNs also promote B-
cell activation, differentiation, antibody production and Ig isotype class switching. Regarding B cells, B-
lymphocyte stimulator (BLyS) and A proliferation-inducing ligand (APRIL) are also upregulated.  This 
upregulation promotes development of both Th1 cells and cytotoxic T cells because of an increase in 
DC cross-presentation and inhibition of T-cell apoptosis.   
Several cytokines have been implicated in lupus pathology. Elevated IL-6 (232, 234) and IL-17 
(235-238) serum levels have been found in patients compared with healthy controls (239). Moreover, 
SLE patients present increased numbers of Th17 cells and double negative T cells (235, 237, 238), 
which are another important source of Il-17 (240). Elevated IL-6 levels are associated with B-cell 
hyperactivity and autoantibody production (241) and secretion of IgG anti-dsDNA antibodies. IL-17 is 
implicated in monocyte and neutrophil recruitment and migration, and also is able to promote B-cell 
differentiation and autoantibody production (242). 
On the other hand, reduced numbers of Tregs, in parallel with reduced expression of IL-2 and IL-
2R  have been associated with SLE (243). Additionally, the tolerogenic functions of those Tregs are 
reported to be impaired in SLE patients (235, 244, 245). 
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Of note, a subset of pro-inflammatory DCs expressing PSGL-1 decorated with an especial 6-sulfo 
N-acetyl lactosamine (SLAN) modification that impairs selectin binding was described to produce high 
amounts of IL-12 and IL-23 in response to TLR7 and TLR8 ligands (246, 247). SlanDCs are increased 
in dermal biopsies of patients with cutaneous lupus and SLE (248), and have been described to enhance 
Th1 and Th17 responses in psoriasis skin lesions (249). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.3 Relationship between SLE and P-selectin 
P-sel levels are elevated in the urine of SLE patients and correlate with disease severity (250). 
Genome-wide linkage studies in humans have suggested an important role for P-sel in SLE. Indeed, the 
P-sel gene is located in the SLE linkage region on human chromosome 1 (1q23) (251, 252). Moreover, 
variations in the upstream region of P-sel are a risk factor for SLE, and two risk alleles have been 
identified potentially affecting the transcription of P-sel and the binding to PSGL-1 (251). 
 
Figure I5. Interplay between innate and adaptive immune systems in SLE. Factors of the innate 
system activate T and B cells of the adaptive compartment, which feedback into the innate arm to 
promote and perpetuate immune activation. Central components of the innate system that feed into the 
adaptive system in SLE include type 1 interferon and other cytokines, MHC II, and apoptotic debris, 
while important factors from the adaptive system promoting innate responses include proinflammatory 
cytokines, autoantibodies, and immune complexes. BAFF=B-cell activating factor. IFN-α = Interferon-
α. IL = interleukin. TGF-β = transforming growth factor β. TNF-α = tumour necrosis factor α. Adapted 
from Lancet. 2013;382 (9894): 819-31 
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3.4 P-selectin and mouse models of SLE 
P-sel/PSGL-1 axis is involved in the generation of Treg (16). PSGL-1 null (Psgl-1
-/-
) mice have 
altered tolerance/immunity balance in the colonic lamina propria and skin, and spontaneously develop 
an autoimmune syndrome similar to human scleroderma (43, 58). Experimental disease models indicate 
that although mice lacking P-sel, E-sel or both are significantly protected from neutrophil-dependent 
injury (32, 253, 254), selectin deficiency induces disease exacerbation in models of glomerulonephritis 
or collagen-induced arthritis, suggesting a protective role for endothelial P-sel in inflammation (32, 59, 
255). Numerous murine models of SLE have been described such as MRL/MpJ
faslpr
 (MRL/lpr), BSXB 
and NZB mice crossed with NZW strains (NZB/W) (256), characterized by high levels of circulating 
autoantibodies, systemic vasculitis, lymphadenopathy, splenomegaly, skin and renal lesions and early 
death due to renal dysfunction, hypertension and spontaneous hemorrhage (256, 257). Studies 
performed with these SLE experimental models described that P-sel deficiency in lupus-prone mice 
resulted in more rapid development of glomerulonephritis and dermatitis and earlier death (56) and that 
P-sel levels appear elevated in the urine of lupus-prone mice (250). 
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Objetives 
 
 
1. To assess whether PSGL-1 deficient mice develop PAH and the molecular mechanisms 
implicated.  
 
2. To evaluate whether P-selectin absence leads to PAH development. 
 
3. To study the impact of P-selectin deficiency in the immune system homeostasis. 
 
4. To characterize the autoimmune syndrome developed by P-selectin deficient mice.  
 
5. To analyze the expression of P-selectin in patients with cutaneous lupus. 
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Materials and Methods 
 
1. Mice 
C57Bl/6 (WT) mice (The Jackson Laboratory) and C57BL/6 PSGL-1
 
deficient
 
and C57BL/6 P-Sel 
deficient mice, kindly provided by Dr. M. K. Wild and Dr. D. Vestweber (Max Planck Institute for 
Molecular Biomedicine, Münster, Germany), were maintained at the Conventional Animal Facility of 
the School of Medicine of the Universidad Autónoma de Madrid (UAM) (register number ES-28079-
0000097) and the Animal Facility of the Centro Nacional de Investigaciones Cardiovasculares (CNIC; 
Madrid, Spain). Mice were sacrificed by cervical dislocation, and blood and internal organs were 
extracted for analysis. All experiments and breeding were performed in accordance with national and 
institutional guidelines for animal care (EU Directive 2010/63/EU for animal experiments). The 
experimental procedures were approved by the Dirección General de Medio Ambiente of Madrid (Ref: 
PROEX 69/14, PROEX 162/15 and PROEX375-15) 
2. Hypoxia, echocardiography and vascular contractility assays 
2.1 Hypoxia Experiments 
Female PSGL-1
-/-
 and WT mice were exposed to hypoxia (mixture of 10% O2 and 90% of N2) for 
24 days in an airtight chamber with inflow and outflow valves. Mice were extracted from the chamber 
to undergo echocardiography at day 10, 18 and 22. At day 24, mice were sacrificed by cervical 
dislocation.  
2.2 Transthoracic Doppler Echocardiography 
All transthoracic echocadiography measurements were obtained with an echocardiography system 
(VEVO 2100, Visualsonics) and an 18-38 Hz ultrasound probe. Chest hair was removed with 
hypoallergenic depilatory cream and animals were kept anesthetized by continuous influx of 2% 
isofluorane with an oxygen flow rate of 1.5 l/min. The B-mode was used for morphometric 
measurement of right ventricle (RV) wall and the pulsed wave Doppler mode was used for measuring 
the pulmonary acceleration time (PAT) and the ejection time (ET) of blood flow in the pulmonary artery 
at the level of the pulmonary valve. The PAT/ET ratio was then calculated and used as an indirect 
evaluation of systolic pulmonary artery blood pressure. The ratio of RV weight to left ventricule (LV) 
weight plus septum (S) (RV/LV + S) was used as an index of RV hypertrophy (Fulton Index) (258). 
2.3 Vascular contractility 
Murine pulmonary arteries were carefully dissected free of surrounding tissue and cut into rings 
(1.8–2 mm length). Vessel segments were mounted on a wire myograph in Krebs physiological solution. 
Buffer solutions were continuously bubbled with 21% O2, 5% CO2, and 74% N2 (pO2¼ 17–19 kPa) 
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(259), and stretched to a transmural pressure equivalent to 30 mmHg. Contractility was recorded by an 
isometric force transducer and a displacement device coupled with a digitalization and data acquisition 
system (PowerLab). To confirm smooth muscle viability, arteries were first stimulated by raising the K+ 
concentration of the buffer to 80 mmol/l and then allowed to recover. After washout, arteries were 
stimulated with serotonin (5-HT) (10
-8–10-5 mol/l; Sigma-Aldrich) in a concentration-response fashion 
performed by cumulative addition. Thereafter, concentration-response curves to acetylcholine (Ach) 
(10
-9–10-5 mol/l) and sodium nitroprusside (SNP, 10-11–10-5 mol/l) were performed by cumulative 
addition to analyze the endothelium-dependent and endothelium-independent vasodilatation, 
respectively.  
3. Autoantibody assays 
Antinuclear antibodies (ANAs) were detected by indirect immunofluorescence. HEp-2 cells and 
Crithidia luciliae were previously fixed on glass slides (Inova Diagnostics).  HEp-2 cells were 
employed for ANA screening and Crithidia luciliae were used for anti–double-stranded DNA (anti-
dsDNA) antibody screening. Blood sera from WT and PSGL-1
-/-
 mice were diluted 1:20 for HEp-2 
incubation and 1:10 for Crithidia luciliae incubation. Diluted serum samples were incubated for 30 
minutes with either HEp-2 cells or C. luciliae. Slides were incubated for 30 minutes with goat anti-
mouse Alexa Fluor 488 (1:100) (Invitrogen). Circulating autoantibodies were measured by enzyme-
linked immunosorbent assay (ELISA) with the specific Quanta Lite kits for SSA, U1 RNP, Sm, Jo-1, 
and Scl-70 antigens (Inova Diagnostics). Horseradish peroxidase–conjugated goat anti-mouse IgG 
(H#L) antibody from Pierce Antibodies (Thermo Scientific) diluted 1:2,500 was used as secondary 
antibody. The cut-off point for positivity on ELISA for a particular autoantibody was determined as the 
mean value (X) plus two standard deviations (SD) obtained from sera of at least 100 WT mice with an 
age ranging from1.5 to 24 months. At least 8 mice per group of age were analyzed. 
4. UV radiation, histology and Immunohistochemistry 
4.1 UV radiation protocol 
Three month-old WT and P-Sel
-/-
 mice were irradiated with an UVB lamp containing a set of six 
tubes (Phillips TL UV, 20 W; Royal Philips Electronics) (wavelength ranging from 290 nm to 320 nm), 
being the energy output at a distance of 15 cm, of 2.5 mW/cm
2
. Mice received three doses of 0.306 
J/cm
2
 every other day for a week, and an additional dose of 0.12 J/cm
2
 three days later. Mice were 
sacrificed 24 hours after the last dose and skin was dissected and processed. 
4.2 Histopathological assessment of mouse tissue 
Organs and tissues were fixed for 24 hours in 4% formaldehyde and then were preserved in 70% 
ethanol. Fixed tissues underwent a dehydration process consisting of serial incubations during 30 
minutes in solutions with rising ethanol concentrations (70%, 95%, 100%) and liquid paraffin. After 
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that, processed samples were embedded in paraffin and sliced into 4-µm sections with a manual 
microtome.  
Hematoxylin and eosin (H&E) staining was performed with Harris’ hematoxylin (Merck) and Eosin 
Y (alcoholic solution; Leica Biosystems). Masson’s trichrome staining was performed with the 
automatic Artisan Gomori’s Green Trichrome Stain kit (Dako).  
4.2.1 Skin: pathological index 
Para-midline, upper back skin samples were evaluated blindly to obtain a semiquantitavive 
measurement by assigning a 3-criteria-based score (260): acanthosis (0, normal; 1, slight thickening of 
epidermis; 2 and 3, presence of two or three layers of stratum spinosum cells, respectively; 4, presence 
of four or more layers of stratum spinosum cells); hyperkeratosis (0, normal; 1, one layer of keratin; 2, 
two layer thick of keratin; 3, minimum three-layer thick of keratin; 4, minimum three-layer thick of 
keratin and formation of a keratin’s plug); hypergrannulosis (0, normal; 1, moderate accumulation of 
granular dark material in the stratum granulosum; 2 and 3, two or more than three layers of granular 
dark material; 4, three or more layers of accumulated granular dark material overall section of skin). 
Finally, the total pathology score was calculated by adding the resulting values for the three criteria. 
4.2.2 Kidney: infiltrates and ischemic events 
The scouting for inflammatory infiltrates and architectural abnormalities in the mouse kidney was 
performed on H&E-stained slices. Inflammatory infiltrates were identified as accumulation of little, 
circular and reactive nuclei. The structural damage parameters considered were: enlargement of 
Bowmann’s space, proliferation of mesothelial cells, glomerular sclerosis, and glomerular atrophy.  
The presence of kidney ischemic events (infarcted areas) was assessed in Masson’s trichrome-
stained sections. Infarcted areas were identified by light blue-stained areas with tissue architecture 
disruption and fibrosis.  
Images were obtained with a Leica DM2500 light microscope and a Leica DFC450 camera. All 
sections were examined by an observer unaware of sample origin. 
4.2.3 Lung: evaluation of non specific interstitial pneumonia (NSIP) 
Nonspecific interstitial pneumonia (NSIP) was evaluated in whole H&E-stained lung sections. 
Increment in interstitial cellularity, thickening of the alveolar walls and structure alteration of the lung 
parenchyma were considered as NSIP features. We differentiated between 3 stages of increasing NSIP 
severity: 1) focal NSIP affecting one lobule; 2) the presence of several NSIP foci affecting distinct 
lobules (generalized NSIP); 3) the presence of one or several large and widespread NSIP areas (diffuse 
NSIP). 
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4.3 Immunohistochemistry 
4.3.1 Anti α-SMA immunohistochemistry in lung sections 
Immunohistochemistry against murine α-smooth muscle actin (α-SMA) was performed in paraffin-
embedded lung sections. Paraffin was removed with xylene, sections were rehydrated and antigen 
retrieval was performed with boiling sodium citrate buffer (10mM Sodium Citrate, 0.05% Tween 20, 
pH 6.0) during 2 minutes. Endogen peroxidase activity was inhibited by 30 minute incubation with 3% 
H2O2 in methanol. After blocking with phosphate buffered saline (PBS) 1x 4% bovine serum albumin 
(BSA), sections were incubated with anti-α-SMA 1:250 (Dako) for 2 hours at room temperature. For 
revealing, Universal LSAB+ Kit Rabbit/Mouse/Goat (DAB+) (Dako) was used. The small blood vessel 
(diameter of <50 µm) wall thickness was calculated by measuring, with ImageJ (NIH), the internal and 
total vessel diameter of anti–α-SMA–stained lungs, and calculating the vessel wall area. Then, the mean 
wall thickness area was calculated. 
4.3.2 Anti-CD45 immunohistochemistry in lung sections 
Paraffin-embedded lung sections were deparaffinated and rehydrated as described in the previous 
paragraph, and antigen retrieval was performed with boiling citrate buffer. Endogen peroxidase activity 
was inhibited by 30 minute incubation with 3% H2O2 in methanol. After blocking with PBS 1x 4% 
BSA, sections were incubated with anti-CD45 1:300 (BD Pharmingen) for 2 hours at room temperature. 
For revealing, Universal LSAB+ Kit Rabbit/Mouse/Goat (DAB+) (Dako) was used. At least 5 males 
and 5 females were evaluated per genotype and age. 
4.3.3 Immunocomplex detection in skin and renal sections 
Skin and glomerular immunoglobulin deposition were evaluated by IHC with an antibody cocktail 
against Fab regions of IgA, IgG, IgM (1:250) (Abcam). Tissue preparation and antigen retreavel was 
performed following the protocol described in the previous section, and the primary antibodies were 
incubated overnight at 4ºC. For revealing, Universal LSAB+ Kit Rabbit/Mouse/Goat (DAB+) (Dako) 
was used. At least 5 males and 5 females were evaluated per genotype and age. 
5. Human skin samples 
Skin biopsies from 4 chronic/subacute cutaneous lupus erythematosus (cLE) patients and from 4 
aged-matched healthy controls were obtained from the Pathology Department, Hospital de la Princesa 
(Madrid, Spain). The investigations were conducted in accordance with the principles of the Declaration 
of Helsinki and were approved by the Clinical Research Ethics Committee of the Hospital de la 
Princesa, Madrid, Spain (Register number: PI-654, date of approval 07-02-2013). Informed consent was 
obtained from all the patients and healthy controls. 
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5.1 Immunohistochemistry of human skin sections 
Consecutive tissue sections of sun-exposed skin biopsies underwent immunohistochemistry with 
the Dako REAL EnVision Detection System Peroxidase/DAB+ kit (Dako), using as primary antibodies 
anti-human P-selectin (10 µg/ml) (R&D Systems) and anti-human CD31 (1/50) (Abcam). Paraffin was 
removed with xylene, sections were rehydrated and antigen retrieval was performed with boiling sodium 
citrate buffer pH 6.0 during 2 minutes. Endogen peroxidase activity was inhibited by 30 minute 
incubation with 3% H2O2 in methanol. After blocking with PBS 1x 4% BSA, sections were incubated 
with either anti-P-selectin or anti-CD31 for 2 hours at room temperature. After washing, samples were 
incubated (15 minutes, room temperature) with horseradish peroxidase (HRP)-conjugated secondary 
antibodies directed against Fc regions of mouse and rabbit immunoglobulins. After washing, DAB 
(1/50) was added for signal detection. Samples were rehydrated, counterstained with hematoxylin (1 
minute) and mounted with water-miscible resin (Eukitt). 
The whole biopsies were scouted for blood vessels in a blinded manner. Vessels were identified by 
positive staining by CD31, localized in the consecutive P-selectin-stained section, and classified 
depending on the expression of P-selectin as follows:  
1) Unstained, negative blood vessels. 
2) Partially stained blood vessels. 
3) Fully stained blood vessels. 
6. Flow cytometry 
6.1 Single-cell sample preparation 
6.1.1 Spleen 
Spleens were dissected and mechanically disrupted in PBS 1X, 0.5% BSA, 5 mM 
ethylenediaminetetraacetic acid (EDTA). Cell aggregates and undigested pieces of tissue were 
eliminated by using a 70 µm cell strainer (BD Falcon). Cells were then washed with 25 ml of PBS 1X, 
0.5% BSA, 5 mM EDTA and concentrated in 700 µl. Then, samples were filtered again with a 30 µm 
cell strainer (BD Pharmingen). 
6.1.2 Skin and Lung 
Skin or lung samples were weighed, minced into ~1 mm
2
 pieces and digested for 1 hour with 
RPMI1640 medium complemented with 1 mg/ml collagenase A (Sigma-Aldrich; San Luis, MI, USA), 
2.5 mg/ml dispase II (Roche; Basel, Switzerland) and 40 µg/ml DNase (Sigma).  Cell aggregates and 
undigested pieces of tissue were eliminated by using a 70 µm cell strainer (BD Falcon). Cells were then 
washed with 25 ml of PBS 1X, 0.5% BSA, 5 mM EDTA and concentrated in 700 µl. Then, samples 
were filtered again with a 30 µm cell strainer (BD Pharmingen). 
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6.1.3 Peripheral blood 
Blood was extracted by intracardiac injection with a 25G x 5/8 needle (0.5mm x 16mm) (BD 
Pharmingen). 70 IU of heparin (Sigma) were used to prevent coagulation of 250 µl of blood. 
6.2 Antibody staining 
Before staining, samples were incubated with 1:200 Fc Block (BD Pharmingen) to saturate Fc 
receptors on the surface of myeloid cells. Then, samples were incubated with the mix of surface 
antibodies. After that, cells were permeabilized by 15 minute incubation with 2 ml of FACS Lysing 
Solution (BD Pharmingen). This solution also lyses erythrocytes and fixes cells. After centrifugation 
and washing, the cocktail of antibodies directed against intracellular cytokines was added and samples 
were incubated during 30 minutes at 4 ˚C. Finally, unbound antibody was eliminated by washing with 
2ml of PBS 1X, 0.5% BSA, 5 mM EDTA. The list of antibodies used in this thesis is summarized in 
Table MM1. 
Samples were analyzed with a FACSCanto II (BD Pharmingen) and FACS Diva Software (BD 
Pharmingen). 
6.3 Gating strategy 
6.3.1 Spleen 
 Immune cells were identified as CD45
+
. T cells were identified as CD3
+
 and were separated into 
CD3
+
CD4
+
 helper T (Th) cells and CD3
+
CD8
+
 cytotoxic T (Tc) cells.  
Follicular Th cells were gated as CD3
+
CD4
+
PD-1
high
CXCR5
high
.  
The subpopulations of T cells according to CD44 and CD62L expression were classified as: 
 Naïve (CD44negCD62L+) 
 Central Memory (CD44+CD62L+) 
 Effector Memory (CD44+CD62Lneg) 
 Effector (CD44negCD62Lneg) 
B cells were identified as low complexity CD11c
-
B220
+
 cells. Among them, germinal centre B cells 
were gated as CD11c
-
B220
+
FAS-L
+
GL-7
+
. Plasma cells were gated as CD19
+
B220
-
IgD
-
CD138
+
. 
6.3.2 Peripheral bllod 
Low complexity CD3
+
 and B220
+
 cells were gated as T cells and B cells, respectively. T cell were 
then classified into CD3
+
CD4
+
 (Th) and CD3
+
CD8
+
 (Tc). CD11c−CD11b
+
 cells were gated as 
monocytes. CD11c
+
 cells were gated as DC: CD11c
+
 CD11b
+
 B220− were gated as cDCs; and CD11c
+
 
CD11b−B220
+
 were gated as pDCs. 
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Table MM1. Antibodies used for flow cytometry 
Antibody Fluorochrome Dilution Reference Manufacturer 
GL-7 eFLUOR660 1:100 50-5902-82 eBioscience 
CD3ε PE-Cy7 1:100 25-0031-82 eBioscience 
CD11c PE-Cy7 1:100 25-0114-82 eBioscience 
FOXp3 FITC 1:100 11-5773-82 eBioscience 
IgD Biotin 1:100 13-5993-82 eBioscience 
F4/80 PE-Cy7 1:100 25-4801-82 eBioscience 
CD11c Biotin 1:100 553800 BD Pharmingen 
FAS-L Biotin 1:400 556998 BD Pharmingen 
CD3ε APC 1:100 553066 BD Pharmingen 
CD25 APC 1:100 557192 BD Pharmingen 
CD45R/B220 APC 1:100 553092 BD Pharmingen 
IFN-γ APC 1:100 554413 BD Pharmingen 
IL-4 APC 1:100 554436 BD Pharmingen 
IL-17A APC-Cy7 1:100 560821 BD Pharmingen 
CD45.2 BV421 1:100 562895 BD Pharmingen 
CD62L PE 1:100 553151 BD Pharmingen 
CD11b FITC 1:100 553310 BD Pharmingen 
CD45.2 FITC 1:100 553772 BD Pharmingen 
CD31 BV421 1:100 563356 BD Pharmingen 
CD31 APC 1:100 551262 BD Pharmingen 
CD138 PE 1:200 553714 BD Pharmingen 
CD4 FITC 1:50 130-102-541 Miltenyi Biotec 
CD8a PerCP 1:50 130-102-468 Miltenyi Biotec 
CD8a FITC 1:50 130-102-490 Miltenyi Biotec 
CD44 APC 1:50 130-102-563 Miltenyi Biotec 
CD45R/B220 APC-Vio770 1:50 130-102-818 Miltenyi Biotec 
CD19 VioBlue 1:50 130-103-139 Miltenyi Biotec 
MHC-II APC 1:50 130-102-898 Miltenyi Biotec 
MHC-II PE 1:50 130-102-186 Miltenyi Biotec 
CD62P PE 1:100 130-105-536 Miltenyi Biotec 
CD62E APC 1:100 130-105-468 Miltenyi Biotec 
CD4 PE 1:50 22150044 Immunotools 
CXCR5 PE/Dazzle594 1:100 145521 BioLegend 
PD-1 BV421 1:100 135217 BioLegend 
IL-10 PerCP-Cy5.5 1:100 505028 BioLegend 
γδ TCR PerCP-Cy5.5 1:100 118118 BioLegend 
Streptavidin PerCP 1:100 405213 BioLegend 
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6.3.3 Skin 
Immune cells were identified as CD45
+
. T cells were identified as CD3
+
 and were separated into 
CD3
+
CD4
+
 (Th) and CD3
+
CD8
+
 (Tc). CD11c+ cells were gated as DC: CD11c
+
CD11b
+
B220
- 
were 
gated as cDCs; and CD11c
+
CD11b
-
B220
+
 were gated as pDCs. CD11c
-
B220
+
 cells, with low 
size/complexity index were considered B lymphocytes. CD11c
-
CD11b
+
 cells were gated as 
macrophages. 
6.3.4 Lung 
Immune cells were identified as CD45
+
. T cells were identified as CD3
+
 and were separated into 
CD3
+
CD4
+
 (Th) and CD3
+
CD8
+
 (Tc). Alveolar macrophages were gated as F4/80
+
CD11c
+
 cells. 
Interstitial macrophages were gated as F4/80
+
CD11c
-
. DCs were gated as F4/80
-
CD11c
+
 cells: cDCs 
were gated as F4/80
-
CD11c
+
B220
-
; and pDCs were gated as F4/80
-
CD11c
+
B220
+
. CD11c
-
B220
+
 cells 
were considered B lymphocytes. In other staining, B lymphocytes were gated as CD3
-
CD19
+
. 
7. ELISA of lung samples 
The left lung was mechanically disrupted in PBS 1X. After four freeze/thaw cycles to break cell 
membranes, samples were centrifuged at 5000g and supernatants were recovered. Then, AngII and ET-1 
concentrations were measured with specific ELISA kits: Angiotensin II (ANG-II), Mouse, ELISA Kit 
CSB-E04495m (Cusabio) and Endothelin-1 ELISA kit #17165 (IBL). 
8. Western blot 
The right lung was frozen, pulverized and lysed in RIPA buffer (1% Triton X-100, 0.24M sodium 
deoxycolate 10%, 0.35M SDS in 1xTBS) complemented with phosphatase inhibitors. Samples were 
then centrifuged at 13000 rpm and supernatant was used for assays. 
Antibody Origin Dilution Reference Manufacturer 
Anti-ACE Rabbit 1/1000 LS-C291661/61036 LifeSpan BioSciences 
Anti-ACE2 Rabbit 1/1000 NBP1-76614 Novus Biologicals 
Anti-AT1R Rabbit 1/1000 NBP1-77078 Novus Biologicals 
Anti-AT2R Rabbit 1/1000 NBP1-77368 Novus Biologicals 
Anti-ETA Rabbit 1/1000 NBP1-87467 Novus Biologicals 
Anti-ETB Rabbit 1/1000 NBP2-16334 Novus Biologicals 
Anti-β-actin Rabbit 1/5000 V4505-100UL Sigma Aldrich 
Anti-Vinculin Rabbit 1/2000 A5316-100UL Sigma Aldrich 
Anti-eNOS Mouse 1/1000 610297 BD Pharmingen 
Table MM2. Antibodies used for immunoblotting 
50µg of protein were loaded in a 13% acrilamide-bisacrilamide gel, and then transferred to a 
nitrocellulose membrane. Membranes were blocked for nonspecific binding in TBS 1x 5% BSA 0.2% 
Tween 20 and primary antibodies were incubated overnight at 4ºC. HRP-conjugated goat anti rabbit IgG 
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secondary antibody was incubated during 1 hour and signal was detected by chemiluminiscence with the 
LuminataTM Forte Western HRP Substrate (Merck KGaA). Antibodies used for western blot are 
summarized in Table MM2.  
Band intensity was analyzed with ImageJ and results were normalized to the expression of β-actin 
or vinculin considered as loading controls. 
9. Statistical analysis 
Statistical significance between two groups was calculated using two-tailed Student’s t test for 
parametric variables and Mann-Whitney’s U test for nonparametric variables. Statistical significance 
between three groups in parametric variables was calculated by one-way ANOVA with Bonferroni post 
hoc test. The chi-squared (df=1) test was used for statistical comparison of frequencies. Mantel-Cox chi-
squared (df=1) test was used to analyze survival data. Differences were considered statistically 
significant with p<0.05 (*) and highly significant at p<0.01 (**) and p<0.005 (***). All statistical 
analyses were performed using SPSS 15.0 program (IBM). Graphic representations of skin pathology 
score and association between ENAs and urine parametres were performed with GraphPad Prism 6 
(Graphpad). 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Results 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                         RESULTS 
 
49 
 
Results 
1. Assessment of PAH development in PSGL-1 deficient mice and the molecular 
mechanisms implicated 
1.1 PSGL-1
-/-
 mice exhibit remodeling of pulmonary small vessels  
Immunohistochemical staining of lung sections from wild-type (WT) and PSGL-1
-/-
 mice with an 
antibody against α-smooth muscle actin (αSMA) revealed a thicker medial wall of small vessels in 
PSGL-1
-/-
 lung (Figure R1A). Quantification demonstrated a significant increase of the relative wall area 
in almost all groups of PSGL-1
-/-
 vessels independently of age (Figure R1B), becoming twice as thick in 
PSGL-1
-/-
 animals as in WT, especially in aged animals (Figure R1B). 
 
1.2 PSGL-1
-/-
 mice present altered echocardiographic parameters consistent with PAH  
Given the remodeling observed in the lung small vessels and our previous observation of an 
elevated rate of death in PSGL-1
-/-
 mice after reaching one year of age (58), echocardiography and 
Doppler were used to measure parameters that change to adapt RV to the increasing vascular load in 
high pulmonary pressure, including PAT/ET ratio and RV wall thickness. Follow-up transthoracic 
Doppler echocardiography performed on WT and PSGL-1
-/-
 mice at the age of 14, 18 and 22 months 
showed an increased pulmonary artery pressure detected by a reduction in PAT/ET in 14-month aged 
female PSGL-1
-/-
 mice as compared with WT mice, which was maintained throughout the longitudinal 
study (Figures R2A-C and R3A). Interestingly, this was not observed in male PSGL-1
-/-
 mice (Figure 
R3A). Likewise, we found remodeling of RV consisted in an increased ventricular wall thickness in 
aged female PSGL-1
-/-
 mice that was statistically significant at 14 months (Figure R3B). 
Figure R1. Vascular 
remodeling in pulmonary 
small vessels of PSGL-1
-/- 
mice. (A) Representative 
microphotographs (40x) of 
anti-αSMA-immunostained 
lung sections of 1.5, 12 and 
>20-month-old mice (n = 
5–6 per group). Scale bar = 
50 m. (B) Percentage of 
vessel wall area in <50 
µm-diameter pulmonary 
blood vessels at 1.5, 12 and 
>20 months of age (>150 
vessels analyzed for each 
group of age). Data are 
expressed as the mean ± 
SD. *P < 0.05, **P < 0.01, 
***P < 0.005, by 2-tailed 
Student’s t test. 
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To determine the age at which the elevation in pulmonary artery pressure takes place, periodical 
echocardiography was performed on WT and PSGL-1
-/-
 female littermates between the ages of 1.5 and 
18 months. Recurrent tendency to reduced PAT/ET ratio was observed in animals from 3 months of age 
(Figure R4A). Because a group of three PSGL-1
-/-
 females died between 15 and 18 months of age, we 
differentiated the dead and survivor groups. The group of PSGL-1
-/-
 mice that died prematurely showed 
Figure R3. RV echocardiographic 
parameters of PAH in PSGL-1
-/- 
mice. (A-B) Longitudinal study of 
PAT/ET (A) and RV wall thickness 
(B) in male and female WT and 
PSGL-1
-/-
 mice at 14, 18 and 22 
months of age (n = 5 mice per 
group). Data are expressed as the 
mean ± SD. *P < 0.05, **P < 0.01, 
***P < 0.005, by 2-tailed Student’s 
t test. 
Figure R2. Echocardiographic plane for PAT/ET measurement. (A) B-Mode showing the 
echocardiographic plane used for Doppler pulmonary flow acquisition. PV=pulmonary valve; 
PA=pulmonary artery; AA=ascending aorta. (B) Representative Doppler pulmonary artery flow of aged 
female WT and PSGL-1
-/-
 mice. (C) Magnification of a representative Doppler wave from WT and PSGL-
1
-/-
 mice. Data are expressed as the mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.005, by 2-tailed Student’s 
t test. 
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increased pulmonary artery pressure detected by a reduced PAT/ET ratio as compared not only with WT 
mice, but also with the surviving group of PSGL-1
-/-
 mice (Figure R4A). Surviving PSGL-1
-/- 
mice 
maintained PAT/ET ratio below that observed in WT mice along their life. At 18 months, animals were 
sacrificed and the Fulton index was calculated for each mouse. Surviving female PSGL-1
-/-
 mice 
presented a higher Fulton index than their female WT littermates (Figure R4B).  
 
1.3 Decreased endothelial NO-dependent relaxing response in pulmonary arteries from PSGL-1
-/-
 
female mice  
We next assessed vascular reactivity in pulmonary and mesenteric arterial rings using wire 
myography. When compared with littermates WT females, pulmonary arteries isolated from female 
PSGL-1
-/-
 mice showed increased vasoconstriction in response to 80 mM KCl (Figure R5A), whereas 
the contractile response to serotonin (5-HT) was similar (Figure R5B). The vasodilating response to 
acetylcholine (Ach) was impaired in PSGL-1
-/-
 arterial rings (Figure R5C); however, the addition of an 
external NO donor (SNP) was sufficient to fully relax both WT and PSGL-1
-/-
 arterial rings (Figure 
R5D). Conversely, vascular reactivity was not different between mesenteric arterial rings of PSGL-1
-/-
 
and WT littermates (Figures R5E and R5F), suggesting that the endothelial dysfunction is not systemic. 
1.4 Reduced pulmonary endothelial NO production in PSGL-1
-/- 
mice 
The percentage of NO-producing lung endothelial cells was reduced in aged PSGL-1
-/- 
mice 
(Figures R6A and R6B), although this was significant only among the highest NO-producing 
endothelial cell subset (Figures R6A and R6C). Additionally, the mean fluorescence intensity (MFI) for 
the NO-sensing probe diaminorhodamine-4M acetoxymethyl ester (DAR-4M AM) was lower in lung 
endothelial cells of PSGL-1
-/-
 than of WT mice (Figure R6D). These changes were not observed in 3-
month-old mice 
Figure R4. PAT/ET and Fulton index 
measurement in WT and PSGL-1
-/- 
female mice. (A) Longitudinal study of 
PAT/ET between 1.5 and 18 months of 
age in WT mice (n = 4), surviving PSGL-
1
-/-
 mice (n = 6) and PSGL-1
-/-
 mice 
dying prematurely (n = 3). (B) Fulton 
index (RV/LV+S) measured in WT and 
surviving PSGL-1
-/-
 mice. Data are 
expressed as the mean ± SD. * WT vs 
surviving PSGL-1
-/-
; # WT vs dead 
PSGL-1
-/-
; $ surviving PSGL-1
-/-
 vs dead 
PSGL-1
-/-
 mice, by one-way ANOVA 
with Bonferroni post hoc test. 
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1.5 Unaltered eNOS expression in the lung of PSGL-1
-/-
 mice  
Given the reduced NO production by PSGL-1
-/-
 lung endothelial cells, eNOS protein expression 
was measured in lung lysates and no differences were found between WT and PSGL-1
-/-
 females 
(Figures R7A and R7B). 
 
 
 
 
 
 
1.6 Impaired adaptation of PSGL-1
-/-
 females to chronic hypoxia  
Exposure to chronic hypoxia (10% O2) killed 40% (2 out of 5 animals) of PSLG-1
-/-
 mice during the 
first week, and surviving animals showed decreased PAT/ET ratio as compared with WT littermates 
(Figure R8A). The Fulton index at day 24 was similar between WT and PSGL-1
-/-
 mice (Figure R8B). 
PSGL-1
-/-
 lung arteries showed a trend toward a greater vasoconstriction response to 5-HT than those of 
WT animals, but differences did not reach statistical significance (Figure R8C). The relaxing response 
to Ach was lower in PA from WT mice exposed to hypoxia (Figure R8D) than from WT mice in 
normoxia (Figure R5C). Thus, after hypoxic exposure, the relaxation induced by Ach was similar 
between WT and PSGL-1
-/-
 arteries (Figure R8D). Likewise, the relaxation in the presence of an 
external NO donor was similar in WT and PSGL-1
-/-
 lung arteries (Figure R8E). 
Figure R5. Vascular response to 
vasoconstrictor and vasodilator 
agents. (A-B) Contractile 
response to KCl (A) and serotonin 
(B) in pulmonary arterial rings 
obtained from 18-month-old 
female WT and PSGL-1
-/-
 mice. 
A.E.P.: Active Effective Pressure. 
(C-D) Vasodilating response to 
acetylcholine (C) and SNP (D) in 
pulmonary arterial rings obtained 
from 18-month-old female WT 
and PSGL-1
-/-
 mice. (E and F) 
Vascular response of mesenteric 
arterial rings to KCl (E) and 
acetylcholine (F) obtained from 
18-month-old female WT and 
PSGL-1
-/-
 mice. Data are 
expressed as the mean ± SD. *P < 
0.05, **P < 0.01 by 2-tailed 
Student’s t test. 
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1.7 Reduced endothelin-1 concentration in the lung of aged PSGL-1
-/-
 mice  
As ET-1 is a key mediator involved in PH, we measured its level in lung tissue of young PSGL-1
-/-
 
and WT female mice and found no differences; however, it was reduced in aged male and female PSGL-
1
-/-
 mice (Figure R9). No significant differences were found for endothelin-1 receptor A (ETA) and B 
(ETB) protein expression between WT and PSGL-1
-/-
 females (Figures R10A and R10B).  
 
Figure R7. Quantification of 
pulmonary eNOS expression. 
(A-B) Western blot showing 
eNOS expression in the lungs of 
female WT (n=4) and PSGL-1
-/-
 
(n=4) mice (A) and its 
densitometry quantification (B). 
Vinculin was used as loading 
control.   Data are expressed as 
the mean ± SD. Non significant 
(n.s.) differences were found by 
Mann-Whitney’s U test. 
Figure R6. Quantification of 
NO production by lung 
endothelial cells. (A) 
Representative dot plots showing 
DAR-4M AM fluorescent lung 
endothelial cells (CD45
neg
CD31
+
) 
from WT and PSGL-1
-/-
 female 
mice. (B-C) Percentage of lung 
endothelial cells producing 
moderate (B) or high (C) 
amounts of NO measured in 3 
and >18-month-old female WT 
and PSGL-1
-/-
 mice. (D) Fold 
change of medium fluorescence 
intensity (M.F.I.) for the NO-
sensing probe DAR-4M AM 
measured in lung endothelial cells 
of 3 and >18-month-old female 
WT and PSGL-1
-/-
 mice. Data are 
expressed as the mean ± SD. *P < 
0.05, **P < 0.01 by 2-tailed 
Student’s t test.  
                                                                                         RESULTS 
 
54 
 
 
 
 
 
 
1.8 Aged PSGL-1
-/-
 female mice present increased pulmonary levels of AngII and reduced 
expression of AT2R 
 No differences were found in the pulmonary concentration of AngII between young WT and 
PSGL-1
-/-
 females; however, AngII was significantly higher in aged PSGL-1
-/-
 female mice 
(78.02±28.09 pg/g lung tissue) than in aged WT mice (48.70±5.13 pg/g lung tissue) (Figure R10, left 
panel). By contrast, AngII levels in aged males were similar between the two genotypes (Figure R11).  
 
 
Figure R9. Endothelin-1 
concentration in the lung of WT 
and PSGL-1
-/-
 mice. ET-1 
concentration in lung lysates of 
WT (n = 4) and PSGL-1
-/-
 (n = 4) 
mice. Data are expressed as the 
mean ± SD. *P < 0.05 by Mann-
Whitney’s U test. 
 
Figure R8. Effects of 24-day exposure to 10% O2 on WT and PSGL-1
-/-
 mice. (A) PAT/ET 
measures from basal to day 22 of hypoxia in female WT (n = 4) and surviving PSGL-1
-/-
 (n = 5) 
mice. In red: percentage of dead PSGL-1
-/-
 mice before day 10. (B) Fulton index calculated at day 
24 of hypoxia. (C) Contractile response to serotonin of pulmonary arterial rings obtained from 
female WT and PSGL-1
-/-
 mice exposed to hypoxia. (D-E) Vasodilating response to acetylcholine 
(D) and SNP (E) of pulmonary arterial rings obtained from female WT and surviving PSGL-1
-/-
 
mice exposed to hypoxia. Data are expressed as the mean ± SD. *P < 0.05 by 2-tailed Student’s t 
test. 
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Figure R11. Angiotensin II 
concentration in the lung of WT 
and PSGL-1
-/-
 mice. (A) AngII 
concentration in lung lysates of 
WT (n = 4) and PSGL-1
-/-
 (n = 4) 
mice. Data are expressed as the 
mean ± SD. *P < 0.05 by Mann-
Whitney’s U test. 
Figure R10. Expression of endothelin receptors in lungs of WT and PSGL-1
-/-
 mice. (A) Western blot 
showing ETA and ETB expression in the lungs of female WT (n = 4) and PSGL-1
-/-
 (n = 4) mice and (B) 
densitometry quantification. β-actin and vinculin were used as loading controls.  Data are expressed as the 
mean ± SD. *P < 0.05 by Mann-Whitney’s U test. 
 
Figure 12. ACE and ACE2 expression in the lung of WT and PSGL-1
-/-
 mice. (A-B) 
Immunoblots showing ACE (A) and ACE2 (B) levels in the lungs of female WT (n = 4) and PSGL-
1
-/-
 (n = 5) mice, and densitometric quantification (right panels). Vinculin was used as loading 
controls. Data are expressed as the mean ± SD. *P < 0.05 by Mann-Whitney’s U test. 
 
 
 
 
 
 
 
 
Although not statistically significant, the expression of ACE was lower both in young and aged 
PSGL-1
-/-
 females than in WT (Figure R12A). Levels of ACE2 were similar between WT and PSGL-1
-/-
 
females (Figure R12B).  
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Figure R13. AT1R and AT2R expression in the lung of WT and PSGL-1
-/-
 mice. (A-B) 
Immunoblots showing AT2R (A) and AT1R (B) levels in the lungs of female WT (n = 4) and 
PSGL-1
-/-
 (n = 5) mice, and densitometric quantification (right panels). Vinculin was used as 
loading controls. Data are expressed as the mean ± SD. *P < 0.05 by Mann-Whitney’s U test. 
Regarding AngII receptors, the expression of AT2R was lower in young (WT: 0.227±0.088 vs KO: 
0.089±0.024) and aged PSGL-1
-/- 
females than in WT (WT: 0.337±0.094 vs KO: 0.189±0.072) (Figure 
R13A), whereas no differences were found for the expression of AT1R (Figure R13B). 
 
 
 
 
1.9 Gamma-interferon (IFN-γ) producing T cells, B cells and macrophages are overrepresented in 
the lung of aged PSGL-1
-/-
 female mice 
Analysis of the resident lung immune system in WT and PSGL-1
-/-
 females revealed that the 
percentages of T and B cells producing IFN-γ were already higher (FigureS R14A and R14B) in young 
PSGL-1
-/-
 females than in WT, becoming statistically significant in aged mice. IL-10
+
 T cells were 
reduced in PSGL-1
-/-
 lungs, and IL-17
+
 T and B cell subpopulations were similar between WT and 
PSGL-1
-/-
 females (Figures R14A and R14B). 
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Figure R14. Cytokine production 
by pulmonary T and B cells of 
WT and PSGL-1
-/-
 mice. (A) 
Percentage of T lymphocytes 
producing IL-10, IFN-γ, IL-17 in 3 
and >18-month-old WT and PSGL-
1
-/-
 female mice. (B) Percentage of 
B lymphocytes producing IL-10, 
IFN-γ, IL-17 in 3 and >18-month-
old WT and PSGL-1
-/-
 mice. *P < 
0.05 by 2-tailed Student’s t test. 
 
Moreover, the percentage of IFN-γ+ cells in the alveolar macrophage subset was higher in young 
PSGL-1
-/-
 females than in WT (Figures R15B and R15C) and a higher percentage of IFN-γ+ interstitial 
macrophages was found in aged PSGL-1
-/-
 females as compared with WT mice (FigureS R15B and 
R15D). 
 
According to the increased IFN-g production by T cells, B cells and alveolar or interstitial 
macrophages, increased frequencies of P-sel and E-sel expressing cells were found among lung 
endothelial cells (CD45
neg
CD31
+
) (Figures R16B-D). However, the percentage of total endothelial cells 
was similar between WT and PSGL-1
-/-
 female mice (Figure R16A). 
 
 
Figure R15. IFN-γ production by 
pulmonary DC and macrophage 
populations of WT and PSGL-1
-/-
 
mice. (A) Dot plot illustrating the 
classification of macrophage and 
DC populations according to the 
expression of F4/80 and CD11c 
markers. (B) Percentage of 
macrophages and dendritic cells 
producing IFN-γ in 3 and >18-
month-old WT and PSGL-1
-/-
 
mice. (C) Representative dot plots 
showing IFN- producing AM and 
MФ of aged WT and PSGL-1-/- 
female mice. AM: alveolar 
macrophages; DC: dendritic cells; 
MФ: interstitial macrophages.*P < 
0.05, **P < 0.01 by 2-tailed 
Student’s t test. 
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2. Evaluation of PAH development in P-selctin deficient mice 
2.1 PAH development and low NO production by lung endothelial cells in aged P-selectin deficient 
female mice 
As PSGL-1 requires binding to P-sel for triggering the tolerogenic program, we wondered whether 
P-selectin knockout mice (P-sel
-/-
) also presented signs of PAH. To achieve this issue, follow-up 
transthoracic Doppler echocardiography was performed on WT and P-sel
-/-
 mice at the age of 14, 18 and 
22 months, revealing an increased pulmonary artery pressure detected by a reduction in PAT/ET in 18 
and 22-month aged female PSGL-1
-/-
 mice as compared with WT mice (Figure R17A). This reduction 
was observed in neither WT nor P-sel
-/-
 male mice. At 18 months, 2 out of 5 female P-sel
-/-
 mice had 
died, explaining the decrease in RV wall thickness from 14 to 18 month-old P-sel
-/-
 female mice (Figure 
R17B). 
 
 
Figure R16. Lung endothelial cell expression of P- and E-selectin in WT and PSGL-1
-/-
 
mice. (A) Dot plots showing the gating strategy of CD45
neg
CD31
+
 endothelial cells. (B) 
Representative dot plots of P- and E-selectin expression in lung endothelial cells of aged WT 
and PSGL-1
-/-
 female mice. (C-D) Percentages of lung endothelial cells expressing P-selectin 
(C) or E-selectin (D) of 3 months-old and >18 months-old WT and and PSGL-1
-/-
 female mice. 
*P < 0.05, by 2-tailed Student’s t test. 
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Coinciding with the reduction of PAT/ET, that indicates PAH, diminished levels of NO production 
by lung endothelial cells were found in aged P-sel
-/-
 female mice (Figures R17C-F). As in PSGL-1
-/-
 
mice, reduced percentages of NO
+
 and NO
++
endothelial cells were detected in lung single cell 
suspensions of aged P-sel
-/-
 female mice (Figures R17C, R17D and R17F). Moreover, the mean 
fluorescence intensity for the NO-sensing probe was also reduced in P-sel
-/-
 lung endothelial cells 
(Figure R17E).  
 
Figure R17. Echocardiographic PAH signs and reduced NO production by lung EC in aged P-
sel
-/-
 female mice. (A-B) Longitudinal study of PAT/ET (A) and RV wall thickness (B) in male and 
female WT and P-sel
-/-
 mice at 14, 18 and 22 months of age (n = 5 mice per group). (C-D) 
Percentage of lung endothelial cells producing moderate (C) or high (D) amounts of NO measured 
in 3 and >18-month-old female WT and P-sel
-/-
 mice. (E) Fold change of medium fluorescence 
intensity (M.F.I.) for the NO-sensing probe DAR-4M AM measured in lung endothelial cells of 3 
and >18-month-old female WT and P-sel
-/-
 mice. (F) Representative dot plots representing DAR-
4M AM fluorescent lung endothelial cells (CD45
neg
CD31
+
) from WT and P-sel
-/-
 female mice.  Data 
are expressed as the mean ± SD. *P < 0.05, **P < 0.01 by 2-tailed Student’s t test. 
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3. Impact of P-selectin absence in the immune system homeostasis 
In this thesis, we have previously described that, like PSGL-1
-/-
 female mice, P-sel
-/-
  females 
develop PAH and endothelial dysfunction with aging. As PAH is one of the most severe manifestations 
of connective tissue diseases, we wondered whether P-sel
-/-
 presented some kind of connective tissue-
related disease. 
3.1 Presence of circulating autoantibodies in P-sel
-/-
 mice 
We first analyzed the presence of circulating autoantibodies and found that sera from P-sel
-/-
 mice 
contained anti-cytoplasmic and anti-nuclear autoantibodies with a speckled or mitotic pattern (Figure 
R18A), but not anti-centromere autoantibodies. ELISA identified several extractable nuclear antigens 
(ENAs) recognized by these autoantibodies, including topoisomerase I (Scl-70), U1-RNP, Sm and t-
RNA synthetase (Jo-1) (Figure R18B).  
 
 
 
 
Sera were also positive in the Crithidia assay for anti-dsDNA autoantibodies (Figure R19), a 
hallmark of human lupus erythematosus (3, 32, 33). The anti-Sm, anti-topoisomerase I, and anti-dsDNA 
antibodies could be already detected at 3 months of age. The autoantibodies were co-expressed in the 
same animals and the percentage of mice with autoantibodies increased as a function of age, reaching a 
maximum at 12-18 months (Figure R18B) and decreasing at 18-24 months, especially anti-Sm and anti-
Scl-70 (Figure R18B). The prevalence of anti-dsDNA autoantibodies increased gradually with ageing, 
from 10% in the 3-month-old group to 30% in the 18-24-month-old group (Figure R19).  
Figure R18. Spontaneous generation of autoantibodies related to CTD in P-sel
-/-
 mice. (A) 
Representative immunofluorescence photomicrographs of HEp-2 cells incubated with serum from 2 
independent wild-type (WT) and 2 independent P-sel
-/- 
mice. (B) Percentage of mice positive for 
anti-Sm, RNP, Scl-70 and Jo-1 autoantibodies (n=8-10 animals per group); *p<0.05 by Chi-square 
test.  
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3.2 Augmented splenic reactivity of P-sel
-/-
 mice 
Consistent with this exacerbation of humoral immunity, we observed a remarkable spleen 
enlargement in both male and female 1.5-3-month-old P-sel
-/-
 mice (Figures R20A and R20B), which 
has been described previously in lupus-prone mouse strains (261, 262). Considering the increased 
cellularity and the increased number of splenic B cells of 3 month-old P-sel
-/-
 spleens (Figures R20C 
and R20D), we analyzed by flow cytometry the follicular helper T cell (Tfh), the germinal centre (GC) 
B cell and the plasma cell subsets.  
 
 
 
 
The Tfh cell compartment (CD3
+
CD4
+
PD-1highCXCR5high) was augmented in the spleen of P-
sel
-/-
 mice (Figures R21A-C), with a significant increase in the percentage (Figure R21B) and a tendency 
to increased total numbers (Figure R21C) of Tfh cells in knockout mice. 
 
Figure R20. Splenomegaly in 
P-sel
-/-
 mice. (A) Photograph 
of representative spleens of 
1.5-3-month-old WT and P-
sel
-/- 
mice. (B) Spleen 
weight/body weight ratio of 
female and male 1.5-3-month-
old WT and P-sel
-/- 
mice (n=6 
mice per group). (C-D) Total 
number of cells (C) and B 
cells (D) per spleen of WT and 
P-sel
-/- 
mice. *p<0.05; 
***p<0.005 by Student’s two-
tailed t-test. Bars show the 
mean±standard deviation 
(SD). 
Figure R19. Presence of anti-dsDNA 
autoantibodies in P-sel
-/-
 mice. 
Percentage of mice positive for anti-
dsDNA autoantibodies (n=8-10 mice 
per group); *p<0.05 by Chi-square test. 
Immunofluorescence photomicrographs 
of C. luciliae incubated with serum of a 
P-sel
-/- 
mouse (right panel). 
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Likewise, both GC B cells and plasma cells were overrepresented in the spleen of young P-Sel
-/- 
mice (Figures R22A-E). A significant increment in the frequency of GC B cells (CD11c
-
B220
+
FAS-
L
+
GL-7
+
) was found in P-sel
-/-
 mice (Figures R22A and R22B), whereas the total numbers were 
moderately increased (Figure R22C). In the case of the plasma cells (CD19
+
B220
-
IgD
-
CD138
+
), which 
are the antibody secreting cells, a tendency to increased percentage of plasma cells was detected 
(Figures R22D and R22E). Altogether, these data indicate a more reactive state of P-sel
-/-
 spleens. 
 
 
Figure R22. Increased 
percentages of GC B cells and 
plasma cells in P-sel
-/-
 mice. (A) 
Representative dot plots of 
germinal center (GC) B cells in 
1.5-3-month-old male WT and P-
sel
-/- 
mice. (B-C) Percentage (B) 
and total number (C) of splenic  
GC B cells in 1.5-3-month--old 
male WT and P-sel
-/- 
mice. n = 4-6. 
(D) Representative dot plots of 
splenic plasma cells in 1.5-3-
month-old male WT and P-sel
-/- 
mice. (E) Percentage of splenic 
plasma cells 1.5-3-month-old male 
WT and P-sel
-/- 
mice. n = 
4.*p<0.05; ***p<0.005 by 
Student’s two-tailed t-test. Bars 
show the mean±standard deviation 
(SD).  
Figure R21. Increased percentage 
of Tfh cells in P-sel
-/-
 mice. (A) 
Representative dot plots of follicular 
T helper (Tfh) cells in 1.5-3-month-
old male WT and P-sel
-/- 
mice. (B-
C) Percentage (B) and total number 
(C) of splenic in 1.5-3-month-old 
male WT and P-sel
-/- 
mice. n = 6. 
*p<0.05; ***p<0.005 by Student’s 
two-tailed t-test. Bars show the 
mean±standard deviation (SD). 
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3.3 Altered circulating immune cell homeostasis in P-sel
-/-
 mice  
Taking the increased splenic reactivity of P-sel
-/-
 mice, the distribution of peripheral blood 
leukocyte population was checked (Figures R23 and R24). 1.5-3-month-old male mice showed an 
important increase in the B cell compartment of P-Sel
-/-
 mice (Figure R24A). In contrast, the T cell 
compartment was reduced, mainly because of the decrease in the CD4
+
 T cell subset (Figure R24A). 
Additionally, the monocytic population was also reduced in P-sel
-/-
 animals (Figure R24A). However, in 
aged animals, only the granulocyte compartment was augmented (Figure R24B). 
 
 
 
 
 
 
 
 
 
 
Figure R23. Peripheral blood immune system characterization in P-sel
−/−
 mice. Gating 
strategy followed for the identification of the different immune cell subpopulations: B cells, 
CD4
+
 T cells, CD8
+
 T cells, granulocytes, monocytes, cDC and pDC. 
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Then, we studied the cytokine production of circulating immune populations and we found a 
reduction in the percentage of IL-10
+
 producing cells in 1.5-3-month-old P-Sel
-/-
 mice, that was 
statistically significant among cDC and close to statistical significance in the B cell population (Figures 
R25A and R25B). Peripheral blood mononuclear cells of >18-month-old mice showed a statistically 
significant reduction in the percentage of IL-10
+
 producing monocytes and B cells (Figure R25B).  
 
 
 
 
 
 
Regarding T cells, a significant reduction in the TCD4
+
IL-10
+
 compartment was found in 1.5-3 
month-old P-sel
-/-
 mice (Figures R26A and R26B), whereas WT and P-sel
-/-
 mice showed no difference 
Figure R25. IL-10 
production by peripheral 
immune cells of P-sel
−/−
 
mice. (A) Representative 
dot plots of IL-10
+
 cDC of 
1.5-3-month-old WT and 
P-sel−
/− mice. (B-C) 
Percentage of IL-10
+
 cDC, 
pDC, monocytes, 
granulocytes and B cells in 
1.5-3-month-old (B) and > 
18-month-old (C) WT and 
P-sel−
/− mice. n = 4. Bars 
represent the mean ± SD. 
*p < 0.05; **p < 0.01; 
***p < 0.005, by Student’s 
two tailed t test. 
Figure R24. Peripheral blood immune system characterization in P-sel
−/−
 mice.  (A-B) Relative 
frequency of peripheral blood leukocyte populations of 1.5–3-month-old (A) and >18 months-old (B) 
WT and P-sel−
/− mice. In all cases, n = 4 mice per group. Bars represent the mean ± SD. *p < 0.05; **p < 
0.01; ***p < 0.005, by Student’s two tailed t test. 
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in the percentage of IL-17
+
 T cells (Figures R26A and R26B). On the other hand, the IL-17
+
 CD4
+
 
(Th17) population was increased in aged P-sel
-/-
 mice (Figure R26C). 
 
 
 
 
 
3.4 Altered naïve/effector T lymphocyte balance in the spleen of P-sel
-/-
 mice  
To evaluate the effector and memory state of T cells, we analyzed the expression of CD62L and 
CD44 on splenic CD4
+
 and CD8
+
 T cells (Figures R27A and R27B). Naïve (CD62L
+
CD44
neg
) and 
central memory (CD62L
+
CD44
+
) subsets were decreased in 1.5-month-old P-sel
-/-
 CD8
+
 splenic T cells, 
while effector (CD62L
neg
CD44
neg
) CD8
+
 T cells were augmented (Figures R27A and R27B). In the case 
of splenic CD4
+
 T cells, the naïve subset was severely diminished in the P-sel
-/-
, while the effector 
(CD62L
neg
CD44
neg
) and effector memory (CD62L
neg
CD44
+
) compartments were highly increased 
(Figures R27A and R27B). Regarding >18-month-old mice, as compared with the WT mice, we found 
an increment in the percentages of CD8
+ 
and CD4
+ 
effector T lymphocytes, and a decrease of CD4
+ 
central memory T lymphocytes in P-sel
-/-
 mice (Figure R27A). 
 
 
 
 
Figure R26. IL-10 and IL-17 production by T cells in P-sel
−/−
 mice. (A) Representative dot 
plots of IL-10 and IL-17 producing CD4
+
 T cells in 1.5-months old WT and P-sel−
/− mice. (B-C) 
frequency of IL-10 and IL-17 producing CD4
+
 and CD8
+
 T lymphocytes, in 1.5-month-old (B) 
and > 18-month-old (C) WT and P-sel−
/− mice. n = 4. Bars represent the mean ± SD. *p < 0.05, 
by Student’s two tailed t test. 
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3.5 Altered skin homeostasis in P-sel
-/-
 mice 
Regarding the skin, one of the main organs affected in human lupus, we did not find significant 
changes in the different immune subpopulations in 1.5-3-month-old mice (Figures R28, R29 and R30) 
except from an increased percentage of pDC in P-sel
-/-
 animals (Figure R29A). The frequencies of 
CD11b
+
 macrophages, cDC (Figure R28B and R28C), B cells (Figure R29B) and T cells (Figure R30C) 
remained unaltered in 1.5-3-month-old P-sel
-/-
 mice. 
 
 
Figure R27. Spleen T cell characterization in P-sel
−/−
 mice. (A) Phenotyping of CD4
+
 and CD8
+
 
splenic T lymphocytes according to the expression of the naïve/memory/effector markers L-selectin 
(CD62L) and CD44 in 1.5–3-month-old and > 18 month-old WT and P-sel−/− mice. (B) Representative 
dot plots showing the distribution of 1.5–3-month-old mice splenic populations according to the 
expression of L-selectin and CD44. In all cases, n = 4 mice per group. Bars represent the mean±SD. *p < 
0.05; **p < 0.01; ***p < 0.005, by Student’s two tailed t test. 
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However, in aged animals, we found a reduced population of macrophages (Figures R28A and 
R28B), and a significant increment in the pDC (Figure R29A) and T cell subsets (Figures R30A and 
R30C). Among T cells, we did not find any difference in the percentage of gamma/delta (γδ) T cells 
either at 1.5-3 months or at >18 months (Figures R30B and R30D).  
 
 
 
 
 
 
 
Figure R29. Frequency of pDC and B cells in the skin of P-sel
−/−
 mice.  (A-B) Relative frequency 
of skin pDc (A) and B cells (B) of 1.5–3-month-old and > 18-month-old WT and P-sel−/− mice. In all 
cases, n = 4 mice per group. Bars represent the mean±SD. *p < 0.05; **p < 0.01; ***p < 0.005, by 
Student’s two tailed t test. 
Figure R28. Frequency of CD11b+ and cDC in the skin of P-sel
−/−
 mice. (A) Representative 
dot plots comparing the frequency of CD11b
+
 macrophages and DC between aged WT and and 
P-sel−
/− mice. (B-C) Relative frequency of skin CD11b
+
 macrophages (B) and cDC (C) of 1.5–
3-month-old and > 18-month-old WT and P-sel−
/− mice. In all cases, n = 4 mice per group. Bars 
represent the mean±SD. *p < 0.05; **p < 0.01; ***p < 0.005, by Student’s two tailed t test. 
                                                                                         RESULTS 
 
68 
 
 
 
 
We also studied the cytokine production of the different populations, and only the >18-month-old 
P-sel
-/-
 mice showed a reduction in the percentages of IL-10
+
 macrophages, cDC, pDC and B cells 
(Figures R31A and R31B). Accordingly, aged knockout mice displayed an increased IL-17
+
 (Figures 
R32A and R32B) and a reduced FOXP3
+
 (Figures R32C and R32D) T cell populations. We did not find 
significant differences in cytokine production in 1.5-3-month-old mice. 
 
Figure R31. Frequency of T 
cells in the skin of P-sel
−/−
 
mice. (A) Percentage of IL-10
+
 
macrophages (CD11b
+
), 
conventional dendritic cells 
(cDC), plasmacytoid DC (pDC) 
and B cells, in 1.5–3-month-old 
and >18-month-old WT and P-
sel−
/− mice. (B) Representative 
dot plots of IL-10
+
 cDCs in >18-
month-old WT and P-sel−
/− 
mice. *p < 0.05; **p < 0.01 by 
Student’s two tailed t test. n = 6 
mice per genotype. 
Figure R30. Frequency of T cells in the skin of P-sel
−/−
 mice. (A-B) Representative dot plots 
comparing the frequency of T cells (A) and γδ T cells (B) between aged WT and and P-sel−/− 
mice. (C) Relative frequency of skin T cells in 1.5–3-month-old and > 18-month-old WT and P-
sel−
/− mice. (D) Relative frequency of skin γδ T cells in 1.5–3-month-old and > 18-month-old 
WT and P-sel−
/− mice. In all cases, n = 4 mice per group. Bars represent the mean±SD. **p < 
0.01, by Student’s two tailed t test. 
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4. Characterization of a lupus-like syndrome in P-selectin-deficient mice 
Given the presence of circulating autoantibodies and the dermal and systemic immune system 
deregulation in P-sel
-/-
, with an imbalance between the regulatory (IL-10
+
 cells and FOXP3
+
 T cells) and 
the pro-inflammatory compartment (IL-17
+
 T cells), we searched for tissue damage in target organs of 
SLE: skin, kidney and lung. 
4.1 Histological alterations in the skin of P-sel
-/-
 mice  
Histological examination of the skin revealed that, compared with WT counterparts, male and 
female P-sel
-/-
 mice had a reduced hypodermal layer (lipoatrophy), frequently infiltrated by leukocytes 
(panniculitis) (Figure R33). We also found that, apart from a remarkable infiltration, >18-month-old P-
sel
-/-
 mice presented hyperproliferation of the epidermal layer (acanthosis), accumulation of keratin in 
the corneal layer (hyperkeratosis) and keratin plugs inside hair follicles (Figure R34), described as 
murine lupus-like lesions (263-266). 
 
 
 
Figure R32. Frequency of T cells in the skin of P-sel
−/−
 mice. (A) Percentage of IL-17
+
 T cells in 
1.5–3-month-old and >18-month-old WT and P-sel−/− mice. (B) Representative dot plots of IL-17+ T 
cells in >18-month-old WT and P-sel−
/− mice. (C) Percentage of FOXP3
+
 T cells in 1.5–3-month-old 
and >18-month-old WT and P-sel−
/− mice. (D) Representative dot plots of FOXP3
+
 T cells in >18-
month-old WT and P-sel−
/− mice. *p < 0.05, by Student’s two tailed t test. n = 6 mice per genotype. 
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.  
 
 
 
 
 
 
Quantification of these observations by measuring the total thickness of the dermal, epidermal and 
corneal layers of WT and P-sel
-/-
 mice showed that male and female P-sel
-/-
 mice presented an enlarged 
dermis and incremented width of the epidermal and corneal layers in P-sel
-/-
 mice that was more evident 
when mice were > 18 months-old (Figure R35).  
 
Figure R34. Lupus 
dermatitis in aged P-sel
−/−
 
mice. Photomicrographs of 
representative H&E-stained 
skin sections (10x) of 23-
month-old male and female 
WT or P-sel
−/−
 mice. Black 
arrowheads point acanthosis. 
Black arrows show 
hyperkeratosis. n = 8-10. Scale 
bars represent 200 µm. 
 
Figure R33. Lupus 
dermatitis in young P-sel
−/−
 
mice. Photomicrographs of 
representative H&E-stained 
skin sections (10x) of 1.5-3-
month-old male and female 
WT or P-sel
−/−
 mice. Black 
arrowheads point incipient 
panniculitis. n = 8-10. Scale 
bars represent 200 µm. 
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Accordingly, the severity of the skin lesions estimated by grading scale was higher in young P-Sel
-/-
 
mice (female P-sel
-/-
 0.30±0.48 vs female WT 0.00±0.00; male P-sel
-/-
 0.73±1.44 vs male WT 
0.00±0.00) and remarkably more severe in the aged mice (>18 months-old: female P-sel
-/-
 3.13±1.81 vs 
female WT 0.40±0.52; male P-sel
-/-
 4.57±4.83 vs male WT 0.00±0.00) (Figure R36).  
 
 
4.2 Exposure to UV-B radiation 
The exposure of 3-4-month-old female WT and P-sel
-/-
 to UV radiation provoked an extensive 
dermatitis in P-sel
-/-
 mice with ulcers in the exposed skin, but not in WT counterparts (Figure R37A). 
Histopathological analysis revealed a severe epidermal lesion in female P-sel
-/-
 mice consisting of 
acanthosis and hyperkeratosis, immune infiltration in the dermis, and deposition of extracellular matrix 
components in the hypodermal layer (Figure R37B). Consequently, the severity of the lesions was 
significantly higher in UV-irradiated P-sel
-/-
 mice (P-sel
-/-
 7.25±2.99 vs WT 3±1.41) (Figure R37C).  
Figure R36.  Semiquantitative 
evaluation of the lupus 
dermatitis of P-sel
−/−
 mice. 
Pathological activity index of 
skin samples obtained from WT 
and P-Sel−
/− mice. Graphs show 
the mean index value (red bar). n 
= 8-10. *p < 0.05; **p < 0.01; 
***p < 0.001 by Student’s two 
tailed t test.  
Figure R35. Quantification of dermal layers in WT and P-sel
-/-
 mice. (A-C) Quantification 
of dermis (A), epidermis (B) and corneal layer (C) width of WT and P-sel−
/− mice. n = 8-10. 
Bars represent mean±SD. *p < 0.05; **p < 0.01; ***p < 0.001 by Student’s two tailed t test.  
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4.3 Histological alterations in the kidney of P-sel
-/-
 mice  
Histological examination of kidney tissue of WT and P-sel
-/-
 mice showed that P-sel
-/-
 mice 
presented some glomerular alterations. Among them, we found a high proportion of glomeruli with a 
dilated Bowman’s space (Figure R38A). Additionally, some glomeruli presented tubularization of the 
Bowman’s capsule (Figure R38A). We also found some sclerotic glomeruli (Figure R38A). 
 
 
 
 
 
 
Figure R38. Glomerular damage 
and immune infiltration in kidney 
of P-sel
−/−
 mice. (A) Representative 
photomicrographs (40x) of H&E 
stained kidney glomeruli of WT and 
P-sel
−/−
 mice. Yellow arrow denotes 
a dilated Bowman’s space. Yellow 
arrowhead denotes a tubularized 
glomerulus. (B) Photomicrographs 
(10x) of kidney sections showing an 
immune infiltrate (yellow 
arrowhead) in P-sel
−/−
 mice. (C) 
Prevalence of immune infiltration in 
WT and P-sel
−/−
 mice (n = 8–10 
mice per group). *p < 0.05; **p < 
0.01; ***p < 0.005 by Chi-square 
test. 
Figure R37. UV-induced lupus 
dermatitis in young P-sel
−/−
 mice. (A) 
Lesions developed in the back of UV-
irradiated 3-month-old female WT and 
P-Sel−
/− mice. (B) Photomicrographs 
(5x) of representative H&E-stained skin 
sections of UV-irradiated 3-month-old 
female WT and P-Sel−
/− mice. n = 4 
mice per genotype. Representative 
experiment of three independent 
replicates. Scale bars represent 500 µm. 
(C) Pathological activity index of skin 
samples obtained from UV irradiated 3-
month-old female WT and P-Sel−
/− mice. 
Graph shows the mean index value (red 
bar). *p < 0.05; **p < 0.01; ***p < 
0.005 by Student’s two tailed t test.  
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We found also interstitial infiltrates in P-sel
-/-
 mice (Figure R38B), whose prevalence increased 
from 40% at 1.5-3 months of age to 84% in mice older than one year (12-24 months-old) (Figure 
R38C), while only 20% of aged WT and none of the young WT mice presented interstitial infiltration. 
We also observed that 30% of the 3-month-old P-sel
-/-
 mice had infarcted foci (Figure R39A). The 
prevalence of infarcts increased as mice grew older (Figure R39B), reaching to 60% of females and 
80% of males in the >18-month-old population of P-sel
-/-
 mice. 
 
 
 
4.4 Biochemical analysis of renal failure parameters.  
Although not statistically significant, we found increased levels of urea and creatinine and lower 
levels of albumin in the sera from >18-month-old P-sel
-/- 
mice compared with equivalent WT mice 
(Figure R40). Conversely, the analysis of urine revealed that 13% and 38% of P-sel
-/-
 mice had 
proteinuria and hematuria, respectively (Figure R41A). 
 
 
 
 
 
Figure R40. Biochemical analysis of renal failure parameters in P-sel
−/−
 mice. (A-C) 
Quantification of albumin (A), urea (B) and creatinine (C) in serum of WT and P-sel
-/-
 mice. n 
= 4 per group. Non significant differences were found by two-tailed Student’s t test. 
Figure R39. Renal infarcts 
in P-sel
−/−
 mice. (A) 
Masson’s trichrome-stained 
kidney sections of WT and P-
sel
−/−
 mice (10x), showing 
healthy and infarcted tissue 
(red arrowhead), respectively. 
(B) Prevalence of renal 
infarcts in WT and P-sel
−/−
 
mice (n = 8–10 mice per 
group). *p < 0.05; **p < 0.01; 
***p < 0.005 by Chi-square 
test. 
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Moreover, ENA+ P-sel
-/- 
mice showed higher levels of proteinuria and hematuria than ENA 
negative knockout mice (Figure R41B), indicating the existence of an association between high titers of 
autoantibodies and more severe renal disease. 
 
4.5 Immunocomplex deposition in the skin and kidney of P-sel
-/-
 mice 
We found deposits of immune complexes in the glomerular basal membrane in 100% of female and 
25% of male P-sel
-/-
 mice older than 18 months, but only in 25% of WT females and none in WT males 
(Figure 42). In the skin, we found deposits of immune complexes in 60% of male and 40% of female P-
sel
-/-
 mice over 18 months of age but in none of WT mice (Figure R42). 
 
 
 
 
 
 
Figure R42. Urine evaluation in P-sel
−/−
 
mice. Representative photomicrographs of 
anti-IgM+IgA+IgG-stained kidney (upper 
panels) and skin (lower panels) sections 
(20x). n = 4–5 mice per group. Yellow 
arrow points to the dermoepidermal 
junction. 
Figure R41. Urine evaluation in P-sel
−/−
 mice. (A) Frequency of proteinuria and hematuria in 
>12-month-old WT and P-Sel−
/− mice (n = 14–16 mice per group). **p < 0.01 by Chi-square 
test. (B) Association of higher levels of proteinuria and hematuria with the presence of serum 
extractable nuclear antigens (ENAs). Grey bars show the mean. *p < 0.05; **p < 0.01 by two-
tailed Student’s t test 
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4.6 Histological alterations in the lungs of P-sel
-/-
 mice 
P-sel
-/-
 mice presented structural lung abnormalities consisting of alveolar wall thickening and 
increased interstitial cellularity due to leukocyte infiltration (Figure R43A), characteristics of 
nonspecific interstitial pneumonia (NSIP). At 1.5-3 months of age, NSIP was found in approximately 
30-40% of P-sel
-/-
 but not in WT mice (Figure R43B). At 12-24 months, the presence of NSIP among P-
sel
-/-
 mice rose to 75% in females and 53% in males, while among WT animals, NSIP was found only in 
15% of 12-24-month-old females (Figure R43B). At 1.5-3 months, NSIP was focal and restricted to a 
single lobule (Figure R43C). With ageing, the prevalence of NSIP increased and the lesion became 
generalized (affecting all the lung lobes) and more severe, increasing the presence of diffuse NSIP when 
mice were 12-24 months old (Figures R43A and R43C). CD45
+
 immune cell infiltration was confirmed 
by immunohistochemistry (Figure R44). 
 
 
 
 
 
Figure R43. Nonspecific interstitial pneumonia (NSIP) in P-sel
-/-
 mice. (A) Representative 
photomicrographs of H&E-stained lung sections from WT and P-sel
-/-
 mice. (B) Incidence of 
NSIP in WT and P-sel
-/-
 mice (n = 8-12 mice per group); ***p<0.005 by Chi-square test. (C) 
Incidence of NSIP according to the distribution a severity of the inflammation.  
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4.7 Reduced lifespan in P-sel
-/- 
mice.  
To analyze the impact of the autoimmune syndrome progression during the lifespan of P-sel
-/-
 mice, 
we carried out a survival study with 20 WT and 23 P-sel
-/-
 mice from 6 to 100 weeks of age. P-sel
-/-
 
mice started to die at week 47 and we observed a peak of mortality at around week 80. At week 100, 
90% of WT mice remained alive whereas only 61% of the P-sel
-/-
 mice were still alive (Figure R45).  
 
 
5. Analysis of P-selectin expression in human cutaneous lupus 
To assess the relevance of P-sel in human lupus, we compared by immunohistochemical staining 
the expression of P-sel in endothelial cells of the dermal vessels of skin biopsies obtained from 
cutaneous lupus erythematosus (cLE)  patients and healthy controls. We identified all the blood vessels 
(CD31
+
) in the whole biopsy and classified them into three categories depending on the expression of P-
sel (Figures R46A and R46B): 1) unstained, 2) partially stained, and 3) fully stained.  
We found a deep reduction of fully stained blood vessels in cLE biopsies, which were accompanied 
by a remarkable elevation in the percentage of negative vessels for P-sel expression (Figure R46C).  
 
 
 
Figure R45.  Increased mortality of P-
sel
-/-
 mice. Kaplan-Meier survival curves 
for WT and P-sel−
/− mice (n = 20 WT and 
23 P-sel−
/− mice); p=0.033 by Mantel-Cox 
test.  
 
 
Figure 44. Immune cell infiltration 
in the lung of P-sel
-/-
 mice. 
Representative photomicrographs 
(40x) of anti-CD45-stained lung 
sections of WT and P-sel
-/- 
mice. 
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We also found unspecific binding to infiltrating leukocytes, that has been already reported by other 
authors (267, 268). 
 
Moreover, the expression of endothelial P-sel in human biopsies was also tested by 
immunofluorescence. The levels of P-sel were reduced in dermal small blood vessels of patients of cLE 
compared with age-matched controls (Figure R47). 
Figure R46. Decreased expression of P-sel in human cLE biopsies. (A) Representative 
photomicrographs (20x) of anti-CD31 and anti-P-sel stained skin biopsies of healthy donors and SLE 
patients. Black arrows point blood vessels. (B) 200% magnification of representative blood vessels from 
the original images are represented. (C) Classification and quantification of CD31
+
 dermal blood vessels 
according to the expression level of P-sel (healthy controls, n = 4; cLE patients, n = 4); bars show the 
mean±SD. **p < 0.01; ***p < 0.001 by Student’s two tailed t test. 
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Figure R47. Decreased expression levels of P-sel in human cLE biopsies. (A) Representative 
photomicrographs (63x) of anti-CD31 (green) and anti-P-sel (red) stained skin biopsies of healthy donors 
and cLE patients. White scale bars represent 50 µm. Healthy controls, n = 4; cLE patients, n = 4. 
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Discussion 
 
PSGL-1 binding to endothelial selectins during the extravasation processes may trigger different 
regulatory signals depending on the immune cell type that contacts the endothelium. In dendritic cells 
and monocytes, PSGL-1 absence drives to the upregulation of costimulatory molecules such as MHC-II, 
CD80 and CD86, that together with the reduced expression of IL-10, TGF-β and IDO would lead to 
higher rate of differentiation of naïve T cells to pro-inflammatory effector T cells (16, 43). In the case of 
T cells, lack of PSGL-1 signalling would lead to decreased levels of the T cell exhaustion marker PD-1 
(62) and increased TCD8
+
 proliferation, contributing to a more robust and long-lasting immune 
response.  
In this thesis, a relevant role for adhesion molecules in vascular and immune homeostasis has been 
highlighted. PSGL-1 arises as an immune checkpoint regulator for the immune system, controlling both 
dendritic cell (43, 58, 269) and T cell function (62). In this context, lack of PSGL-1 signalling on 
leukocytes lowers the threshold for autoimmunity, leading to an increased systemic humoral response 
with an augmented germinal centre reaction, and to a local cellular Th1 or Th17, depending on the 
target organ and the mouse model analyzed. Both PSGL-1
-/-
 and P-sel
-/-
 mice develop autoimmune 
syndromes sharing the reduction of the immunomodulatory cytokine IL-10 and lung endothelial 
dysfunction   that ultimately leads to PAH and premature death. 
Much less is known about the implication of P-sel in endothelial cell biology. Some studies pointed 
out that rolling and transmigration of neutrophils and monocytes could modify the integrity of 
endothelial cell tight junctions by the regulation of intracellular Ca
2+
 concentration (270, 271). Later, it 
was described that, in histamine-activated HUVEC, monoclonal antibodies against P-sel were able to 
trigger an increment of intracellular Ca
2+
 levels (272), indicating that P-sel can transduce external 
signals into second messenger in the cytoplasm.  Recent studies with Pentraxin-3 (PTX3), a soluble 
glycoprotein that binds P-sel in vitro and in vivo, demonstrated that PTX3 can interfere with PSGL-1/P-
sel (72, 273). The administration of PTX3 to wild-type mice induced endothelial dysfunction and 
increased blood pressure (273). Interestingly, PTX3 circulating levels were elevated in patients with 
hypertension (273) and SSc (274). These data suggest that, after binding to PSGL-1, signals transduced 
by P-sel on endothelial cells may by implicated in the maintenance of the correct endothelial function 
and integrity. The absence of P-sel signaling, due to either lack of PSGL-1 or P-sel itself, may lead to 
the endothelial dysfunction observed in both knockout models. 
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1. Pulmonary arterial hypertension and PSGL-1/P-selectin interaction 
1.1 Spontaneous development of PAH in PSGL-1 and P-selectin deficient mice 
PAH is a particularly severe, life-threatening complication of some CTDs that leads to RV 
remodeling, right heart failure and premature death  (110). Although great effort has been invested in 
searching for an efficient treatment for PAH, no curative therapy is available. In the present study, we 
highlight the importance of leukocyte-endothelium interactions for the maintenance of vascular 
homeostasis and protection against PAH. Deficiency for leukocytic PSGL-1, which interacts with P-sel 
and E-sel on the surface of activated endothelium, induces reduced pulmonary AT2R expression and 
endothelial dysfunction characterized by reduced vasodilation response due to impaired NO production, 
coinciding with an increase in pulmonary AngII concentrations. This impairment in endothelial function 
drives to vascular remodeling, which would elevate flow resistance and lead to PAH and, ultimately, to 
premature death in mice. Our work contributes to the identification of new pathways and possible 
pharmaceutical targets for the treatment of PAH, which is crucial to improve the survival and the long-
term prognosis of patients with this disease. 
The increase in relative vessel wall area in lung vasculature has been described as a histological 
marker of PAH in both animal models and patients with PAH (77, 80, 110), and is considered as one of 
the first events occurring in the development of PAH (81, 114). We did not observe plexiform lesions 
(endothelial cell proliferation that reduce the blood vessel lumen) or intimal fibrosis in the lung of 
PSGL-1
-/- 
mice, although these lesions do not appear in all the rodent models of PAH (275). In general 
terms, the animal models that reproduce the plexiform arteropathy are “second hit” models such as 
MCT + pneumonectomy in young rats (under 200 g of weight) and Sugen 5416 + hypoxia in rats and 
mice; or knock-in genetic models such as IL-6- and S100A4-overexpressing transgenic mice (275). Of 
note, only female PSGL-1
-/-
 and P-sel
-/-
 develop PAH with aging. In humans, PAH is a rare disease with 
a high sex-bias. In fact, women are more frequently affected by PAH (2:1) (75, 76). PSGL-1
-/-
 male 
mice also presented lung vascular remodeling, but did not show either reduced expression of AT2R nor 
PAT/ET ratio. Other mouse models such as hypoxia or MCT did not reproduce the sex bias of PAH, 
showing similar affectation of male and female mice (275), thus constituting a relevant 
pathophysiological feature of PSGL-1
-/-
 and P-sel
-/-
 CTD-associated PAH mouse models. 
The vascular remodeling observed in PSGL-1
-/-
 mice might cause an increase in the lung vascular 
resistance to blood flow, the main consequence of which would be the elevation of the pressure in the 
pulmonary artery. Transthoracic Doppler echocardiography is a non-invasive diagnostic tool for patients 
with suspected PAH, giving information not only on diagnosis but also providing further information on 
the causes or consequences of the PAH (110, 276). This method has been validated for estimating 
pulmonary artery pressure (PAP) in patients with PAH and in rat and mouse models of PAH (277-279), 
and is becoming increasingly more relevant in the study of murine models of heart diseases (280). Using 
this echocardiography modality, and in accordance with the pulmonary vessel remodeling, we found a 
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reduced PAT/ET ratio in the pulmonary artery of PSGL-1
-/-
 female mice. Our results from a longitudinal 
study show a consistently increased pulmonary artery pressure detected by a reduced PAT/ET ratio in 
PSGL-1
-/-
 female mice from 3 months of age consistent with lung vascular remodeling, suggesting that 
PSGL-1
-/-
 mice are already susceptible to PAH at young age. 
1.2 Exposure to hypoxia and endothelial damage in PSGL-1
-/-
 female mice 
Chronic hypoxia killed 40% of PSGL-1
-/-
 females during the first days of treatment, suggesting that 
some PSGL-1
-/-
 mice are unable to adapt to reduced O2 pressure. WT and surviving PSGL-1
-/- 
females 
showed increased pulmonary artery pressure during the first week of hypoxia and both groups were able 
to partially compensate pulmonary artery pressure (increase PAT/ET ratio) during the next two weeks of 
exposure, although the recovery was slower for PSGL-1
-/-
 mice. However, WT and PSGL-1
-/-
 littermates 
showed a similar Fulton index and loss of NO-dependent relaxation, indicating that some hypoxia-
induced changes are not additive to the endothelial dysfunction provoked by PSGL-1 absence after the 
3-week exposure to low oxygen pressure. These data suggest that the endothelial dysfunction promoted 
by hypoxia in WT mice is already present in PSGL-1
-/-
 females. Importantly, and in accordance with 
this hypothesis, we found that lung of aged PSGL-1
-/-
 females, in addition to having a lower expression 
of AT2R, showed increased AngII concentration and reduced NO production by endothelial cells, which 
might explain the higher contractility and reduced relaxation capability of lung arteries at this age, 
ultimately leading to elevated flow resistance and hence to increased pulmonary pressure and reduced 
PAT/ET.  
1.3 Implication of the RAAS in the development of PAH by PSGL-1
-/-
 female mice 
Molecular systems implicated in the control of vascular tone, such as ET-1, AngII and NO, have 
been described to be altered in several animal models and in patients with PAH (77, 110, 160). Thus, 
hypoxic and MCT-treated rats showed increased AngII and AT1R levels (159, 174, 281), and patients 
with iPAH showed higher levels of pulmonary AngII due to increased activity of ACE, as well as 
increased expression and signaling of AT1R, resulting in augmented VSMC proliferation (282). 
Inhibitors of the RAAS have been proven to have an effect in reducing mPAP and other PAH signs in 
some animal models and also in pilot studies with small patient cohorts, underscoring the role of RAAS 
in the pathology of PAH. For example, treatment with losartan (AT1R antagonist) or captopril (inhibitor 
of ACE) was able to reduce mPAP, RV hypertrophy and lung vascular remodeling in rats exposed to 
hypobaric hypoxia for 14 days (169, 282). Furthermore, treatment with captopril showed a clear effect 
in reducing PAP in some studies, whereas in others captopril was unable to lower mPAP (160).  
Increased levels of AngII II are associated with the downregulation of miR-204 in PASMC (81). 
The reduction in the expression of miR-204 induces the upregulation and activation of STAT3, which in 
turns promotes PASMC proliferation and increases resistance to apoptosis (283). Moreover, the 
expression of miR-204 is decreased in both patients with PAH and MCT-treated rats (283). According 
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to these data, high AngII levels could directly induce vascular remodeling in aged PSGL-1
-/-
 mice 
through the downregulation of miR-204. However, young female PSGL-1
-/-
 mice did not present higher 
AngII titers in the lung, but showed reduced expression levels of AT2R, suggesting that the balance 
between AT1R/AT2R might be responsible for the lung vascular remodeling, modulating the expression 
of miR-204. 
NO is a critical regulator of vascular homeostasis, not only by modulating vascular tone, but also by 
controlling VSMC proliferation and migration as well as leukocyte adhesion to the endothelium (103, 
110). We found reduced NO production by PSGL-1
-/-
 lung endothelial cells in aged females, but similar 
expression levels of eNOS. However, differences in eNOS activity due to changes in the post-
translational modifications could account for the reduced NO levels of PSGL-1
-/-
 lung endothelial cells 
(284). It has been previously reported that reduced levels of NO can trigger vascular remodeling, with 
increased proliferation of VSMC (174-177). However, in young female PSGL-1
-/-
, pulmonary vascular 
remodeling was not associated with decreased NO production by lung endothelial cells, suggesting that 
other mechanisms could be mediating the first steps of endothelial dysfunction in PSGL-1
-/-
 mice. The 
reduced expression levels of AT2R may account for an increased vascular tone and maintained 
vasoconstriction, and may contribute to the proliferation of the VSMC, as it was described to occur in 
patients with PAH (168, 171, 285). 
The increased levels of pulmonary AngII found in aged PSGL-1
-/-
 female mice might be explained 
by either an enhanced activity of ACE, which has been previously reported for patients with PAH and 
animal models (282, 286), or an overexpression/overactivity of chymase. Mast cell chymase, expressed 
mainly in kidney and heart tissue and also in endothelial cells, is an enzyme that cleaves both 
angiotensin(1-12) and angiotensinogen into AngII (164-166). It can be released by mast cell 
degranulation, and might account for the elevated AngII levels not only in inflammatory conditions such 
as atherosclerosis but also in heart failure (179). Interestingly, the chymase-dependent increase of 
cardiac AngII is related to aging (165) and aged PSGL-1
-/-
 mice are massively infiltrated by immune 
cells, as previously reported (58).  
1.4 Relationship between PAH, AngII and inflammation 
 Also, it has been reported that an increase in AngII could lead to eNOS uncoupling, which results 
in reduced NO production (287). In addition, several reports have highlighted the relevant role of 
inflammation and the immune system in endothelial dysfunction (275, 287, 288).  In this context, 
vascular dysfunction in aortic endothelial cells can be mediated by inflammatory monocytes and NK 
cells producing IFN-γ and IL-12 in an AngII-dependent manner (287, 288). A similar mechanism could 
be operating in the pulmonary vasculature of female PSGL-1
-/-
 mice, in which aging increases IFN-γ 
production in macrophages, B cells and T cells, and AngII pulmonary levels that can account for the 
endothelial dysfunction and eNOS uncoupling with the ensuing reduction in the endothelial NO. 
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Inflammation has emerged as a pivotal contributor to the development of PAH (151, 289, 290). 
Perivascular infiltration of mononuclear immune cells has been reported in almost all animal models, 
especially in rodents subjected to chronic hypoxia or MCT administration, and in IL-6 knock-in 
transgenic mice (275). Additionally, the upregulation of chemokines (CCL-2, CCL-5, RANTES, 
fractalkine) and pro-inflammatory cytokines (IL-6, IL-1, IFN-γ) has been described in patients with 
severe PAH (77, 146, 147, 291-293). In the case of CTD-associated PAH, it has been proposed that 
autoantibodies (anti-U1-RNP and anti-dsDNA) forming immune complexes could trigger the 
upregulation of endothelial ligands for leukocytes, such as ICAM-1 or E-sel, initiating or contributing to 
lung vasculopathology (294). Interestingly, PSGL-1
-/-
 mice showed increased expression of P-sel and E-
sel in lung endothelial cells. The activation of lung endothelium has been previously described for PAH 
patients. Plasma levels of soluble (s)P-sel, sE-sel, sICAM-1 and sVCAM-1 were reported to be higher in 
patients with PAH than in healthy controls (147, 151, 295). In another study, treatment with 
prostacyclin reduced the levels of sP-sel in a cohort of mainly iPAH patients(296). Similar results have 
been reported in MCT-induced PAH in rats, which present increased expression of pulmonary ICAM-1, 
VCAM-1 and E-sel (289). Moreover, it has been demonstrated by immunohistochemistry that infusion 
of AngII was able to induce the expression of P-sel, E-sel, ICAM-1 and VCAM-1 in mesenteric 
arterioles and venules in rats (178). Nevertheless, in this thesis we describe that the absence of P-
selectin also drives to PAH development with ageing, coinciding with the increase of AngII in the lungs 
and reduction of NO production by pulmonary endocelial cells. 
 
2. SLE-like syndrome in P-selectin knockout mice 
In this thesis, we show that the absence of P-sel breaks immune tolerance and triggers the 
development of a progressive autoimmune lupus-like syndrome displaying most of the features 
previously described in lupus-prone mice. Importantly, we show that human biopsies of cLE have 
reduced number of P-sel stained vessels. 
 2.1 Autoantibody production and autoimmunity in P-sel
-/-
 mice 
Given that PSGL-1 deficient mice develop a scleroderma-like syndrome, we have analyzed whether 
the absence of P-sel, main ligand of PSGL-1, also triggered autoimmunity. We found  the production of 
anti-dsDNA and anti-Sm autoandibodies, hallmarks of SLE in humans (297). Interestingly, anti-Sm and 
anti-dsDNA autoantibodies are detected at an early age in P-sel
-/-
 mice. Despite the frequency of anti-
dsDNA autoantibodies is not as high as in MLR/lpr strain, P-sel
-/-
 and MLR/lpr mice are the two only 
murine models of spontaneous SLE expressing both anti-Sm and anti-U1 RNP. The frequency of 
appearance of anti-Sm in our cohort of mice is comparable with the prevalence described in humans (5-
30% in patients versus 8-37% in P-sel
-/-
 mice) (226, 228). It has also been reported that, in MLR/lpr 
mice, the frequency of a speckled autoantibody pattern in Hep-2 cell assay reaches 25% (261). This 
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pattern is traditionally associated with anti-ribonucleoprotein and anti-Sm antibodies, and, in our mice 
the combined frequency of mice bearing Sm or RNP is quite similar (31%). The high rate of 
autoantibodies probably favours, as in human SLE, the formation and deposition of immune complexes 
in anatomic sites characterized by high blood pressure including capillaries of the skin and glomeruli, 
among others. Accordingly, we found a high rate of immune complexes deposition in renal glomeruli 
and skin of aged P-sel
-/- 
which is a characteristic of both human and murine lupus (56, 228, 263, 298).  
To understand the autoantibody production, we studied the impact of P-sel absence in the 
homeostasis of the immune system and analyzed the effector and regulatory leukocyte subsets in blood, 
spleen and skin of WT and P-sel deficient mice, and found that the immune homeostasis is altered in P-
sel
-/-
 mice. We found higher percentage of germinal center B cell, plasma cells and Tfh subpopulations, 
indicating more reactive germinal centers in the spleen of young animals. The frequency of Tfh cells has 
been correlated with the number of plasma cells and disease activity in human SLE (299). In addition, 
SLE patients with active disease showed a marked expansion in plasma cells, and the frequency of 
circulating plasma cells correlated with disease activity scores, anti-dsDNA titers and serum 
immunoglobulin production (300, 301). 
We also found reduced circulating CD4
+ 
T cells and monocytic populations, in association with an 
increment in the B cell compartment in P-sel
-/-
 mice. Interestingly, at young age we found a reduction in 
the circulating tolerogenic IL-10-producing cDC and monocyte subsets, as well as in the IL-10
+
 B cell 
compartment (Breg), whose reduction has been recently implicated in the development of human SLE 
(302). Although young P-sel
-/-
 mice did not have alterations in Th1, Th2 and Th17 subsets, reduction in 
the IL-10-producing CD4
+
 T cells implies an imbalanced Teff/Treg ratio, as it has been described for 
both murine and human SLE (303). This reduction in IL-10
+
 cells could be explained by the lack of 
tolerogenic signal supplied by P-sel interaction with PSGL-1, as previously described (16). Remarkably, 
we found a shift through a Th17 response with aging in the blood of P-sel
-/-
 mice coinciding with the 
worsening of the disease. Increased serum levels and numbers of Th17 cells have been found in patients 
with SLE, and the levels of serum IL-17 correlate with disease activity. In fact, IL-17 promotes the 
recruitment of T cells, monocytes and granulocytes to the inflammatory foci, activates B cells and 
contributes to the synthesis of IgG and anti-dsDNA autoantibodies (232). Accordingly, we report that, 
in P-sel
-/-
 mice, the effector subpopulations of splenic CD4
+
 and CD8
+
 T cells were increased, with the 
consequent and relevant reduction among the naïve subset. SLE patients show reduced numbers of 
CD45RA
+
 naive T cells and increased numbers of CD45RO
+
 memory T cells (304). Interestingly, it has 
been described that mouse CD8
+
CD122
+
 Treg have a central memory phenotype (CD44
high
CD62L
high
) 
(305) that could explain the reduction of this compartment in the P-sel
-/-
 mice, as well as the reduced 
populations of IL-10 producing T cells. In addition, this subset has been described to regulate T cell 
homeostasis and to suppress both autoimmune and alloimmune responses (305).  
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 2.2 Lupus dermatitis: immune and histological alterations 
Given that the skin is one of the main organs affected in lupus patients, we have also analyzed 
whether the dermal immune system is also altered in P-sel
-/-
 mice. Our results indicate that dermal pDC 
subpopulation is increased from youth and that aging also increases the T cell subset. Of note, increased 
numbers of pDC have been reported to infiltrate skin lesions of cLE patients, associated with an 
elevation in the production of IFN-α (306). pDC are the most important IFN-α producing cells in the 
organism, and IFN-α binds to its receptor in almost all leukocyte populations, inducing the expression of  
a large number of genes. This cluster of genes is called "lupus signature", and it has been found in 
patients with SLE and most of SLE murine models (286, 117). 
Importantly, coinciding with the appearance of the lupus skin lesions, we have found a high 
reduction in dermal IL-10 producing immune cells and FOXP3
+
 Treg population, together with an 
important expansion of IL-17 producing T lymphocytes. Our data are in accordance with the expanded 
Th17 population and reduced Treg subset described for human patients (307). IL-17 producing cells can 
infiltrate skin, lung, and kidneys of SLE (235, 308-310) and contribute to organ damage by enhancing 
the recruitment of T cells, monocytes and neutrophils to the inflammed tissue. IL-17 can synergize with 
BAFF and IL-6 to activate B cells and potentiate the production of autoantibodies (242). It has been 
described that different mechanisms can be implicated in the breakage of immunological tolerance (311) 
and our work indicates that a defect in P-sel expression and function, probably through PSGL-1 
interaction, could be implicated in maintaining the immune system immunity/tolerance balance. 
Dysfunction or low expression of P-sel and PSGL-1 could favor the use of alternative molecules for 
leukocyte extravasation and consequently, the loss of the tolerogenic signal triggered by PSGL-1/P-sel 
interaction. This hypothesis is supported by the fact that the number of SlanDCs is increased in skin 
biopsies of SLE and cLE patients (133). SlanDCs do express PSGL-1, but the SLAN glucidic group 
abrogates its binding to P-sel, conferring them a highly proinflammatory phenotype. Indeed, SlanDCs 
are strong producers of TNF-α, IL-12 and IL-23 after TLR7 or TLR8 signaling. SlanDC have found to 
play an important role in the pathogenesis of other autoimmune and inflammatory diseases, such as 
Crohn's disease, rheumatoid arthritis, , and psoriasis. In psoriatic skin, SlanDCs are important mediators 
of Th1 and Th17 responses (134).   
The skin histological features described in this work for aged P-sel
-/-
 mice, such as hyperkeratosis, 
acanthosis and immune cell infiltration, have been previously reported for MRL/lpr mice (264, 312). 
According to our data, it has been reported that P-sel or PSGL-1 deficiency in MRL/lpr mice results in 
an increase in the severity of dermatitis and glomerulonephritis (56). Apart from the lupus dermatitis 
features, in P-sel deficient mice, the overall frequency of dermal  immunoglobulin deposition reached 
50%, which is lower than that mentioned for MRL/lpr mice (313). However, in a model of cutaneous 
lupus induced by 5-fluorouracil plus UV-B light, the prevalence of IgG deposition in the 
dermoepidermal junction was only 66% (314). 
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We observed that UV irradiation could accelerate and intensify the appearance of the above 
mentioned  lesions in 3-4-month-old P-sel
-/-
 mice, whereas non lupus-prone strains are considered to be 
resistant to UV-induced DNA damage (297). Interestingly, more than 50% of SLE patients show 
photosensitivity (297, 315, 316).  
2.3 Lupus nephritis and lung involvement 
Glomerulonephritis and renal involvement are the most prevalent manifestations in SLE patients 
(40–70%) (183). Leukocyte infiltration is a common feature shared by humans and lupus-prone mice 
(317). Accordingly, we found leukocytic infiltration in both glomerular and tubulointerstitial 
compartments of the kidney in P-sel
-/-
 mice. Additionally, P-sel
-/-
 mice presented a high frequency of 
renal infarcts, indicating vascular dysfunction. Renal and systemic vasculitis have been described in 
patients and experimental models of SLE (256) and, together with immune infiltration, have been 
associated with loss of renal function (318). In agreement with our data, mice deficient for P-sel are 
more sensitive to glomerulonephritis (56, 319). 
Anti-DNA autoantibodies have been traditionally associated with lupus nephritis (38). 
Accumulating data have suggested that anti-dsDNA could directly bind to different resident renal cells, 
such as podocytes and mesangial cells, and also to extracellular matrix components, inducing 
inflammation and imparing normal cell function (320). The increase in anti-dsDNA prevalence in P-sel
-
/- 
coincides with the worsening and the increased frequency of immune infiltration and ischemic events. 
Several autoantibodies have been reported to be potentially implicated in lupus nephritis pathogeny, 
such as anti-Ro/SSA and Sm, among others (181, 321, 322). Accordingly, the prevalence of Sm in our 
cohort of P-sel
-/-
 mice rose to its maximum at 12-18 months. Moreover, we found an association 
between renal dysfunction and presence of circulating autoantibodies, with higher levels of proteinuria 
and hematuria among ENA
+ 
P-sel deficient mice. 
B cells and T cells have been shown to play a critical role in lupus nephritis (323). Th1 and Th17 
responses have been reported in lupus nephritis (232, 324). Depletion of B cells could prevent from 
lupus nephritis in MRL/lpr lupus prone mice (325). The pathogenic effect of B cells in lupus nephritis is 
not limited to autoantibody production, as MRL/lpr unable to secrete antibodies were still able to 
develop lupus nephritis (326). 
According to our results, it has been reported that the lack of either P-sel or PSGL-1 in murine 
lupus models enhances both skin and renal inflammation (56) and  that the tissue expression of P- and 
E-sel in the MLR/lpr mice was not upregulated regarding the non-inflammed MRL
+/+
 mice (327), giving 
further evidence that lack of selectins may potentiate the autoimmune phenotype in established mouse 
models of SLE, or that at least they are not necessary for the immune infiltration in both kidney and 
skin. 
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Lung involvement is more frequent in P-sel
-/-
 mice than in SLE patients (183). In mice, more than 
70% of P-sel
-/- 
animals showed NISP, whereas lung involvement appears in up to 13% of patients with 
SLE (183). There is abundant evidence indicating that increased P-sel expression in lung post-capillary 
venules is crucial for leukocyte extravasation, particularly for neutrophils (328, 329). Considering the 
relevance of P-sel/PSGL-1 interaction for leukocyte trafficking in the lung, it would be reasonable to 
assume that the absence of P-sel could lead to the severe impairment of lung immune homeostasis found 
in P-sel
-/-
 mice. Consistent with a previous report in MRL/lpr mice (330), mononuclear immune cell 
infiltrates were dispersed among the perivascular, peribronchiolar and the alveolar areas in P-sel
-/-
 mice 
and promoted NSIP, whose severity increased with ageing. 
 As the lupus-like syndrome developed by P-sel deficient mice is progressive, together with the 
main features of the lupus-like syndrome, such as the severe and widespread form of NSIP, the highest 
frequency of renal infarcts, the most aggressive skin manifestations and immunoglobulin depositions, 
we found a rapid decrease of the body weight (caquexia) followed by sudden death when animals are 
over 18 months of age. 
 2.4 P-selectin implication in the pathology of human lupus erythematosus  
According with our data in P-sel
-/-
 mice, we found a reduction in the expression of P-sel in the 
dermal blood vessels of patients with cLE. This important result does not concur with the higher levels 
of P-sel that have been traditionally associated with other autoimmune and inflammatory diseases like 
glomerulonephritis, rheumatoid arthritis, psoriasis or atopic dermatitis (41, 268) (331). It has been 
reported that TNF-α and LPS can downregulate human P-sel. The increased levels of TNF-α in the 
serum of SLE patients are consistent with the low expression of P-sel that we found in the skin of lupus 
patients.  
In summary, we show that P-sel expression is crucial for the immune system homeostasis and that 
its absence promotes the spontaneous development of a lupus-like syndrome in mice. Accordingly, 
patients with cutaneous lupus showed lower expression of P-sel in the endothelium of dermal vessels, 
suggesting that the reduced expression of P-selcould be implicated in the pathogenesis of this disease. 
As SLE pathogenesis is not well understood and there is not a universally curative treatment for lupus in 
humans, it would be very important to discover new molecules implicated in the development of the 
different forms of this disease that could be used as targets for new treatments. Importantly, our work in 
this thesis will contribute to the understanding of lupus pathogenesis and points that P-sel KO mice 
could be used as a new experimental model for in vivo assays to evaluate new treatments or 
combination of treatments against the progression of the disease that could prevent organ damage 
associated with SLE.  
As a summary, the data presented in this thesis indicates that PSGL-1/P-selectin interaction plays 
an important role in controlling the immune and vascular homeostasis. The absence of either PSGL-1 or 
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P-selectin breaks immune tolerance and leads to the development of autoimmunity. Moreover, breakage 
of immune tolerance by lack of PSGL-1 or P-selectin induces endothelial dysfunction which promotes 
vascular remodeling in lungs and drives to pulmonary arterial hypertension, right ventricle dysfunction 
and death. Thus, this thesis highlights the relevance of leukocyte/endothelial communication and their 
interdependence for maintaining the immune system and cardiovascular homeostasis. 
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Conclusions 
 
1. Female PSGL-1 deficient mice present lung vascular remodeling and incipient increment in the 
pulmonary pressure from 1.5 months.  
2. Female PSGL-1 deficient mice, with aging, develop pulmonary arterial hypertension, associated 
with a reduction in the endothelial nitric oxide-dependent vasodilator response. 
3. Female PSGL-1 deficient mice present reduced expression of the angiotensin II receptor 2 in 
lung lysates, from 1.5-3 months. Aging induces in females an increment in the angiotensin II 
levels in the lung, coinciding with a reduction in nitric oxide production by endothelial lung 
cells. 
4. Aged female PSGL-1 deficient mice show enhanced levels of P-selectin and E-selectin in lung 
endotelial cells, and higher frequencies of IFN-γ producing macrophages, T cells and B cells in 
the lung. 
5. With aging, female P-selectin deficient mice develop non specific interstitial pneumonia and 
pulmonary arterial hypertension, associated with a reduced production of nitric oxide by lung 
endothelial cells. 
6. P-selectin deficient mice showed an increased Th17 circulating population, reduced expression 
of IL-10 by circulating leukocytes, increased splenic reactivity and an increase in the T cell 
effector compartment in the spleen. As a consequence, they develop a severe autoinmune 
syndrome that leads to premature death, characterized by the production of circulating 
autoantibodies related to human connective tissue diseases, incluing anti-dsDNA, and immune 
complex deposition. These mice  
7. P-selectin deficient mice show lupus dermatitis, with a reduction in the percentages of IL-10 
producing immune cells, a diminished Treg population and an augmented population of IL-17 
producing T lymphocytes in the skin. 
8. P-selectin deficient mice present lupus nephritis, with increased frequency of inflammatory 
infiltrates and ischemic events, and elevated levels of proteinuria and hematuria.  
9. Patients with cutaneous lupus erythematosus present lower expression of P-selectin in dermal 
blood vessels. Futhermore, they show a reduced number of vessels expressing P-selectin in the 
skin. 
10. Leukocyte/endothelial interaction through PSGL-1 and P-selectin is crucial for the maintenance 
of immune and vascular homeostasis, acting as a barrier for autoimmunity and pulmonary 
hypertension.  
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Conclusiones 
 
1. Los ratones hembra deficientes en PSGL-1 presentan una remodelación de los vasos sanguíneos 
del pulmón y un aumento incipiente de la presión pulmonar desde los 1,5 meses de edad. 
2. Los ratones hembra deficientes en PSGL-1, con el envejecimiento, desarrollan hipertensión 
arterial pulmonar, asociada a una menor respuesta vasodilatadora dependiente de óxido nítrico 
endotelial. 
3. Los ratones hembra deficientes en PSGL-1 presentan reducida la expresión del receptor 2 de la 
angiotensina II en lisados pulmonares, desde los 1,5-3 meses de edad. El envejecimiento induce 
en las hembras el aumento de la concentración de AngII en el pulmón, coincidiendo con la 
disminución en la producción de óxido nítrico por las células endoteliales pulmonares. 
4. Las hembras envejecidas que carecen de PSGL-1 muestran niveles elevados de P-selectina y E-
selectina en las células endoteliales pulmonares y un mayor porcentaje de macrófagos, 
linfocitos T y linfocitos B productores de IFN-γ en el pulmón. 
5. Las hembras deficientes en P-selectina desarrollan, con el envejecimiento, neumonia intersticial 
no específica e hipertensión arterial pulmonar, asociada a una menor producción de óxido 
nítrico por las células endoteliales pulmonares. 
6. Los ratones deficientes en P-selectina muestran un aumento de la población Th17 circulante, 
una reducción en la expresión de IL-10 por parte de los leucocitos de sangre periférica, mayor 
reactividad y aumento la población de linfocitos T efectores en el bazo. Como consecuencia, 
desarrollan un síndrome autoimmune severo que conduce a una muerte prematura, caracterizado 
por la producción de autoanticuerpos circulantes relacionados con enfermedades humanas de 
tejido conectivo, incluidos anti-dsDNA y depósito de inmunocomplejos. 
7. Los ratones deficientes en P-selectina presentan dermatitis lúpica, con una reducción en los 
porcentajes de células que expresan IL-10, una disminución de la población de Treg disminuida 
y un aumento de linfocitos productores de IL-17 en la piel. 
8. Los ratones deficientes en P-selectina muestran nefritis lúpica, con mayor frecuencia de 
infiltrados inflamatorios y eventos isquémicos, y elevados niveles de proteinuria y hematuria. 
9. Los enfermos con lupus cutáneo presentan menor expresión de P-selectina en los vasos de la 
piel y, además, tienen reducido el número de vasos que expresan P-selectina. 
10. La interacción leucocito/endotelio a través de PSGL-1y P-selectina es muy importante para el 
mantenimiento de la homeostasis del sistema inmune y el sistema vascular, actuando como una 
barrera frente a la autinmunidad y la hipertensión pulmonar. 
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P-Selectin preserves immune 
tolerance in mice and is reduced  
in human cutaneous lupus
Rafael González-Tajuelo1, Javier Silván1,*, Alicia Pérez-Frías1,*, María de la Fuente-Fernández1, 
Reyes Tejedor2, Marina Espartero-Santos1, Esther Vicente-Rabaneda3,4, Ángeles Juarranz4, 
Cecilia Muñoz-Calleja2, Santos Castañeda3, Carlos Gamallo5 & Ana Urzainqui1
Mice deficient in P-Selectin presented altered immunity/tolerance balance. We have observed that 
the absence of P-Selectin promotes splenomegaly with reduced naïve T cell population, elevated 
activated/effector T cell subset, increased germinal center B and Tfh populations and high production 
of autoreactive antibodies. Moreover, 1.5-3-month-old P-selectin KO mice showed reduced IL-
10-producing leukocytes in blood and a slightly reduced Treg population in the skin. With aging 
and, coinciding with disease severity, there is an increase in the IL17+ circulating and dermal T cell 
subpopulations and reduction of dermal Treg. As a consequence, P-Selectin deficient mice developed 
a progressive autoimmune syndrome showing skin alterations characteristic of lupus prone mice and 
elevated circulating autoantibodies, including anti-dsDNA. Similar to human SLE, disease pathogenesis 
was characterized by deposition of immune complexes in the dermoepidermal junction and renal 
glomeruli, and a complex pattern of autoantibodies. More important, skin biopsies of cutaneous 
lupus erythematosus patients did not show increased expression of P-Selectin, as described for other 
inflammatory diseases, and the number of vessels expressing P-Selectin was reduced.
Selectins (E-, L- and P-Selectin) mediate leukocyte rolling during their extravasation through interactions of their 
N-terminal lectin domains with a sialyl Lewis x (sLex) capping structure on leukocytic P-Selectin glycoprotein 
ligand-1 (PSGL-1)1,2. P-Selectin is stored in the α -granules of platelets and Weibel-Palade bodies of endothelial 
cells, and is rapidly mobilized to the membrane upon activation by complement, oxygen-derived free radicals 
or thrombin3–6, without requiring new protein synthesis. Additionally, TNF, IL-1β , or LPS increase also murine 
P-Selectin mRNA and protein in endothelial cells7–10.
Systemic lupus erythematosus (SLE) is a chronic, inflammatory autoimmune disease characterized by the 
production of autoantibodies against double strand DNA (dsDNA) and nuclear antigens, immune complex 
deposition, complement activation and polyclonal expansion of autorreactive lymphocytes11,12. SLE predomi-
nantly affects women (6–10:1 ratio of women to men) in the childbearing years12,13. Clinical manifestations of 
SLE include inflammation of the skin and internal organs, which are translated into non-specific symptoms like 
fever, arthralgia, skin rashes and anemia12. P-Selectin levels are elevated in the urine of SLE patients and correlate 
with disease severity14. Genome-wide linkage studies in humans have suggested an important role for P-Selectin 
in SLE. Indeed, the P-Selectin gene is located in the SLE linkage region on human chromosome 1 (1q23)15,16. 
Moreover, variations in the upstream region of P-Selectin are a risk factor for SLE, and two risk alleles have 
been identified potentially affecting the transcription of P-Selectin and the binding to P-Selectin glycoprotein 
ligand-1 (PSGL-1)15, the main ligand for P-Selectin expressed on all leukocyte subsets, and also a ligand for E- 
and L-Selectin3,17–19.
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P-Selectin/PSGL-1 axis is involved in the generation of regulatory T (Treg) cells20. PSGL-1 null (Psgl-1−/−) 
mice have altered tolerance/immunity balance in the colonic lamina propria and skin, and spontaneously develop 
an autoimmune syndrome similar to human scleroderma21,22. Experimental disease models indicate that although 
mice lacking P-Selectin, E-Selectin or both are significantly protected from neutrophil-dependent injury5,23,24, 
selectin deficiency induced disease exacerbation in models of glomerulonephritis or collagen-induced arthri-
tis, suggesting a protective role for endothelial P-Selectin in inflammation5,25,26. Numerous murine models of 
SLE have been described such as MRL/MpJfaslpr (MRL/lpr), BSXB and NZB mice crossed with NZW strains 
(NZB/W)27, characterized by high levels of circulating autoantibodies, systemic vasculitis, lymphadenopathy, 
splenomegaly, skin and renal lesions and early death due to renal dysfunction, hypertension and spontaneous 
hemorrhage27,28. Studies performed with this SLE experimental models described that P-Selectin deficiency in 
lupus-prone mice resulted in more rapid development of glomerulonephritis and dermatitis and earlier death29 
and that P-Selectin levels appear elevated in the urine of lupus-prone mice14.
Given all these data, we sought to determine whether P-Sel−/− mice develop a connective tissue-related auto-
immune syndrome sharing some characteristics with Psgl-1−/− mice.
Results
Presence of circulating autoantibodies and augmented splenic reactivity in P-Sel−/− mice. Sera 
from P-Sel−/− mice contained anti-cytoplasmic and anti-nuclear autoantibodies with a speckled or mitotic pattern 
(Fig. 1a), but not anti-centromere autoantibodies. ELISA identified several antigens recognized by these autoan-
tibodies, including topoisomerase I (Scl-70), U1-RNP, Sm and t-RNA synthetase (Jo-1) (Fig. 1b). Sera were also 
positive in the Crithidia assay for anti-dsDNA autoantibodies (Fig. 1c), a hallmark of human lupus erythemato-
sus1,3,5, whereas none of the WT sera were positive in the same conditions. The anti-Sm, anti-topoisomerase I, and 
anti-dsDNA antibodies could be already detected at 3 months of age. The autoantibodies were co-expressed in 
the same animals and the percentage of mice with autoantibodies increased as a function of age, reaching a max-
imum at 12–18 months (Fig. 1b) and decreasing at 18–24 months, especially anti-Sm and anti-Scl-70 (Fig. 1b). 
The prevalence of anti-dsDNA autoantibodies increased gradually with ageing, from 10% in the 3-month-old 
group to 30% in the 18–24-month-old group (Fig. 1c). Consistent with this exacerbation of humoral immunity, 
we observed a remarkable spleen enlargement in both male and female 1.5-3-month-old P-Sel−/− mice (Fig. 1d), 
which has been described previously in lupus-prone mouse strains30,31. Considering the increased cellularity of 3 
month-old P-Sel−/− spleens (Fig. 1d, lower panel), we analyzed the germinal centre (GC) B cell and the follicular 
helper T cell subsets (Tfh). We found an increase in both lymphocytic populations, indicating a more reactive 
state of P-Sel−/− spleens (Fig. 1e,f).
Figure 1. Spontaneous generation of autoantibodies related to connective tissue autoimmune diseases 
in P-Sel−/− mice. (a) Representative immunofluorescence photomicrographs of HEp-2 cells incubated with 
serum from 2 independent wild-type (WT) and 2 independent P-Sel−/− mice. (b) Percentage of mice positive 
for anti-Sm, RNP, Scl-70 and Jo-1 autoantibodies (n = 8–10 animals per group); *p < 0.05 by Chi-square test. 
(c) Percentage of mice positive for anti-dsDNA autoantibodies (n = 8–10 animals per group); *p < 0.05 by Chi-
square test. Immunofluorescence photomicrographs of C. luciliae incubated with serum of a P-Sel−/− mouse 
(right panel). (d) Photograph of representative spleens of 3-month-old WT and P-Sel−/− mice (upper panel). 
Spleen weight/body weight ratio of female and male 3-month-old WT and P-Sel−/− mice (middle panel) (n = 6 
mice per group). Total number of cells per spleen of WT and P-Sel−/− mice (lower panel). (e,f) Percentage of 
splenic follicular T helper (Tfh) cells (e) and germinal center (GC) B cells (f) in 3-month-old male WT and 
P-Sel−/− mice. *p < 0.05; ***p < 0.005 by Student’s two-tailed t-test. Bars show the mean ± standard deviation 
(SD).
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Immune homeostasis imbalance in P-Sel−/− mice blood and spleen. The study of the peripheral 
blood leukocyte populations of 1.5-3-month-old male mice showed an important increase in the B cell compart-
ment of P-Sel−/− mice. In contrast, the T cell compartment was reduced, mainly due to the decrease of the CD4+ 
T cell subset. Additionally, the monocytic population was also reduced in P-Sel−/− animals (Fig. 2a).
We studied the cytokine production of the circulating immune populations and we found a reduction in the 
percentage of IL-10+ producing cells of 1.5-3-month-old P-Sel−/− mice, that was statistically significant among cDC 
and CD4+ T lymphocytes and close to the statistical signification in the B cell population (Fig. 2b,c, left panels). 
Circulating leukocytes of > 18-month-old mice showed a statistically significant reduction in the percentage of 
IL-10+ producing monocytes and B cells (Fig. 2d, left and middle panels). Interestingly, the IL-17+ CD4+ (Th17) 
population was increased in aged P-Sel−/− mice (Fig. 2d, right panels).
To evaluate the effector and memory state of T cells, we analyzed the expression of CD62L and CD44 splenic 
CD4+ and CD8+ T cells (Fig. 2e,f). Naïve (CD62L+CD44neg) and central memory (CD62L+CD44+) subsets were 
decreased in 1.5-month-old P-Sel−/− CD8+ splenic T cells, while effector (CD62LnegCD44neg) CD8+ T cells were 
augmented. In the case of splenic CD4+ T cells, the naïve subset was severely diminished in the P-Sel−/−, while 
the effector (CD62LnegCD44neg) and effector memory (CD62LnegCD44+) compartments were highly increased 
(Fig. 2e, upper panels). Regarding > 18-month-old mice, as compared with the WT mice, we found an increment 
in the rates of effector TCD8+ and TCD4+ lymphocytes, and a decrease of central memory TCD4+ lymphocytes 
in P-Sel−/− mice (Fig. 2e, lower panels and 2f).
Immune homeostasis imbalance in the skin of P-Sel−/− mice. Regarding the skin, one of the main 
organs affected in human lupus, we did not find significant changes in the different immune subpopulations 
in 1.5-3-month-old mice, except from an increased percentage of plasmacytoid DC (pDC) in P-Sel−/− animals 
(Fig. 3a, upper panels). However, in aged animals, we found a reduced population of macrophages and a signif-
icant increment in the T cell and pDC subsets (Fig. 3a, lower panels). Among T cells, we did not find any differ-
ence in the percentage of gamma/delta (γ δ ) T cells (Fig. 3a, right panels). We studied the cytokine production of 
the different populations, and only the > 18-month-old P-Sel−/− mice showed a reduction in the percentages of 
IL-10+ macrophages, cDC, pDC and B cells (Fig. 3b, lower panels; Fig. 3c). Accordingly, aged knocked-out mice 
displayed a reduced FOXP3+ (Fig. 3d and e) and an increased Il-17+ T cell populations (Fig. 3f and g). We did not 
found significant differences in cytokine production in 1.5-3-month-old mice.
Histological alterations in the skin of P-Sel−/− mice. Histological examination of the skin revealed 
that, compared with WT counterparts, male and female P-Sel−/− mice had a reduced hypodermal layer (lipoat-
rophy), frequently infiltrated by leukocytes (panniculitis) (Fig. 4a). We also found that, apart from a remarka-
ble infiltration, > 18-month-old P-Sel−/− mice presented hyperproliferation of the epidermal layer (acanthosis), 
accumulation of keratin in the corneal layer (hyperkeratosis) and keratin plugs inside hair follicles (Fig. 4a, 
lower panels), described as murine lupus-like lesions32–35. Quantification of these observations by measuring 
the total thickness of the dermal, epidermal and corneal layers of WT and P-Sel−/− mice showed that male and 
female P-Sel−/− mice presented an enlarged dermis and incremented width of the epidermal and corneal layers in 
P-Sel−/− mice that was more evident when mice were > 18 months-old (Fig. 4b). Accordingly, the severity of the 
skin lesions estimated by grading scale was higher in young P-Sel−/− mice (female P-Sel−/− 0.30 ± 0.48 vs female 
WT 0.00 ± 0.00; male P-Sel−/− 0.73 ± 1.44 vs male WT 0.00 ± 0.00) and remarkably more severe in the aged mice 
(> 18 months-old: female P-Sel−/− 3.13 ± 1.81 vs female WT 0.40 ± 0.52; male P-Sel−/− 4.57 ± 4.83 vs male WT 
0.00 ± 0.00) (Fig. 4c).
The exposure of 3–4-month-old female WT and P-Sel−/− to UV radiation provoked an extensive dermati-
tis in P-Sel−/− mice with ulcers in the exposed skin, but not in WT counterparts (Fig. 4d). Histopathological 
analysis revealed a severe epidermal lesion in female P-Sel−/− mice consisting of acanthosis and hyperkerato-
sis, immune infiltration in the dermis, and deposition of extracellular matrix components in the hypodermal 
layer (Fig. 4e). Consequently, the severity of the lesions was significantly higher in UV-irradiated P-Sel−/− mice 
(P-Sel−/− 7.25 ± 2.99 vs WT 3.00 ± 1.41) (Fig. 4f).
Kidney alterations and deposits of immune complexes in skin and kidneys of P-Sel−/− 
mice. Histological examination of kidney sections of WT and P-Sel−/− mice showed that P-Sel−/− mice 
had a high proportion of glomeruli with a dilated Bowman’s space (Fig. 5a). Additionally, some glomeruli pre-
sented tubularization of the Bowman’s capsule (Fig. 5a). We found also interstitial infiltrates in P-Sel−/− mice 
(Fig. 5b), whose prevalence increased from 40% at 1.5–3 months of age to 84% in mice older than one year 
(12–24 months-old) (Fig. 5c), while only 20% of aged WT and none of the young WT mice presented interstitial 
infiltration.
We also observed that 30% of the 3-month-old P-Sel−/− mice had infarcted foci (Fig. 5d). The preva-
lence of infarcts increased as mice grew older (Fig. 5e), reaching to 60% of females and 80% of males in the 
>18-month-old population of P-Sel−/− mice.
We found deposits of immune complexes in the glomerular basal membrane in 100% of female and 25% of 
male P-Sel−/− mice older than 18 months, but only in 25% of WT females and none in WT males (Fig. 5f). In the 
skin, we found deposits of immune complexes in 60% of male and 40% of female P-Sel−/− mice over 18 months of 
age but in none of WT mice (Fig. 5f).
According to the structural renal damage and the immune complex deposition, we found that 13% of > 18 
months P-Sel−/− mice developed proteinuria, while 38% of P-Sel−/− mice develop hematuria (Fig. 5g).
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Figure 2. Peripheral blood and spleen immune system characterization in P-Sel−/− mice. (a) Relative 
frequency of peripheral blood leukocyte populations of 1.5–3 month-old WT and P-Sel−/− mice.  
(b,d) Percentage of IL-10+ conventional dendritic cells (cDC), plasmacytoid DC (pDC), monocytes, 
granulocytes and B cells; and frequency of IL-10 and IL-17 producing CD4+ and CD8+ T lymphocytes, in 
1.5-month-old (b) and > 18-month-old (d) WT and P-Sel−/− mice. (c) Representative dot plots of IL-10+ cDCs 
and IL-10 and IL-17 producing CD4+ T cells in 1.5-months old WT and P-Sel−/− mice. (e) Phenotyping of 
CD4+ and CD8+ splenic T lymphocytes according to the expression of the naïve/memory/effector markers 
CD62L and CD44 in 1.5–3 months-old (upper panels) and > 18 month-old (lower panels) WT and P-Sel−/− 
mice. (f) Representative dot plots showing the distribution of 1.5–3-month-old mice splenic populations 
according to the expression of L-Selectin and CD44. In all cases, n = 4 mice per group. In all cases, n = 4 mice 
per group. Bars represent the mean ± SD. *p < 0.05; **p < 0.01; ***p < 0.005, by Student’s two tailed t test.
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Figure 3. Characterization of the skin immune system of P-Sel−/− mice. (a) Relative frequency of skin 
leukocyte populations of 1.5–3 month-old and > 18-month-old WT and P-Sel−/− mice. (b) Percentage of 
IL-10+ macrophages (CD11b+), conventional dendritic cells (cDC), plasmacytoid DC (pDC) and B cells, in 
1.5–3-month-old and > 18-month-old WT and P-Sel−/− mice. (c) Representative dot plots of IL-10+ cDCs in  
> 18-month-old WT and P-Sel−/− mice. (d) Percentage of IL-17+ T cells in 1.5–3-month-old and > 18-month-
old WT and P-Sel−/− mice. (e) Representative dot plots of IL-17+ T cells in > 18-month-old WT and P-Sel−/−  
mice. (f) Percentage of FOXP3+ T cells in 1.5–3-month-old and > 18-month-old WT and P-Sel−/− mice.  
(g) Representative dot plots of FOXP3+ T cells in > 18-month-old WT and P-Sel−/− mice. *p < 0.05; **p < 0.01 
by Student’s two tailed t test. n = 6 mice per genotype.
www.nature.com/scientificreports/
6Scientific RepoRts | 7:41841 | DOI: 10.1038/srep41841
Reduced lifespan of P-Sel−/− mice. To analyze the impact of the autoimmune syndrome progression 
during the lifespan of P-Sel−/− mice, we carried out a survival study with 20 WT and 23 P-Sel−/− mice from 6 to 
100 weeks of age. P-Sel−/− mice started to die at week 47 and we observed a peak of mortality at around week 80. 
At week 100, 90% of WT mice remained alive whereas only 61% of the P-Sel−/− mice were still alive (Fig. 5h).
Decreased expression of P-Selectin in SLE skin biopsies. To assess the relevance of P-Selectin in 
human lupus, we compared by immunohistochemical staining the expression of P-Selectin in endothelial cells 
of the dermal vessels of skin biopsies obtained from cutaneous lupus erythematosus (cLE) patients and healthy 
controls. We identified all the blood vessels (CD31+) in the whole biopsy and classified them into three categories 
depending on the expression of P-Selectin (Fig. 6a and b): (1) unstained, (2) partially stained, and 3) fully stained. 
We found a deep reduction of fully stained blood vessels in cLE biopsies, which were accompanied by a remark-
able elevation in the percentage of negative vessels for P-Selectin expression (Fig. 6c). We also found unspecific 
binding to infiltrating leukocytes, that has been already reported by other authors36,37.
Discussion
In this work, we show that the absence of P-Selectin breaks the immune tolerance and triggers the develop-
ment of a progressive autoimmune lupus-like syndrome displaying most of the features previously described 
in lupus-prone mice. Importantly, we show that human biopsies of cutaneous lupus have reduced number of 
P-Selectin stained vessels.
Given that PSGL-1 deficient mice develop a scleroderma-like syndrome, we have analyzed whether 
the absence of P-Selectin, main ligand of PSGL-1, also triggered autoimmunity. We found the production of 
Figure 4. Histological alterations in the skin of P-Sel−/− mice. (a) Photomicrographs (10× ) of hematoxylin 
and eosin (H&E)-stained skin sections of 1.5 month-old (upper panels) and 24-month-old female and male 
WT and P-Sel−/− mice (lower panels). Blue arrowheads show panniculitis. Black arrowheads show acanthosis; 
arrows show hyperkeratosis and keratin plugs. Scale bars represent 200 μ m. (b) Quantification of dermis, 
epidermis and corneal layer width of WT and P-Sel−/− mice. (c) Pathological activity index of skin samples 
obtained from WT and P-Sel−/− mice. (d) Lesions developed in the back of UV-irradiated 3-month-old female 
WT and P-Sel−/− mice. (e) Photomicrographs (5× ) of representative skin sections of UV-irradiated 3-month-
old female WT and P-Sel−/− mice. n = 4 mice per genotype. Representative experiment of three independent 
replicates. Scale bars represent 500 μ m. (f) Pathological activity index of skin samples obtained from UV-
irradiated 3-month-old female WT and P-Sel−/− mice. (b,c,f) Bars show the mean ± SD *p < 0.05; **p < 0.01; 
***p < 0.005 by Student’s two tailed t test. n = 8–10 mice per genotype.
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anti-dsDNA and anti-Sm autoandibodies, hallmarks of SLE in humans38. Interestingly, anti-Sm and anti-dsDNA 
autoantibodies are detected at an early age in P-Sel−/− mice. The high rate of autoantibodies probably favours, 
as in human SLE, the formation and deposition of immune complexes in anatomic sites characterized by high 
blood pressure including capillaries of the skin and glomeruli, among others. Accordingly, we found a high rate 
of immune complexes deposition in renal glomeruli and skin of aged P-Sel−/− which is a characteristic of both 
human and murine lupus29,32,39,40.
To understand the autoantibody production, we studied the impact of P-Selectin absence in the homeostasis 
of the immune system and analyzed the effector and regulatory leukocyte subsets in blood, spleen and skin of WT 
and KO mice, and found that the immune homeostasis is altered in P-Sel−/− mice. We found higher percentage of 
germinal center B cell and Tfh subpopulations, indicating more reactive germinal centers in the spleen of young 
animals as well as reduced circulating TCD4+ and monocytic populations, in association with an increment 
in the B cell compartment. Interestingly, at the young age we found a reduction in the circulating tolerogenic 
IL-10-producing cDC and monocyte subsets, as well as in the IL-10+ B cell compartment (Breg), whose reduction 
Figure 5. Kidney alterations and deposits of immune complexes in skin and kidneys of P-Sel−/− mice.  
(a) Representative photomicrographs (40× ) of H&E-stained kidney glomeruli of WT and P-Sel−/− mice.  
Yellow arrow denotes a dilated Bowman’s space. Yellow arrowhead denotes a tubularized glomerulus.  
(b) Photomicrographs (10× ) of kidney sections showing an immune infiltrate (yellow arrowhead) in P-Sel−/− 
mice. (c) Prevalence of immune infiltration in WT and P-Sel−/− mice (n = 8–10 mice per group). (d) Masson’s 
trichrome-stained kidney sections of WT and P-Sel−/− mice (10× ), showing healthy and infarcted tissue (red 
arrowhead), respectively. (e) Prevalence of renal infarcts in WT and P-Sel−/− mice (n = 8–10 mice per group). 
(f) Representative photomicrographs of anti-IgM+ IgA+ IgG-stained kidney (upper panels) and skin  
(lower panels) sections (20× ). n = 4–5 mice per group. Yellow arrow points to the dermoepidermal junction.  
(g) Frequency of proteinuria and hematuria in > 12-month-old WT and P-Sel−/− mice (n = 14–16 mice 
per group). (h) Kaplan-Meier survival curves for WT and P-Sel−/− mice (n = 20 WT and 23 P-Sel−/− mice); 
p = 0.033 by Mantel-Cox test. (c,e,g) *p < 0.05; **p < 0.01; ***p < 0.005 by Chi-square test.
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has been recently implicated in the development of human SLE41. Although young P-Sel−/− mice did not have 
altered the presence of Th1, Th2 and Th17 populations, reduction in the IL-10-producing CD4+ T cells implies an 
imbalanced Teff/Treg ratio, as it has been described for both murine and human SLE42. This reduction in IL-10+ 
cells could be explained by the lack of tolerogenic signal supplied by P-Selectin interaction with PSGL-1, as previ-
ously described20. Remarkably, we found a shift through a Th17 response with aging in the blood of P-Sel−/− mice 
coinciding with the worsening of the disease, in agreement with the described role of PSGL-1 expression on 
Treg in the attenuation of persistent T cell activation during the immune response43. In fact, IL-17 promotes the 
recruitment of T cells, monocytes and granulocytes to the inflammatory foci, activates B cells and contributes to 
the synthesis of IgG and anti-dsDNA autoantibodies44. Accordingly, we report that, in P-Sel−/− mice, the effector 
subpopulations of splenic CD4+ and CD8+ T cells were increased, with the consequent and relevant reduction 
among the naïve subset. SLE patients show reduced numbers of CD45RA+ naïve T cells and increased numbers 
of CD45RO+ memory T cells45. Interestingly, it has been described that mouse CD8+ CD122+ Treg have a central 
memory phenotype (CD44highCD62Lhigh)46 what could explain the reduction of this compartment in the P-Sel−/− 
mice, as well as the reduced populations of IL-10 producing T cells. In addition, this subset has been described to 
regulate T cell homeostasis and to suppress both autoimmune and alloimmune responses46.
Given that the skin is one of the main organs affected in lupus patients, we have also analyzed whether the 
dermal immune system is also altered in P-Sel−/− mice. Our results indicate that dermal pDC subpopulation is 
increased from youth and that aging also increases the T cell subset. Importantly, coinciding with the appearance 
of the lupus skin lesions, we have found a high reduction in the dermal IL-10 producing immune cells and the 
FOXP3+ Treg population, together with an important expansion of the IL-17 producing T lymphocytes. Our data 
are in accordance with the expanded Th17 population and reduced Treg subset described for human patients47. It 
has been described that different mechanisms can be implicated in the breakage of the immunological tolerance48 
and our work indicates that a defect in P-Selectin expression and function, probably through PSGL-1 interac-
tion, could be implicated in maintaining the immune system immunity/tolerance balance. Dysfunction or low 
expression of P-Selectin and PSGL-1 could favor the use of alternative molecules for leukocyte extravasation and 
consequently, the loss of the tolerogenic signal triggered by PSGL-1/P-Selectin interaction.
The skin histological features described in this work for aged P-Sel−/− mice, such as hyperkeratosis, acanthosis 
and immune cell infiltration, have been previously reported for MRL/lpr mice33,49. According with our data, it 
has been reported that P-Selectin or PSGL-1 deficiency in MRL/lpr mice results in an increase in the sever-
ity of dermatitis and glomerulonephritis29. We observed that UV irradiation could accelerate and intensify the 
appearance of the above mentioned lesions in 3–4-month-old P-Sel−/− mice, whereas non lupus-prone strains 
are considered to be resistant to UV-induced DNA damage38. Interestingly, more than 50% of SLE patients show 
photosensitivity38,50,51.
Glomerulonephritis and renal involvement are the most common manifestations in SLE patients (40–70%)52. 
Leukocyte infiltration is a common feature shared by humans and lupus-prone mice11. Accordingly, we found 
leukocytic infiltration in both glomerular and tubulointerstitial compartments of the kidney in P-Sel−/− mice. 
Additionally, P-Sel−/− mice presented a high frequency of renal infarcts, indicating vascular dysfunction. Renal 
and systemic vasculitis have been described in patients and experimental models of SLE27 and, together with 
immune infiltration, have been associated with loss of renal function53. In agreement with our data, mice deficient 
for P-Selectin are more sensitive to glomerulonephritis29,54. Importantly, as a consequence of the renal damage, we 
found increased prevalence of proteinuria and hematuria in P-Sel−/− mice.
Figure 6. Decreased expression of P-Selectin in human SLE biopsies. (a) Representative photomicrographs 
(20× ) of anti-CD31 and anti-P-Selectin stained skin biopsies of healthy donors and SLE patients (upper panels). 
Black arrows point blood vessels. (b) 200% magnification of representative blood vessels from the original 
images are represented (lower panels). (c) Classification and quantification of CD31+ dermal blood vessels 
according to the expression level of P-Selectin (healthy controls, n = 4; SLE patients, n = 4); bars show the 
mean ± SD. **p < 0.01 by Student’s two tailed t test.
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We also report that the lifespan of P-Sel−/− mice is reduced compared to WT animals, showing an augmented 
death rate at approximately 1 year of age (47 weeks), which is sharply increased at 80 weeks coinciding with dis-
ease worsening. This increased death along P-Sel−/− mice could underestimate the prevalence of some clinical 
observations such as anti-DNA autoantibodies, skin lesions or proteinuria.
Finally, it has been reported that the lack of either P-Selectin or PSGL-1 in murine lupus models enhances 
both skin and renal inflammation29 and that the tissue expression of P- and E-Selectin in the MLR/lpr mice was 
not upregulated regarding the non-inflammed MRL+/+ mice55. Importantly, when analyzed in patients, although 
E-selectin expression was increased in skin biopsies56, according with our data in P-Sel−/− mice, we found a 
reduction in the expression of P-Selectin in the dermal blood vessels of patients with cutaneous lupus. This 
important result does not concur with the higher levels of P-Selectin that have been traditionally associated with 
other autoimmune and inflammatory diseases like glomerulonephritis, rheumatoid arthritis, psoriasis or atopic 
dermatitis37,57,58. It has been reported that TNFα and LPS downregulated human P-Selectin7. The increased levels 
of TNFα in the serum of SLE patients are consistent with the low expression of P-Selectin that we found in the 
skin of lupus patients.
In summary, we show that P-Selectin expression is crucial for the immune system homeostasis and that its 
absence promotes the spontaneous development of a lupus-like syndrome in mice. Accordingly, patients with 
cutaneous lupus showed lower expression of P-Selectin in the endothelium of the dermal vessels, suggesting that 
the reduced expression of P-Selectin could be implicated in the pathogenesis of this disease. As SLE pathogenesis 
is not well understood and there is not a universally curative treatment for lupus in humans, it is very important to 
discover new molecules implicated in the development of the different forms of this disease that could be used as 
targets for new treatments. Our work will contribute to the understanding of lupus pathogenesis, and our future 
research will explore the role of P-Selectin in the development of human lupus and other autoimmune diseases. 
In addition, our work suggests that P-Selectin KO mice could be used as a new experimental model for in vivo 
assays to evaluate new treatments or combination of treatments against the progression of the disease that could 
prevent organ damage associated with SLE.
Methods
Mice. C57Bl/6 (WT) mice (The Jackson Laboratory) and C57Bl/6-P-Sel−/− mice, kindly provided by 
Dr. D. Vestweber (Max Planck Institute for Molecular Biomedicine, Münster, Germany), were maintained at 
the Conventional Animal Facility of the School of Medicine of the Universidad Autónoma de Madrid (UAM) 
(register number ES-28079-0000097). Mice were sacrificed by cervical dislocation, and blood and internal organs 
were extracted for analysis. All experiments and breeding were performed in accordance with national and insti-
tutional guidelines for animal care (EU Directive 2010/63/EU for animal experiments). The experimental pro-
cedures were approved by the Director General de Medio Ambiente of Madrid (Ref: PROEX 69/14 and PROEX 
162/15).
UV radiation protocol. Three month-old WT and P-Sel−/− mice were irradiated with an UVB lamp contain-
ing a set of six tubes (Phillips TL UV, 20 W; Royal Philips Electronics, Amsterdam, Netherlands) (ranging from 
290 nm to 320 nm), being the energy output, at a distance of 15 cm, of 2.5 mW/cm2. Mice received three doses of 
0.306 J/cm2 every other day for a week and an additional dose of 0.12 J/cm2 three days later. Skin was processed 
24 hours after the last dose.
Autoantibody assays. The presence of anti-nuclear antibodies (ANAs), the Crithidia assay for anti-dsDNA 
and the characterization and quantification of circulating autoantibodies were performed as previously 
described22. The cut-off point for positivity on ELISA for a particular autoantibody was determined as the mean 
value (X) plus two standard deviations (SD) obtained from sera of at least 100 WT mice with an age ranging 
from1.5 to 24 months. At least 8 mice per group of age were analyzed.
Histopathological assessment and immunohistochemical (IHC) staining of mouse skin and kid-
ney. Masson’s trichrome staining was performed with the Artisan Gomori’s Green Trichrome Stain kit (Dako; 
Glostrup, Denmark). Images were obtained with a Leica DM2500 light microscope and a Leica DFC450 camera. 
All sections were examined by a pathologist blinded to the sample origin.
Para-midline, upper back skin samples were evaluated blindly to obtain a semiquantitavive measurement by 
assigning a 3-criteria-based score59: acanthosis (0, normal; 1, slight thickening of epidermis; 2 and 3, presence of 
two or three layers of stratum spinosum cells, respectively; 4, presence of four or more layers of stratum spinosum 
cells); hyperkeratosis (0, normal; 1, one layer of keratin; 2, two layer thick of keratin; 3, minimum three-layer thick 
of keratin; 4, minimum three-layer thick of keratin and formation of a keratin’s plug); hypergrannulosis (0, nor-
mal; 1, moderate accumulation of granular dark material in the stratum granulosum; 2 and 3, two or more than 
three layers of granular dark material; 4, three or more layers of accumulated granular dark material overall sec-
tion of skin). Finally, the total pathology score was calculated by adding the resulting values for the three criteria.
The presence of kidney ischemic events (infarcted areas) was assessed in Masson’s trichrome-stained sections.
Skin and glomerular immunoglobulin deposition were evaluated by IHC with an antibody cocktail against 
Fab regions of IgA, IgG, IgM (1/250) (Abcam; Cambridge, UK), following manufacturer’s instructions of the 
Universal LSAB+ Kit Rabbit/Mouse/Goat (DAB+ ) (Dako). At least 5 males and 5 females were evaluated per 
genotype and age.
Urine analyses. Urinary protein and haemoglobin were determined using Combur Test M dipsticks (Roche; 
Basel, Switzerland). The cut-off for positivity in the proteinuria test was the lowest value in P-Sel−/− mice not 
reached by any of the WT mice analyzed.
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Human skin samples. Skin biopsies from 4 chronic/subacute cutaneous lupus erythematosus patients and 
from 4 aged-matched healthy controls were obtained from the Pathology Department, Hospital de la Princesa 
(Madrid, Spain). The investigations were conducted in accordance with the principles of the Declaration of 
Helsinki and were approved by the Clinical Investigation Ethical Committee of the Hospital de la Princesa, 
Madrid, Spain (Register number: PI-654, date of approval 07-02-2013). Informed consent was obtained from all 
the patients and healthy controls.
Immunohistochemistry of human skin sections. Consecutive tissue sections of sun-exposed skin biop-
sies underwent immunohistochemistry with the Dako REAL EnVision Detection System Peroxidase/DAB+ kit 
(Dako), using as primary antibodies anti-human P-Selectin (10 μ g/ml) (R&D Systems; Minneapolis, MN, USA) 
and anti-human CD31 (1/50) (Abcam). The whole biopsies were scouted for blood vessels in a blinded manner. 
Vessels were identified by positive staining by CD31, localized in the consecutive P-Selectin-stained section, and 
classified depending on the expression of P-Selectin as follows: 1) unstained, negative vessels; 2) partially stained; 3) 
fully stained blood vessels.
Flow cytometry. Blood, skin and spleens from 1.5–3 month and > 18 month-old male WT and P-Sel−/− 
were analyzed. Spleens were dissected and mechanically disrupted in PBS 1X, 0.5% BSA, 5 mM EDTA. Skin 
samples were minced into ~1 mm2 pieces and digested with RPMI1640 medium complemented with 1 mg/ml 
collagenase A (Sigma-Aldrich; San Luis, MI, USA), 2.5 mg/ml dispase II (Roche; Basel, Switzerland) and 40 μ g/ml 
DNase (Sigma). Cells were blocked with 1:200 Fc Block (BD Pharmingen; San Jose, CA, USA), labelled with 
the mix of antibodies recognising surface cell markers for 10 minutes at 4 °C and analyzed with a FACSCanto II 
(BD Pharmingen). For intracellular cytokine staining, after surface labelling, cells were fixed/permeabilized by 
15 minute incubation with 2 ml of FACS Lysing Solution (BD Pharmingen), washed, incubated during 30 minutes 
at 4 °C with the cocktail of antibodies directed against intracellular cytokines and analyzed with a FACSCanto II.
Reagents: GL-7-eFLUOR660, CD3e-PE-Cy7 and CD11c-PE-Cy7 (eBioscience, San Diego, CA, USA); 
FAS-L-Biotin, CD3-APC, CD25-APC, CD45R/B220-APC, IFNg-APC, IL-4-APC, IL-17A-APC-Cy7, 
CD45.2-BV421, CD62L-PE and CD11b-FITC (BD Pharmingen); CD4-FITC, CD8a-PerCP, CD44-APC, 
CD8a-FITC, B220-APC-Vio770, MHC II-APC, and MHC II-PE (Miltenyi Biotec, Cologne, Germany); CD4-PE 
(Immunotools, Friesoythe; Germany); CXCR5-PE/Dazzle594, PD-1-BV421, IL-10-PerCP/Cy5.5, Gamma/delta 
TCR-PerCP/Cy5.5 and Streptavidin-PerCP (BioLegend, San Diego, CA, USA).
Gating strategy: in tissues, immune cells were identified as CD45+. CD11c−CD11b+ cells were gated as mono-
cytes (peripheral blood) or macrophages (skin). CD11c+ cells were gated as DC: CD11c+ CD11b+ B220− were 
gated as cDCs; and CD11c+ CD11b−B220+ were gated as pDCs. CD11c−B220+ cells, with low size/complexity 
index were considered B lymphocytes. T lymphocytes were gated as CD3+ cells. Follicular Th cells were gated as 
CD3+ CD4+ PD-1highCXCR5high. Germinal centre B cells were gated as CD11c−B220+ FAS-L+ GL-7+. Gamma/
delta T cells were gated as CD3+γ δ +.
Statistical analysis. Statistical significance between two groups was calculated using two-tailed Student’s 
t test for parametric variables and Mann-Whitney’s U test for nonparametric variables. The chi-squared (df = 1) 
test was used for statistical comparison of frequencies. Mantel-Cox chi-squared (df = 1) test was used to analyze 
survival data. Differences were considered statistically significant with p < 0.05 (*) and highly significant at p < 0.01 
(**) and p < 0.005 (***). All statistical analyses were performed using SPSS 15.0 program (IBM, Armonk, NY, 
USA). Skin pathology score graphic representation was performed with GraphPad Prism 6 (La Jolla, CA, USA).
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Development of an Autoimmune Syndrome Affecting
the Skin and Internal Organs in P-selectin Glycoprotein
Ligand 1 Leukocyte Receptor–Deficient Mice
A. Pe´rez-Frı´as, R. Gonza´lez-Tajuelo, N. Nu´n˜ez-Andrade, R. Tejedor, M. J. Garcı´a-Blanco,
E. Vicente-Rabaneda, S. Castan˜eda, C. Gamallo, J. Silva´n, A. Esteban-Villafruela,
L. Cubero-Rueda, C. Garcı´a-Garcı´a, C. Mun˜oz-Calleja, A. Garcı´a-Diez, and A. Urzainqui
Objective. To define and characterize the progres-
sion of the spontaneous autoimmune disease that devel-
ops in mice in the absence of the leukocyte adhesion
receptor P-selectin glycoprotein ligand 1 (PSGL-1).
Methods. Skin-resident immune cells from PSGL-
1–deficient mice and C57BL/6 control mice of different
ages were isolated and analyzed by flow cytometry.
Biochemical parameters were analyzed in mouse serum
and urine, and the presence of serum autoantibodies
was investigated. Skin and internal organs were ex-
tracted, and their structure was analyzed histologically.
Results. Skin-resident innate and adaptive im-
mune cells from PSGL-1!/! mice had a proinflamma-
tory phenotype with an imbalanced T effector cell:Treg
cell ratio. Sera from PSGL-1!/! mice had circulating
autoantibodies commonly detected in connective tissue–
related human autoimmune diseases. Biochemical and
histologic analysis of skin and internal organs revealed
skin fibrosis and structural and functional abnormali-
ties in the lungs and kidneys. Furthermore, PSGL-1!/!
mice exhibited vascular alterations, showing loss of
dermal vessels, small vessel medial layer remodeling in
the lungs and kidneys, and ischemic processes in the
kidney that promote renal infarcts.
Conclusion. Our study demonstrates that im-
mune system overactivation due to PSGL-1 deficiency
triggers an autoimmune syndrome with characteristics
similar to systemic sclerosis, including skin fibrosis,
vascular alterations, and systemic organ involvement.
These results suggest that PSGL-1 expression contrib-
utes to the maintenance of the homeostasis of the
immune system and could act as a barrier for autoim-
munity in mice.
Systemic sclerosis (SSc; scleroderma) is a rare
disease that affects mainly women (3–14 females:1 male)
of !50 years of age. SSc is characterized by widespread
fibrosis of the skin and internal organs, noninflamma-
tory small vessel vasculopathy, and immunologic activa-
tion with production of disease-specific autoantibodies.
These abnormalities lead to a disruption in tissue archi-
tecture and loss of functional integrity of affected inter-
nal organs. The survival expectancy for SSc patients
depends on disease subtype, and the main causes of
death are pulmonary arterial hypertension (PAH) and
pulmonary fibrosis (1).
Several factors are implicated in SSc develop-
ment, such as environmental, chemical, or genetic fac-
tors, immune system dysfunction, or infectious agents
(2–4). SSc pathophysiology includes immune system and
fibroblast activation and endothelial cell dysfunction,
resulting in extracellular matrix protein accumulation,
vascular injury, autoantibody production, and overpro-
duction of inflammatory and profibrotic cytokines (5,6).
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Fibroblasts activated by proinflammatory factors are the
principal effector cells, while activated innate immune
system, matrix-mediated signaling, hypoxia, and oxida-
tive stress are the main perpetuating factors of fibrosis
(7). Though diagnosis of SSc is straightforward once the
disease is established, it is difficult to make an early
diagnosis, which is crucial for the application of early
treatments to prevent tissue damage and loss of organ
function. Immunosuppressive therapies can control the
disease and minimize organ damage in the short term,
but disease remission has not been achieved with any
therapy available thus far (8). Some patients with severe
disease have experienced improvement with autologous
bone marrow (BM) transplantation (9,10), suggesting a
role of the immune system in disease initiation. How-
ever, very little is known about the immune mechanisms
involved in the onset of SSc.
The leukocyte adhesion receptor P-selectin gly-
coprotein ligand 1 (PSGL-1) interacts with P-, E- and
L-selectins (11) and is responsible for the initial inter-
actions of leukocytes with activated endothelium (12)
and their recruitment to sites of inflammation (13).
PSGL-1 is also important for the homeostatic homing
and entry of leukocytes into different tissues and organs
(14–17). PSGL-1 expression is regulated by the metal-
loproteinase ADAM-8 (18), and PSGL-1–P-selectin in-
teractions can be modulated by PSGL-1 modification
with epitopes such as M-DC8 (19,20), indicating the
importance of PSGL-1–P-selectin interaction in immune
system homeostasis.
PSGL-1 signaling through Syk induces human
monocyte-derived dendritic cells (DCs) to become
tolerogenic and promotes the generation of Treg cells.
Accordingly, PSGL-1"/" mice produce less CD4# nat-
ural Treg cells in the thymus and PSGL-1"/" mouse DCs
are more immunogenic than PSGL-1#/# mouse DCs
(21–23). Deficiency in P-selectin or PSGL-1 leads to
accelerated development of glomerulonephritis in lupus-
prone mice and exacerbated disease in several animal
models, for example, bleomycin-induced scleroderma,
Dextran sulfate sodium–induced ulcerative colitis, and
experimental autoimmune encephalomyelitis (24–27).
Moreover, DCs isolated from systemic lupus erythema-
tosus patients are unable to generate Treg cells after
P-selectin interaction (28), and SSc patients show high
serum levels of selectins (29,30), suggesting a connection
between PSGL-1 and these autoimmune diseases. Taken
together, these data suggest that homeostatic PSGL-1–
selectin interactions during leukocyte recirculation and
tissue replenishment are important for the control of
autoimmune reactivity and maintain immune tolerance.
Several animal models have been developed to
study the signaling pathways involved in fibrosis devel-
opment and to identify new therapeutic target mole-
cules. However, none of them completely mimics the
human disease (31,32). Our work shows that PSGL-1"/"
mice present increased basal activation of the immune
system and spontaneously develop an autoimmune dis-
ease similar to SSc, featuring autoantibodies, skin fibro-
sis, vascular alterations, kidney disease, nonspecific in-
terstitial pneumonia, and a high mortality rate,
establishing the possibility that PSGL-1 could be an
important molecule in the pathogenesis of this disease.
MATERIALS AND METHODS
Mice. C57BL/6 PSGL-1"/" mice were kindly provided
by Dr. M. K. Wild and Dr. D. Vestweber (Max Planck Institute
for Molecular Biomedicine, Mu¨nster, Germany). Wild-type
(WT) C57BL/6 mice were obtained from The Jackson Labo-
ratory and were backcrossed with PSGL-1"/" mice. Mice were
kept in pathogen-free conditions at the Animal Facility of the
School of Medicine, Universidad Auto´noma de Madrid
(UAM; Madrid, Spain) and the Animal Facility of the Centro
Nacional de Investigaciones Cardiovasculares (CNIC; Madrid,
Spain). Mice were killed by cervical dislocation at 1.5 months
old (young), 3, 6, and 9 months old (adult), and 12, 15, 18, and
$20 months old (old), and blood and internal organs were
extracted for analysis. All experiments and breeding were
performed in accordance with national and institutional guide-
lines for animal care. The experimental procedures were
approved by the Veterinarian Committee of the UAM (regis-
ter number ES-28079-0000097).
Autoantibody assays. Antinuclear antibodies (ANAs)
were detected by indirect immunofluorescence. Serum from
WT and PSGL-1"/" mice was incubated for 30 minutes with
HEp-2 cells for ANA screening and Crithidia luciliae for
anti–double-stranded DNA (anti-dsDNA) antibody screening,
and fixed on slides (Inova Diagnostics). Sera were diluted 1:20
for HEp-2 incubation and 1:10 for Crithidia luciliae incubation.
Slides were incubated for 30 minutes with goat anti-mouse
Alexa Fluor 488 (1:100) (Invitrogen). Circulating autoantibod-
ies were measured by enzyme-linked immunosorbent assay
(ELISA) with the specific Quanta Lite kits for SSA, U1 RNP,
Sm, Jo-1, and Scl-70 antigens (Inova Diagnostics). Horseradish
peroxidase–conjugated goat anti-mouse IgG (H#L) antibody
from Pierce Antibodies (Thermo Scientific) diluted 1:2,500
was used as secondary antibody. The cutoff for positivity on
ELISA for a particular autoantibody was determined as the
mean value plus 2 SD obtained from the sera of at least 100
WT mice ages 1.5–24 months. At least 25 mice per age group
were analyzed.
Histologic staining. Organs and tissues were embed-
ded in paraffin and sliced into 4-!m sections. Hematoxylin and
eosin (H&E) staining was performed with Harris’ hematoxylin
(Merck) and Eosin Y (alcoholic solution; Leica Biosystems).
Masson’s trichrome staining was performed with Artisan Go-
mori’s Green Trichrome Stain kit (Dako). Picrosirius red
staining was performed in the Pathology Unit at the CNIC. All
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images were obtained with a Leica DM2500 light microscope
and a Leica DFC450 camera. All sections were examined by a
pathologist (CG) who was blinded with regard to the sample
origin.
Collagen quantification. Sircol assay was carried out to
measure tissue collagen concentration using the Sircol kit
(Biocolor).
Histopathologic assessment of dermal fibrosis in mice.
All mouse skin sections were obtained from the para-midline,
upper back region to minimize regional variations in thickness.
Dermal thickness, analyzed using ImageJ software (National
Institutes of Health [NIH]), was defined as the thickness of the
skin from the granular layer to the junction between the dermis
and the subcutaneous fat (hypodermis). The thickest and the
thinnest sections of at least 3 different skin areas were mea-
sured per mouse. At least 5 males and 5 females of each
genotype and age were analyzed.
Histopathologic assessment of renal damage in mice.
Mice were assessed for the presence of tubular interstitial
infiltrates in whole H&E-stained kidney sections, and for the
presence of ischemic events (infarcted areas) in whole H&E-
and Masson’s trichrome–stained kidney sections. At least 5
males and 5 females were evaluated per genotype.
Histopathologic assessment of pulmonary damage in
mice. Whole H&E-stained mouse lung sections were evaluated
for nonspecific interstitial pneumonia. Interstitial cellularity,
thickening of the alveolar walls, and structure alteration of the
lung parenchyma were considered to be features of nonspecific
interstitial pneumonia.
Immunohistochemical staining of mouse skin, kidney,
and lung and evaluation of vascular alteration. Immunohisto-
chemical staining was performed in the Pathology Unit at the
CNIC with an Autostainer Plus Staining System (Dako). Skin
vascular damage was evaluated by staining skin sections (from
4 males and 4 females per genotype) with a polyclonal rabbit
anti-mouse CD31 antibody (Abcam). The total number of
dermal blood vessels in a total of 10 consecutive 40%-objective
fields (total length of section 1,727 !m) was counted for each
mouse. The mean value was calculated for each group of mice.
All CD31-stained structures with an internal lumen, without
diameter restrictions, were considered blood vessels.
Lung interstitial leukocyte infiltration was evaluated by
immunohistochemical staining with a rat anti-mouse CD45
antibody (Becton Dickinson). Lung sections were evaluated in
18–24-month-old mice (5 males and 5 females per genotype).
The small blood vessel (diameter of &50 !m in the
lungs and &20 !m in the kidneys) wall thickness was calculated
by measuring, with ImageJ (NIH), the internal and total vessel
diameter of anti–"-smooth muscle actin (anti–"-SMA)–
stained kidneys and lungs, and calculating the vessel wall area.
The mean wall thickness area was calculated for at least 4
males and 4 females of each genotype.
Urine and serum biochemical analyses. Urinary pro-
tein and hemoglobin measurements were determined with
Combur Test M dipsticks (Roche). The cutoff for positivity in
the proteinuria test was the lowest value in knockout (KO)
mice not reached in any of the WT mice analyzed. Serum levels
of urea, creatinine, and albumin were measured on a Dimen-
sion RxL Max analyzer (Siemens).
Flow cytometric analysis. Rat anti-mouse CD3, CD4,
CD8, CD25, CD11c, F4/80, B220, CD49b, interleukin-12 (IL-
12), IL-10, IL-4, IL-17, interferon-# (IFN#), Gr1, CD62L,
CD69, major histocompatibility complex (MHC) class II,
CD86, and CD40 directly labeled with a fluorochrome or
biotin and streptavidin–PerCP were obtained from Becton
Dickinson. The mouse Th1/Th2 10-plex FlowCytomix kit was
purchased from eBioscience.
Tissue sections (1 mm2) were incubated in RPMI
medium supplemented with 4% fetal calf serum (FCS), 1
mg/ml collagenase IA, 50 !g/ml Dispase, and 40 !g/ml DNAse
(all enzymes from Sigma-Aldrich) in a shaking bath at 37°C
and 100 rpm for at least 1 hour. Cells were then filtered,
washed, immunostained, and analyzed with a FACSCanto II
flow cytometer. Tissue proteins were extracted with T-PER
tissue protein extraction buffer (Thermo Scientific) and quan-
tified with the BCA Protein Assay Kit (Pierce). Tissue cyto-
kines were detected with the FlowCytomix kit (Bender Med-
Systems).
Macrophage generation from mouse BM precursors.
Fresh mouse BM cells were flushed from the tibia and cultured
in petri dishes (BD Biosciences) with differentiation medium
containing RPMI 1640 (Invitrogen) supplemented with 10%
FCS (HyClone), 100 units/ml penicillin, 100 !g/ml streptomy-
cin, 2 mM L-glutamine and 15% L929-conditioned medium
(containing macrophage colony-stimulating factor). Fresh dif-
ferentiation medium was added every 3 days. Macrophages
were phenotyped on days 8–10. Efficiency of differentiation
was assessed by measuring the expression of F4/80 surface
antigen by flow cytometry.
Statistical analysis. Student’s 2-tailed t-test for 2
groups was used for parametric variables, and the Mann-
Whitney U test was used for nonparametric data. For statistical
comparison of frequencies, the chi-square test (1df) was per-
formed. For the survival assay, the Mantel-Cox chi-square test
(1df) was performed. P values less than 0.05 were considered
significant, and P values less than 0.01 were considered highly
significant. All statistical analyses were performed using SPSS
software version 15.0.
RESULTS
Development of skin fibrosis in PSGL-1!/! mice.
We observed a high rate of spontaneous skin lesions on
the backs of adult PSGL-1"/" mice. Such lesions were
absent in WT mice. Raising the hair on the backs of the
3-month-old PSGL-1"/" mice, we detected red skin
zones with circumscribed nonspecific small and sterile
superficial ulcers that were diffuse and more severe in
older mice (Figure 1A). Histologic analysis of lesions
from 3-month-old mice demonstrated small superficial
ulcers with epidermal necrosis and cell debris and a
minimal inflammatory infiltrate in the underlying der-
mis. In contrast, lesions from older mice presented large
ulcers with epidermal necrosis and cell debris, and
horizontally positioned fibroblasts and marked fibrosis
in the underlying dermis (Figure 1A).
Histologic analysis of the skin revealed dermal
thickening with lipoatrophy in both male and female KO
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mice, which was due to increased collagen deposition
(fibrosis), as indicated by Masson’s trichrome staining
(Figure 1B) and a higher collagen content (Figure 1C).
Measurement of dermal thickness revealed enhanced
thickness in PSGL-1"/" mice compared with WT mice,
and this difference was accentuated in 12–24-month-old
mice (Figure 1C). Moreover, picrosirius red staining
indicated that PSGL-1"/" mice had increased amounts
of type III collagen–like fibers (thinner collagen fibers
shown in yellow and green in Figure 1B), including type
Figure 1. Development of skin fibrosis, lipoatrophy, and peripheral vascular alterations in P-selectin glycoprotein ligand 1–knockout (PSGL-1–KO)
mice. A, Left, Photographs of a 3-month-old PSGL-1–KO mouse and a 15-month-old PSGL-1–KO mouse, showing skin lesions. Right,
Photomicrographs of hematoxylin and eosin (H&E)–stained sections of representative skin wounds from young and old mice. B, Photomicrographs
of representative skin sections from 1.5-month-old and 24-month-old female wild-type (WT) and PSGL-1–KO mice, stained with H&E, Masson’s
trichrome (MT), and picrosirius red. Original magnification % 10 in top panels; % 40 in middle panels; % 5 in bottom panels. C, Top, Dermal
thickness in 1.5–3-month-old and 12–24-month-old male and female WT and PSGL-1–KO mice (n ' 8 mice per group). Bottom, Collagen content
in the dermis of 1.5–3-month-old WT and PSGL-1–KO mice (n ' 4 mice per group). D, Photomicrographs of representative upper dermis sections
from WT and PSGL-1–KO mice immunostained with anti-CD31 antibody. Boxed areas in the left panels are shown at a higher-magnification view
in the right panels to better visualize the vessel architecture. Arrowheads indicate blood vessels. The bar graph shows the number of CD31# blood
vessels in a 1,727-!m long dermis section from male and female WT mice (open bars) and PSGL-1–KO mice (solid bars) (n ' 4 mice per group).
In C and D, bars represent the mean ( SD. ! ' P & 0.05; !! ' P & 0.01; !!! ' P & 0.005, by Student’s 2-tailed t-test.
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III collagen and newly formed type I fibers, than type I
collagen–like fibers (thicker collagen shown in fibers
in orange and red in Figure 1B). Additionally, CD31
staining showed that the number of blood vessels in
the dermis of PSGL-1"/" mice was significantly lower
than in WT mice, particularly in the upper dermis
(Figure 1D).
Generation of autoantibodies associated with
connective tissue autoimmune diseases in PSGL-1!/!
mice. Immunofluorescence analysis of sera revealed
antinuclear and anticytoplasmic autoantibodies in
PSGL-1"/" mice that were absent in WT mice (Figure
2A), whereas anticentromere and anti-dsDNA auto-
antibodies (Crithidia luciliae assay) were not detected
in either group. ELISAs indicated that the sera from
PSGL-1"/" mice recognized several autoantigens re-
lated to connective tissue diseases, including topoiso-
merase I, U1 RNP, Sm, tRNA synthetase (Jo-1), and
SSA/Ro (Figure 2B). By studying different groups of
mice at different ages, we found that these autoantibod-
ies were coexpressed in the same animals and that their
levels increased with the age of the animal. Indeed,
anti–topoisomerase I, anti–U1 RNP, and anti-Sm anti-
bodies were detected in the youngest animals, and
antitopoisomerase was the most prevalent antibody de-
tected in 1.5-month-old mice (12.5%). In a followup
study using 15 mice, we performed ELISAs at 1.5
months and again at 3 months. We found that the
1.5-month-old mice that were positive for antitopoi-
somerase antibodies died before reaching 3 months of
age. Consequently, the number of mice with anti–
topoisomerase I antibodies decreased in the 3-month-
old group, increasing again to 15% in the elderly popu-
lation (Figure 2B).
Kidney disease in PSGL-1!/! mice. Histologic
analysis of H&E-stained kidney sections revealed that
12–24-month-old PSGL-1"/" mice had perivascular in-
filtrates (Figure 3A). Quantification of these infiltrates
showed that at 1.5–3 months of age, only female PSGL-
1"/" mice had interstitial infiltrates (30%), but at 12–24
months, 80% of both male and female KO mice had
developed infiltrates (Figure 3A). Closer inspection of
the histologic features (Figure 3A) revealed glomerular
damage as sclerotic glomeruli and tubularization of
Bowman’s capsule in PSGL-1"/" mice. Additionally,
Masson’s trichrome staining of kidney sections revealed
the presence of infarcted areas in KO mice (Figure 3B),
indicating ischemic events. Quantification showed that
almost 50% of male and 28% of female PSGL-1"/" mice
ages 18 months and older had kidney infarcts, while in
the WT group only 10% of the older males showed
infarcts (Figure 3B). Notably, "-SMA staining revealed
a thickening of the kidney small vessel medial layer in
KO mice (Figure 3C), which was calculated to be 10%
thicker in both young and old mice, indicating sustained
kidney vascular alteration (Figure 3C).
Figure 2. Spontaneous generation of autoantibodies related to connective tissue autoimmune diseases in P-selectin glycoprotein ligand 1–knockout
(PSGL-1–KO) mice. A, Representative immunofluorescence photomicrographs of HEp-2 cells incubated with serum from 2 independent wild-type
(WT) mice and 2 independent PSGL-1–KO mice. B, Percentage of mice positive for Scl-70, U1 RNP, Sm, Jo-1, and SSA/Ro autoantibodies (n '
25 or more mice per age group). ! ' P & 0.05; !! ' P & 0.01. P values were determined by chi-square test.
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Figure 3. Renal dysfunction in PSGL-1–KO mice. A, Left, Interstitial infiltration (I) in H&E–stained kidney sections from 23-month-old WT and
PSGL-1–KO mice. Middle, Frequency of interstitial immune infiltrates among WT and PSGL-1–KO mice (n ' 7–17 mice per group). Right,
Glomeruli in kidney sections from 23-month-old WT and PSGL-1–KO mice, showing tubularized (T) and sclerotic (S) glomeruli. B, Left, Masson’s
trichrome–stained kidney sections from 23-month-old WT and PSGL-1–KO mice, showing healthy and infarcted tissue. Right, Frequency of renal
infarcts in 18–24-month-old WT mice (open bars) and PSGL-1–KO mice (solid bars) (n ' 11 or more mice per group). C, Left, Anti–"-smooth
muscle actin (anti–"-SMA)–stained kidney sections from 3-month-old WT and PSGL-1–KO mice. Arrowheads denote stained vessels. Original
magnification % 40. Right, Percentage of blood vessel wall area in blood vessels of &20 !m in diameter in 3-month-old and 18–24-month-old WT
mice (open bars) and PSGL-1–KO mice (solid bars). Bars show the mean ( SD (n ' 4 mice per group). D, Frequency of proteinuria and hematuria
in 18–24-month-old WT and PSGL-1–KO mice, and creatinine, urea, and albumin levels in the serum of WT and PSGL-1–KO mice. Bars in the
middle panels and the right panel show the mean ( SEM (n ' 8–12 mice per group). ! ' P & 0.05; !! ' P & 0.01, by chi-square test in A and B
and by Student’s 2-tailed t-test in C and D. See Figure 1 for other definitions.
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An evaluation of biochemical parameters in urine
and serum revealed proteinuria in 15% of the 18–24-
month-old PSGL-1"/" mice and hematuria in 50% of
the 18–24-month-old PSGL-1"/" mice (Figure 3D). In
addition, serum analysis showed higher levels of creati-
nine and urea and a tendency toward lower levels of
albumin in the sera of 3-month-old PSGL-1"/" mice
compared with WT mice. Taken together, these data
indicate renal dysfunction in PSGL-1"/" mice at 18
months of age and older.
Promotion of nonspecific interstitial pneumonia
by PSGL-1 deficiency. Histologic analysis of lung sec-
tions showed that, in comparison with WT mice, old
PSGL-1"/" mice had increased interstitial cellularity
and thickening of the interstitial space (Figure 4A).
Immunohistochemical staining for CD45 identified the
interstitial cells as infiltrating leukocytes (Figure 4A),
and Masson’s trichrome staining revealed a substantial
increase in the thickness of the interalveolar septa
(Figure 4A). Quantification of nonspecific interstitial
pneumonia lesions in mice showed that at 1.5–3 months
7.8% of male and 16.7% of female PSGL-1"/" mice, but
no WT mice, had nonspecific interstitial pneumonia. At
Figure 4. Nonspecific interstitial pneumonia (NSIP) and lung small vessel remodeling in PSGL-1–KO mice. A, Representative photomicrographs
of H&E-stained, anti-CD45–stained, and Masson’s trichrome–stained lung sections from WT and PSGL-1–KO mice. B, Incidence of nonspecific
interstitial pneumonia in WT and PSGL-1–KO mice (n ' 9 mice per group). !! ' P & 0.01; !!! ' P & 0.005, by chi-square test. C, Left,
Representative photomicrographs of anti–"-smooth muscle actin (anti–"-SMA)–stained lung sections from 3-month-old WT and PSGL-1–KO mice.
Right, Vessel wall area with respect to the total vessel area in vessels of &50 !m in diameter in the lungs of 3-month-old WT and PSGL-1–KO mice.
Bars show the mean ( SD. Statistical significance was determined by Student’s 2-tailed t-test. IHC ' immunohistochemistry (see Figure 1 for other
definitions).
Figure 5. Body weight analysis and mortality in P-selectin glycopro-
tein ligand 1–knockout (PSGL-1–KO) mice. A, Changes in body
weight in male and female wild-type (WT) and PSGL-1–KO mice.
Values are the mean ( SD (n ' 6 or more animals per age and
genotype group). ! ' P & 0.05; !! ' P & 0.01; !!! ' P & 0.005, by
Student’s 2-tailed t-test. B, Kaplan-Meier survival curves for WT
and PSGL-1–KO mice (n ' 87 WT and 99 PSGL-1–KO mice). P '
5.2466 % 10"13 by Mantel-Cox test.
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Figure 6. Skin-resident immune system activation in P-selectin glycoprotein ligand 1–knockout (PSGL-1–KO) mice. A, Left, Percentage of Gr1#
and CD11c# cells, mean fluorescence intensity (MFI) of CD62L and CD69 molecules (top), and intracellular cytokine (CK) staining (bottom) in
the F4/80# subpopulation in the skin of wild-type (WT) and PSGL-1–KO mice. Right, Histograms showing expression levels of major
histocompatibility complex (MHC) class II, CD86, and CD40 on dendritic cells (DCs) obtained from the skin of a representative WT mouse and
a representative PSGL-1–KO mouse (of 4 examined per group) (top) and MFI of intracellular cytokine staining of CD11c# DCs from WT and
PSGL-1–KO mice (bottom). B, Left and middle, Percentage of CD8# (left) and CD4# (middle) T cells expressing interleukin-4 (IL-4; Th2), IL-17
(Th17), interferon-# (IFN#; Th1), and IL-10. Right, Percentage of Treg cells (CD25highFoxP3#) in the CD4# and CD8# subpopulations. C,
Cytokine concentration in 0.5 mg of skin tissue protein. D, Surface expression of molecular markers (left) and intracellular cytokine expression
(right) on macrophages derived from precursors isolated from the bone marrow (BM) of WT and PSGL-1 KO mice. Bars show the mean ( SD
(n ' 4 mice per group in A, B, and D; n ' 6 mice per group in C). ! ' P & 0.05; !! ' P & 0.01; !!! ' P & 0.005, by Student’s 2-tailed t-test.
TNF" ' tumor necrosis factor "; GM-CSF ' granulocyte–macrophage colony-stimulating factor; LFA-1 ' lymphocyte function–associated
antigen 1.
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12–24 months of age, nonspecific interstitial pneumonia
was found in 64.7% of male and 53.8% of female
PSGL-1"/" mice, but only in 14.3% of female WT mice
(Figure 4B). In addition, we found that lung small
vessels had a thickened medial layer, as denoted by
"-SMA staining (Figure 4C), which was almost 50%
thicker in PSGL-1"/" mice than in WT mice.
Increased mortality rate in PSGL-1!/! mice.
Analysis of body weights over a 24-month period showed
that during the first year of life, male and female WT
and PSGL-1"/" mice gradually increased their body
weight. However, during the second year of life, while
WT mice continued to gain weight, male PSGL-1"/"
mice started to lose weight at 15 months of age (Figure
5A) and female PSGL-1"/" mice stopped gaining weight
at 12 months and began losing weight at !18 months
(Figure 5A). At 2 years of age, PSGL-1"/" mice had lost
20% of their body mass, a sign of cachexia and prema-
ture death.
A survival study showed that, whereas WT mice
had a low rate of mortality during the first 2 years of life,
PSGL-1"/" mice had 2 significant peaks of mortality.
The first peak occurred between birth and 3 months of
age, during which time 50% of newborns died, although
neonates did not present with kidney or lung structural
or developmental problems (data not shown). The sec-
ond peak occurred during the second year of life, with
30% of deaths occurring before mice reached 2 years of
age. As a consequence, while 70% of the WT mice
reached 2 years of age, only 20% of the PSGL-1"/" mice
reached this age (Figure 5B).
Altered skin immunity in PSGL-1!/! mice. Since
PSGL-1 is a leukocyte receptor, we assessed whether it
plays a role in maintaining skin immune tolerance. Thus,
we studied the phenotype of different innate and adap-
tive skin-resident immune cell populations. We found
that most PSGL-1"/" mouse skin macrophages were
proinflammatory (Gr1#, CD11c#), with higher expres-
sion levels of CD69, indicating an increased activation
state (Figure 6A). Similarly, PSGL-1"/" mouse skin DCs
expressed higher levels of MHC class II, CD86, and
CD40 (Figure 6A), revealing a more activated state than
corresponding WT mouse DCs. The percentage of skin
macrophages and DCs producing proinflammatory cy-
tokines was also significantly higher in PSGL-1"/" mice
(Figure 6A). Examination of skin T effector (Teff) cells
revealed above-normal numbers of CD4# Teff cells
producing IL-4, IL-17, and IFN# in PSGL-1"/" mice. In
contrast, numbers of IL-10–producing T lymphocytes
and Treg cells were normal, indicating an imbalanced
Teff cell:Treg cell ratio in the skin of PSGL-1"/" mice
(Figure 6B). Accordingly, we found elevated levels of
IL-2, IL-6, IL-13, and IL-22 in the pool of tissue pro-
teins, and a tendency toward increased levels of IL-10,
IL-17, and IL-23 (Figure 6C), confirming a proinflam-
matory and profibrotic microenvironment in the skin of
PSGL-1"/" mice.
Proinflammatory phenotype of PSGL-1!/!
mouse BM-derived macrophages (BMMs). To investi-
gate whether PSGL-1"/" mouse skin–resident macro-
phages become proinflammatory and activated once
they enter the tissue, or if they are generated in the
BM with this phenotype, we obtained macrophages
in vitro from WT and PSGL-1"/" mouse BM precursors
and analyzed markers of inflammation. PSGL-1"/"
mouse BMMs had a proinflammatory phenotype
(Gr1highCD11chigh) and higher expression of CD69 and
MHC class II (Figure 6D). Further, cytokine profiling
showed that PSGL-1"/" mouse BMMs produced higher
levels of IL-17, IL-4, and IL-12 than corresponding
macrophages derived from WT mouse BM precursors
(Figure 6D), indicating that they are generated with a
proinflammatory and more activated phenotype.
DISCUSSION
We have demonstrated that PSGL-1 deficiency in
mice results in the development of a progressive auto-
immune syndrome characterized by skin fibrosis with
involvement of several internal organs and microvascu-
lature alterations. These pathologic events are similar to
SSc, but there are important differences compared to
the human disease, including the nonspecific skin ulcers,
the wide range of autoantibodies, and the kidney pathol-
ogy found in the PSGL-1"/" mice. Clearly, these differ-
ences could be due to different organ structures—and
thus to different expression of autoimmune diseases—in
mice and humans, but they could also be due to the
complete absence of PSGL-1 in KO mice. PSGL-1 is a
crucial molecule for skin homing of leukocytes and we
show that it also contributes to skin homeostasis. Hence,
it is perhaps not surprising that the skin is the first organ
to be highly affected in PSGL-1"/" mice.
SSc is a progressive autoimmune disease charac-
terized by fibrosis and vasculopathy. While fibroblasts,
endothelial cells, and the immune system have been
implicated in the development of SSc, the initial trigger
remains unknown (7). All risk genes related to SSc
susceptibility are immune-related genes. Several studies
have demonstrated that the innate and adaptive immune
systems may participate in SSc pathogenesis, and weak
perivascular infiltrates appear in the skin in early SSc,
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pointing to a role for the immune system in the initiation
of fibrosis (5,33,34). Moreover, increased numbers of
circulating Th1, Th17, and transforming growth factor
$–producing CD4# T cells can be used to distinguish
different SSc subtypes, and the affected skin in SSc
patients has altered immune cell populations (35–37).
Our findings suggest that PSGL-1 is essential for
maintaining skin immune homeostasis in mice. PSGL-
1"/" mouse skin has increased levels of IL-6, IL-13, and
IL-22 and a tendency toward increased levels of IL-10,
IFN#, and IL-17, as expected for a sclerotic skin disor-
der; further, PSGL-1"/" mouse skin has increased Th1,
Th2, and Th17 populations, which could explain the
exacerbation of disease developed by PSGL-1"/" mice
after treatment with bleomycin (27). Interestingly, dur-
ing the acute inflammation phase induced by bleomycin,
Th1 recruitment to the skin was impaired in PSGL-1"/"
mice. However, in the progressive scleroderma-like dis-
ease developed by PSGL-1"/" mice, the Th1 population
is also increased in the skin of 3-month-old animals. The
percentage of skin macrophages and DCs with an acti-
vated proinflammatory phenotype is increased in PSGL-
1"/" mice, contributing to the tissue proinflammatory
microenvironment. Importantly, PSGL-1"/" mouse
BMMs display a proinflammatory phenotype and a
higher activated state compared with PSGL-1#/# mouse
BMMs, as described for PSGL-1"/" mouse DCs (22).
These findings suggest that PSGL-1"/" mouse macro-
phages and DCs arrive activated to the skin and contrib-
ute to the generation of a proinflammatory environment
leading to skin fibroblast activation and increased colla-
gen deposition.
It has previously been demonstrated that the
generation of natural Treg cells, responsible for the
control of self tolerance (38), was reduced in PSGL-1"/"
mice (22). We found an imbalanced Teff cell:Treg cell
(CD25highFoxP3#) ratio in the skin of PSGL-1"/" mice.
This imbalance is involved in the development of auto-
immune diseases (39,40) and could explain the genera-
tion of chronic inflammation and autoimmunity in
PSGL-1"/" mice, thus suggesting a role for PSGL-1 in
the control of the immunity–autoimmunity barrier.
Autoimmune disorders are characterized by the gener-
ation of numerous autoantibodies. The most prevalent
autoantibody in 1.5-month-old PSGL-1"/" mice was
anti–topoisomerase I, which has been shown to be
almost exclusively associated with diffuse cutaneous SSc
(41), while 24-month-old mice had a complex pattern
of coexisting autoantibodies related to other connective
tissue diseases. However, none of the animals had
detectable levels of anticentromere antibodies, which
characterize limited cutaneous SSc (42), or anti-dsDNA
antibody, the serologic marker of SLE (43,44). In hu-
mans, anti–topoisomerase I antibodies are associated
with diffuse skin involvement, pulmonary fibrosis, poor
prognosis, and SSc-related mortality (41). Accordingly,
we found that 1.5-month-old PSGL-1"/" mice positive
for antitopoisomerase autoantibodies died before reach-
ing 3 months of age.
Renal dysfunction in SSc patients is characterized
by the onset of malignant hypertension that progresses
to renal failure (45), with arterial thrombosis associated
with glomerular ischemic collapse. Aged PSGL-1"/"
mice develop ischemic events that promote kidney in-
farcts and have sclerotic glomeruli, but also have tubu-
lointerstitial nephritis, present in many autoimmune
disorders, and a high frequency of glomeruli with tubu-
larization of Bowman’s capsule. These findings, together
with the wide range of autoantibodies, could reflect the
development of an autoimmune disorder similar to some
overlapping syndromes in humans (46).
One of the hallmarks of SSc is vasculopathy, with
loss of arteries and capillaries that is not compensated
due to defects in angiogenesis and vasculogenesis
(47,48). These vascular complications induce the gener-
ation of ulcers in the skin and dysfunction of internal
organs. SSc-associated renal crisis and SSc-associated
PAH are due to microvascular injury that leads to
restricted blood flow and subsequent organ failure (48).
We found that PSGL-1 deficiency resulted in a 50%
reduction in blood vessels in the dermis, ischemic events
in the kidneys, and thickening of the small vessel medial
layer in kidney and lung, suggesting that PSGL-1 may
contribute to maintaining vascular homeostasis in mice.
Importantly, thickening of the lung small vessel medial
layer could produce PAH, the main cause of premature
death among SSc patients (49).
Histologic examination of PSGL-1"/" mice dem-
onstrated that, at 1.5 months, these mice already had
skin fibrosis, and some animals showed nonspecific
interstitial pneumonia, tubulointerstitial infiltrates, and
thickening of the arteriolar medial layer. These findings
suggested that the SSc-like disease was already estab-
lished and that, similar to human disease, it progresses
with age, leading to renal and pulmonary failure which
may be the main causes of death in these animals. SSc
incidence is higher in women than in men and may be
related to hormone production or hormone receptor
expression. Interestingly, no differences in fibrosis, au-
toantibody production, or effects on internal organs
were found between male and female PSGL-1"/" mice,
but a higher incidence of infarcts was apparent in males.
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PSGL-1"/" mice did not receive any external
insult to trigger or accelerate disease progression, sug-
gesting that the basally activated innate immune system,
together with an increased accumulation of effector
lymphocytes, culminates in the rupture of organ struc-
ture and function. These events almost certainly contrib-
ute to weight loss, multiorgan failure, and the high
mortality rate during the second year of life. Interest-
ingly, almost 40% of PSGL-1"/" mice died in the
perinatal period, but did not show lung or kidney
developmental problems.
In summary, we show that the absence of PSGL-1
triggers the spontaneous development of a systemic
autoimmune disease with characteristics that resemble
SSc. Given that preclinical findings in current SSc ani-
mal models have failed to deliver clinical results in SSc
patients (50), it is important to discover new molecules
that can increase our understanding of the pathogenesis
of SSc. SSc-like pathogenesis can be studied using
PSGL-1"/" mice. Future research will explore the role
of PSGL-1 in the development of human SSc and other
autoimmune diseases.
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Abstract 
 
Rationale: Pulmonary arterial hypertension (PAH) is a rare disease whose etiopathogenesis is poorly 
understood, and existing treatments are neither curative nor sufficient for stopping disease progression. 
PAH is one of the major complications of connective tissue diseases, and 7-15% of patients with 
systemic sclerosis (SSc) develop PAH. Mice deficient for the leukocytic receptor P-selectin 
glycoprotein ligand-1 (PSGL-1
-/-
) spontaneously develop a progressive SSc-like autoimmune 
syndrome. 
 
Results and Methods: PSGL-1
-/-
 mice presented vascular remodeling of distal lung blood vessels. 
Accordingly, Doppler pulse echochardiography demonstrated that aged PSGL-1
-/-
 females showed 
reduced pulmonary acceleration time/ejection time ratio (PAT/ET) and heart remodeling, indicating 
PAH. Chronic hypoxia exposure killed 40% of PSGL-1
-/-
 females during the first week. Isolated 
pulmonary arterial rings from aged PSGL-1
-/-
 females presented increased vasoconstriction response to 
KCL and reduced vasodilation response to acetylcholine. Importantly, NO production by lung 
endothelial cells was reduced in aged PSGL-1
-/- 
females. Expression of angiotensin II receptor 2 
(AT2R) was reduced in lungs of PSGL-1
-/-
 females from a young age and, remarkably, ageing 
increased the levels of angiotensin II (AngII) and the percentages of IFN-γ-producing interstitial 
macrophages, T and B lymphocytes in PSGL-1
-/-
 females.  
 
Conclusions: Together, our results show that the absence of PSGL-1 leads to endothelial dysfunction 
and PAH, coinciding with an increase in pulmonary AngII concentration and reduced NO production 
by endothelial cells. These studies implicate leukocyte-endothelium interactions for the maintenance 
of vascular homeostasis and protection against PAH in female mice. 
 
 
Keywords: PSGL-1; pulmonary hypertension; angiotensin II; nitric oxide; immune sytem  
 
Non-standard Abbreviations and Acronyms 
PSGL-1: P-Selectin Glycoprotein Ligand 1 
PAT: Pulmonary Acceleration Time 
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Introduction 
Pulmonary arterial hypertension (PAH) is a rare, progressive and severe disease that affects mainly 
women. PAH is characterized by hypertrophic distal pulmonary vascular remodeling resulting from 
endothelial dysfunction, deregulated vascular smooth muscle cell proliferation and inflammation, 
which together promote medial thickening of pulmonary arteries and luminal obliteration 
1
. These 
pathologic events increase pulmonary vascular resistance and pulmonary artery pressure, which lead to 
increased hemodynamic load on the right ventricle (RV). The RV adapts by a compensatory increase 
in wall thickness and contractility 
2, 3
. PAH develops in 7–12% of patients with systemic sclerosis and 
is a leading cause of death in this setting 
4-6
. Indeed, systemic sclerosis represents the major cause of 
connective tissue disease (CTD)-associated PAH 
4
. 
Several molecular mechanisms have been implicated in the control of pulmonary pressure and to be 
deregulated in PAH. Pulmonary artery endothelial cells from patients with idiopathic PAH (iPAH) 
produce reduced amounts of nitric oxide (NO), a vasodilator that acts primarily through the soluble 
guanylate cyclase-cyclic guanosine monophosphate (cGMP) pathway 
4
. Other important 
vasoregulatory properties of NO include regulation of smooth muscle cell proliferation and migration, 
platelet aggregation, and leukocyte adhesion to endothelium 
7
. Accordingly, sildenafil or tadalafil, type 
5 phosphodiesterase inhibitors, have proven their efficacy in the treatment of PAH 
4
. Another 
molecule implicated in PAH development is angiotensin II (AngII). AngII is the major effector of the 
renin-angiotensin-aldosterone system (RAAS), and is mostly produced by cleavage of angiotensin I by 
angiotensin converting enzyme (ACE), which is located predominantly in lung and renal endothelium
8, 
9
. The main functions of AngII are the control of blood pressure and the maintenance of vascular tone 
in peripheral blood vessels 
8-10
. Control of vascular tone by AngII is mediated via AngII receptors 1 
and 2 (AT1R and AT2R), triggering vasoconstriction by binding to AT1R, and vasodilation by 
binding to AT2R 
9
. In addition, AngII can be hydrolyzed by ACE2 to Ang-(1-7), which counteracts 
the vasoconstrictor effects of AngII 
11
. Thus, elevated levels of renin, ACE, AngII and AT1R receptors 
have been observed in experimental models as well as patients with pulmonary hypertension (PH) 
12-14
.  
PAH progression has also been associated with inflammatory processes such as viral infections 
15
. 
AngII has been described as a proinflammatory molecule by regulating the expression of cytokines 
such as IL-12 or tumor necrosis factor-α (TNF-α) in monocytes and macrophages, as well as by 
producing NO through the activation of AT1R 
8
. Additionally, AngII promotes the expression of 
endothelial adhesion molecules such as E-selectin, P-selectin, VCAM-1 and ICAM-1, facilitating 
leukocyte rolling and extravasation, and consequently driving inflammation 
16
. Moreover, in 
inflammatory conditions, local macrophage chemoattractant protein-1 (MCP-1) augments AngII 
synthesis 
17
. Collectively, these data suggest an important crosstalk between AngII and inflammation. 
P-selectin glycoprotein ligand 1 (PSGL-1) is a leukocytic receptor responsible for the initial contacts 
between white blood cells and endothelium. PSGL-1 interacts with P-, E- and L-selectin, allowing 
leukocyte tethering and rolling before extravasation to the inflammatory foci 
18
. Moreover, PSGL-1 
associates with the tyrosine kinase Syk via the actin-linking proteins moesin and ezrin in an 
immunoreceptor tyrosine-based activation motif (ITAM)-dependent manner, inducing serum response 
element (SRE) transcriptional activity 
19
. PSGL-1/P-selectin interaction triggers a tolerogenic program 
in human monocyte-derived dendritic cells characterized by the upregulation of IL-10, indoleamine 
2,3-dioxygenase (IDO) and TGF-β, and by the downregulation of costimulatory molecules such as 
CD86, MHC-II and CD40, which drive Treg generation 
20
. As a consequence, disease exacerbation has 
been described in PSGL-1-deficient (PSGL-1
-/-
) mice in different experimental inflammatory models 
21-25
. More importantly, PSGL-1
-/-
 mice progressively develop an autoimmune syndrome which shares 
multiple features with human systemic sclerosis (SSc), such as autoimmunity, dermal fibrosis, 
vascular damage, and involvement of internal organs 
21
.  
Given that PSGL-1
-/-
 mice develop an autoimmune syndrome similar to SSc, and that there are not 
good mouse models for SSc-PAH, we questioned whether, as a part of the scleroderma-like syndrome, 
these mice develop PAH. Interestingly, there is a validated non-invasive method 
26
 to assess the 
systolic pressure in the pulmonary artery and right ventricle, by measuring pulmonary acceleration 
time (PAT) corrected by the pulmonary ejection time (ET) at the level of pulmonary valve. The 
reduction in pulmonary acceleration time/ejection time (PAT/ET) is associated in humans 
27
 and in 
4 
 
mice 
26
 with high pulmonary artery pressure. The non-invasive feature of this method allows to 
analyze in-vivo the presence of PAH and, hence, to perform longitudinal studies of functional changes 
in pulmonary pressure and right ventricle remodeling. 
In the present work, we have analyzed the lungs and heart of PSGL-1
-/-
 mice and found pulmonary 
small vessel and heart remodeling and increased pulmonary artery pressure, detected by a reduced 
ratio PAT/ET, in female PSGL-1
-/-
 mice. In addition, pulmonary arteries of aged PSGL-1
-/-
 females 
showed reduced response to the vasodilator acetylcholine. Accordingly, we found decreased levels of 
AT2R from a young age, and increased AngII levels and reduced endothelial NO production in lungs 
of aged female PSGL-1
-/-
 mice. Remarkably, the percentage of IFN- , 
which have been associated with endothelial nitric oxide synthase (eNOS) uncoupling 
28
, was 
significantly increased in lung of PSGL-1
-/-
 female mice.  
 
Methods 
Animals  
C57BL/6 PSGL-1
-/-
 mice were kindly provided by Dr. M. K. Wild and Dr. D. Vestweber (Max Planck 
Institute for Molecular Biomedicine, Münster, Germany). Wild-type (WT) C57BL/6 mice were 
obtained from The Jackson Laboratory and were backcrossed with PSGL-1
-/-
 mice. Mice were kept in 
pathogen-free conditions at the Animal Facility of the School of Medicine, Universidad Autónoma de 
Madrid (UAM; Madrid, Spain) and the Animal Facility of the Centro Nacional de Investigaciones 
Cardiovasculares (CNIC; Madrid, Spain). Mice were sacrificed by cervical dislocation, and blood and 
internal organs were extracted for analysis. All experiments and breeding were performed in 
accordance with national and institutional guidelines for animal care (EU Directive 2010/63/EU for 
animal experiments). The experimental procedures were approved by the Director General de Medio 
Ambiente of Madrid (Ref: PROEX 69/14 and PROEX 162/15). 
Immunohistochemistry and vessel wall thickness calculation 
Immunohistochemistry against murine α-SMA was performed in paraffin-embedded lung sections. 
Small blood vessel (diameter <50 µm) wall thickness was calculated by measuring the internal and 
total vessel diameter of anti-α-SMA-stained lungs and calculating the vessel wall area occupied by the 
vessel wall using ImageJ (NIH). Vessels were clustered according to their diameter and the mean wall 
thickness area was calculated. 
Transthoracic Doppler echocardiography and Fulton Index calculation  
All transthoracic echocadiography measurements were obtained with an echocardiography system 
(VEVO 2100, Visualsonics) and a 18-38 Hz ultrasound probe. Chest hair was removed with 
hypoallergenic depilatory cream and animals were kept anesthetized by continuous influx of 2% 
isofluorane with an oxygen flow rate of 1.5 l/min. The B-mode was used for morphometric 
measurement of right ventricle (RV) wall and the pulsed wave Doppler mode was used for measuring 
the pulmonary acceleration time (PAT) and the ejection time (ET) of blood flow in the pulmonary 
artery at the level of the pulmonary valve. The PAT/ET ratio was then calculated and used as an 
indirect evaluation of systolic pulmonary artery blood pressure. The ratio of RV weight to left 
ventricule (LV) weight plus septum (S) (RV/LV + S) was used as an index of RV hypertrophy (Fulton 
Index)
29
. 
Vascular reactivity  
Murine pulmonary arteries were carefully dissected free of surrounding tissue and cut into rings (1.8–2 
mm length). Vessel segments were mounted on a wire myograph in Krebs physiological solution. 
Buffer solutions were continuously bubbled with 21% O2, 5% CO2, and 74% N2 (pO2¼ 17–19 kPa) 
30
, 
and stretched to a transmural pressure equivalent to 30 mmHg. Contractility was recorded by an 
isometric force transducer and a displacement device coupled with a digitalization and data acquisition 
system (PowerLab). To confirm smooth muscle viability, arteries were first stimulated by raising the 
K+ concentration of the buffer to 80 mmol/l and then allowed to recover. After washout, arteries were 
stimulated with serotonin (5-HT, 10
-8–10-5 mol/l; Sigma-Aldrich) in a concentration-response fashion 
performed by cumulative addition. Thereafter, concentration-response curves to Ach (10
-9–10-5 mol/l) 
5 
 
and sodium nitroprusside (SNP, 10
-11–10-5 mol/l) were performed by cumulative addition to analyze 
the endothelium-dependent and endothelium-independent vasodilatation, respectively.  
Hypoxia experiments  
Female PSGL-1
-/-
 and WT mice were exposed to chronic hypoxia (mixture of 10% O2 and 90% N2) for 
24 days in an airtight chamber with inflow and outflow valves. Mice were removed from the chamber 
to undergo echocardiography at day 10, 18 and 22. Mice were sacrificed at day 24.  
ELISA  
The left lung was mechanically disrupted in PBS. After four freeze/defreeze cycles to break cell 
membranes, samples were centrifuged at 5000 g for 5 min at 4ºC and supernatants were recovered. 
AngII and ET-1 concentrations were measured with the following specific ELISA kits: AngII ELISA 
kit CSB-E04495m (Cusabio) and endothelin-1 ELISA kit #17165 (IBL). 
Western blotting 
The right lung was frozen, pulverized, and diluted in RIPA buffer (1% Triton X-100, 0.24 M sodium 
deoxycolate, 0.35 M SDS in 1xTBS) with protease and phosphatase inhibitors. Lung lysates were used 
for WB assays. Primary antibodies and their corresponding dilutions are listed in Table 1. 
Bound antibodies were visualized by chemiluminiscence with the Luminata
TM
 Forte Western HRP 
Substrate (Merck KGaA) using an HRP-conjugated goat anti rabbit IgG secondary antibody. Band 
intensity was analyzed with ImageJ and results were normalized to the expression of β-actin or 
vinculin considered as loading controls. 
Flow cytometry 
 Lungs were weighed, minced into ~1 mm
2
 pieces and digested for 1 h with 1 mg/ml collagenase A 
(Sigma), 2.5 mg/ml dispase II (Roche) and 40 µg/ml DNase (Sigma) in RPMI 1640 medium. Cell 
aggregates and undigested pieces of tissue were eliminated using a 70-µm cell strainer (BD Falcon). 
Cells were then washed with 25 ml of PBS, 0.5% BSA, 5 mM EDTA, concentrated in 700 µl, and 
filtered through a 30-µm cell strainer (BD Pharmingen). After incubating with 1:200 Fc Block (BD 
Pharmingen) to saturate surface myeloid Fc receptors, cells were stained with the cocktail of surface 
antibodies (1:100). Then, cells were incubated for 15 min at 4ºC with the antibody cocktail to label 
surface markers. Subsequently, cells were permeabilized with 2 ml of FACS Lysing Solution (BD 
Pharmingen) for 15 min, washed, and stained for 30 min at 4 ºC with a cocktail of antibodies directed 
against intracellular cytokines. Flow cytometric analysis was performed on a FACSCanto II using 
FACS Diva Software (BD Pharmingen).  
Cell gating strategy  
T cells and B cells were gated as CD45.2
+
CD3
+
 and CD45.2
+
CD19
+
, respectively. Alveolar 
macrophages were gated as CD45.2
+
CD11c
+
F4/80
+
, interstitial macrophages were gated as 
CD45.2
+
CD11c
-
F4/80
+
, and dendritic cells were gated as CD45.2
+
CD11c
+
F4/80
-
. The expression of 
IL-10, IL-17 and IFNγ was analyzed in these subsets. Lung endothelial cells were identified as 
CD45.2
-
CD31
+
. E and P-selectin-positive cells were gated into the CD45.2
-
CD31
+
 subpopulation.  
Antibodies 
 CD3e-PE-Cy7 and CD11c-PE-Cy7 (eBioscience); IL-17A-APC-Cy7, CD45.2-BV421, CD45.2-FITC, 
CD31-BV421 and CD31-APC (BD Pharmingen); CD62E-APC, CD62P-PE, F4/80-FITC and IFNγ-
APC (Miltenyi Biotec); IL-10-PerCP/Cy5.5 (BioLegend). 
Intracellular NO evaluation 
 After blocking and surface molecules staining (CD45, CD31, P-selectin and E-selectin), cells were 
washed and incubated with the NO-sensing fluorescent probe diaminorhodamine-4M acetoxymethyl 
ester (DAR-4M AM) (5 µM; Sigma) in PBS for 30 min at 37 ºC. Then, cells were fixed and 
erythrocytes were lysed by a 15-min incubation with Lysing Solution, and samples were analyzed with 
a FACSCanto II cytometer. Cells that were not incubated with the probe were used as negative control 
for fluorescence. Two groups of cells could be distinguished according to the fluorescence levels at 
Em=580 nm.   
Statistics 
6 
 
Statistical significance between two groups was calculated using two-tailed Student’s t test for 
parametric variables and Mann-Whitney’s U test for nonparametric variables. Statistical significance 
between three groups was calculated by one-way ANOVA with Bonferroni post hoc test. Differences 
were considered statistically significant with P < 0.05 (*,#,$) and highly significant at P < 0.01 
(**,##,$$) and P < 0.005 (***,###,$$$). All statistical analyses were performed using SPSS 15.0 
program (IBM). 
 
Results 
PSGL-1
-/-
 mice exhibit remodeling of pulmonary small vessels  
Immunohistochemical staining of lung sections from wild-type (WT) and PSGL-1
-/-
 mice with an 
antibody against α-smooth muscle actin ( ) revealed a thicker medial wall of small vessels in 
PSGL-1
-/-
 lung (Figure 1A). Quantification demonstrated a significant increase of the relative wall area 
in almost all groups of PSGL-1
-/-
 vessels independently of age (Figure 1B), becoming twice as thick in 
PSGL-1
-/-
 animals as in WT, especially in aged animals (Figure 1B). 
PSGL-1
-/-
 mice present altered echocardiographic parameters consistent with PAH 
Given the remodeling observed in the lung small vessels and our previous observation of an elevated 
rate of death in PSGL
-/-
 mice after reaching one year of age 
21
, we used echocardiography and Doppler 
to measure parameters that change to adapt RV to the increasing vascular load in high pulmonary 
pressure, including PAT/ET ratio and RV wall thickness. Follow-up transthoracic Doppler 
echocardiography performed on WT and PSGL-1
-/-
 mice at the age of 14, 18 and 22 months showed an 
increased pulmonary artery pressure detected by a reduction in PAT/ET in 14-month aged female 
PSGL-1
-/-
 mice as compared with WT mice, which was maintained throughout the longitudinal study 
(Figure 2A,B). Interestingly, this was not observed in male PSGL-1
-/-
 mice (Figure 2A,B). Likewise, 
we found remodeling of RV consisted in an increased ventricular wall thickness in aged female PSGL-
1
-/-
 mice that was statistically significant at 14 months. (Figure 2C).  
To determine the age at which the elevation in pulmonary artery pressure takes place, periodical 
echocardiography was performed on WT and PSGL-1
-/-
 female littermates between the ages of 1.5 and 
18 months. Recurrent tendency to reduced PAT/ET ratio was observed in animals from 3 months of 
age (Figure 2D). Because a group of three PSGL-1
-/-
 females died between 15 and 18 months of age, 
we differentiated the dead and survivor groups. The group of PSGL-1
-/-
 mice that died prematurely 
showed increased pulmonary artery pressure detected by a reduced PAT/ET ratio as compared not 
only with WT mice, but also with the surviving group of PSGL-1
-/-
 mice (Figure 2D). Surviving 
PSGL-1
-/- 
mice maintained PAT/ET ratio below that observed in WT mice along their life. At 18 
months, animals were sacrificed and the Fulton index was calculated for each mouse. Surviving 
female PSGL-1
-/-
 mice presented a higher Fulton index than their female WT littermates (Figure 2E).  
Decreased endothelial NO-dependent relaxing response in pulmonary arteries from PSGL-1
-/-
 
female mice  
We next assessed vascular reactivity in pulmonary and mesenteric arterial rings using wire 
myography. When compared with littermates WT females, pulmonary arteries (PA) isolated from 
female PSGL-1
-/-
 mice showed increased vasoconstriction in response to 80 mM KCl (Figure 3A), 
whereas the contractile response to serotonin (5-HT) was similar (Figure 3B). The vasodilating 
response to acetylcholine (Ach) was impaired in PSGL-1
-/-
 aterial rings (Figure 3C); however, the 
addition of an external NO donor (sodium nitroprusside) was sufficient to fully relax both WT and 
PSGL-1
-/-
 arterial rings (Figure 3D). Conversely, vascular reactivity was not different between 
mesenteric arterial rings of PSGL-1
-/-
 and WT littermates (Figure 3E,F), suggesting that the endothelial 
dysfunction is not systemic. 
Reduced pulmonary endothelial NO production in PSGL-1
-/- 
mice  
The percentage of NO-producing lung endothelial cells (ECs) was reduced in aged PSGL-1
-/- 
mice 
(Figure 3G), although this was significant only among the highest NO-producing EC subset (Figure 
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3H). Additionally, the mean fluorescence intensity (MFI) for the NO-sensing probe 
diaminorhodamine-4M acetoxymethyl ester (DAR-4M AM) was lower in lung EC of PSGL-1
-/-
 than 
of WT mice (Figure 3I). These changes were not observed in 3-month-old mice. 
Unaltered eNOS expression in the lung of PSGL
-/-
 mice 
Given the reduced NO production by PSGL-1
-/-
 lung endothelial cells, eNOS protein expression was 
measured in lung lysates and no differences were found between WT and PSGL-1
-/-
 females (Figure 
3J). 
Impaired adaptation of PSGL-1
-/-
 females to chronic hypoxia 
 Exposure to chronic hypoxia (10% O2) killed 40% (2 out of 5 animals) of PSLG-1
-/-
 mice during the 
first week, and surviving animals showed decreased TPV/ET ratio as compared with WT littermates 
(Figure 4A). The Fulton index at day 24 was similar between WT and PSGL-1
-/-
 mice (Figure 4B). 
PSGL-1
-/-
 lung arteries showed a trend toward a greater vasoconstriction response to 5-HT than those 
of WT animals, but differences did not reach statistical significance (Figure 4C). The relaxing 
response to Ach was lower in PA from WT mice exposed to hypoxia (Figure 4D) than from WT mice 
in normoxia (Figure 3C). Thus, after hypoxic exposure, the relaxation induced by Ach was similar 
between WT and PSGL-1
-/-
 arteries (Figure 4D). Likewise, the relaxation in the presence of an external 
NO donor was similar in WT and PSGL-1
-/-
 lung arteries (Figure 4E). 
Reduced endothelin-1 concentration in the lung of aged PSGL-1
-/-
 mice 
 As endothelin (ET-1) is a key mediator involved in PH, we measured its level in lung tissue of young 
PSGL-1
-/-
 and WT female mice and found no differences; however, it was reduced in aged male and 
female PSGL-1
-/-
 mice (Figure 5A). No significant differences were found for endothelin-1 receptor A 
(ENDRA) and B (ENDRB) protein expression between WT and PSGL-1
-/-
 females (Figure 5B).  
Aged PSGL-1
-/-
 female mice present increased pulmonary levels of AngII and reduced 
expression of AT2R 
No differences were found in the pulmonary concentration of AngII between young WT and PSGL-1
-/-
 
females; however, AngII was significantly higher in aged PSGL-1
-/-
 female mice (78.02±28.09 pg/g 
lung tissue) than in aged WT mice (48.70±5.13 pg/g lung tissue) (Figure 6A, left and middle panels). 
By contrast, AngII levels in aged males were similar between the two genotypes (Figure 6A, right 
panel).   
Although not statistically significant, the expression of ACE was lower both in young and aged PSGL-
1
-/-
 females than in WT (Figure 6B). Levels of ACE2 level were similar between WT and PSGL-1
-/-
 
females. Regarding AngII receptors, the expression of AT2R was lower in young (WT: 0.227±0.088 
vs KO: 0.089±0.024) and aged PSGL-1
-/- 
females than in WT (WT: 0.337±0.094 vs KO: 0.189±0.072) 
(Figure 6B), whereas no differences were found for the expression of AT1R (Figure 6B). 
Gamma-interferon (IFN-γ) producing T cells, B cells and macrophages are overrepresented in 
the lung of aged PSGL-1
-/-
 female mice 
Analysis of the resident lung immune system in WT and PSGL-1
-/-
 females revealed that the 
percentages of T and B cells producing IFN-γ were already higher (Figure 7A,B) in young PSGL-1-/- 
females than in WT, becoming statistically significant in aged mice. IL-10
+
 T cells were reduced in 
PSGL-1
-/-
 lungs, and IL-17
+
 T and B cell subpopulations were similar between WT and PSGL-1
-/-
 
females (Figure 7A-B). Moreover, the percentage of IFN-γ+ cells in the alveolar macrophage subset 
was higher in young PSGL-1
-/-
 females than in WT (Figure 7C) and a higher percentage of IFN-γ+ 
interstitial macrophages was found in aged PSGL-1
-/-
 females as compared with WT mice (Figure 7D). 
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Discussion 
PAH is a particularly severe, life-threatening complication of some CTDs that leads to RV 
remodeling, right heart failure and premature death
15
. Although great effort has been invested in 
searching for an efficient treatment for PAH, no curative therapy is available. Our work shows that 
female mice deficient for PSGL-1 present reduced expression of pulmonary AT2R and thickened 
small vessel walls. With aging, pulmonary levels of AngII increase in PSGL-1
-/-
 females coinciding 
with increased thickening of pulmonary small vessel walls, greater contractility and reduced capability 
of relaxation of lung arteries, and decreased endothelial NO production, driving RV dysfunction and 
death.  
The increase in relative wall vessel area in lung vasculature has been described as a histological 
marker of PAH in both animal models and patients with PAH 
1, 4, 15
, and is considered as one of the 
first events occurring in the development of PAH 
2, 14
. We did not observe plexiform lesions or intimal 
fibrosis in the lung of PSGL-1
-/- 
mice, although these lesions do not appear in all the rodent models of 
PAH 
31. In general terms, the models that reproduce the plexiform arteropathy are “second hit” models 
such as monocrotaline (MCT) + pneumonectomy in young rats (under 200 g of weight) and Sugen 
5416 + hypoxia in rats and mice; or knock-in genetic models such as IL-6- and S100A4-
overexpressing transgenic mice 
31
.  
The vascular remodeling observed in PSGL-1
-/-
 mice might cause an increase in the lung vascular 
resistance to blood flow, the main consequence of which would be the elevation of the pressure in the 
pulmonary artery. Transthoracic Doppler echocardiography is a non-invasive diagnostic tool for 
patients with suspected PAH, giving information not only on diagnosis but also providing further 
information on the causes or consequences of the PAH 
15, 32
. This method has been validated for 
estimating pulmonary artery pressure (PAP) in patients with PAH and in rat and mouse models of 
PAH 
26, 27, 33
, and is becoming increasingly more relevant in the study of murine models of heart 
diseases 
34
. Using this echocardiography modality, and in accordance with the pulmonary vessel 
remodeling, we found a reduced PAT/ET ratio in the pulmonary artery of PSGL-1
-/-
 female mice. Our 
results from a longitudinal study show a consistently increased pulmonary artery pressure detected by 
a reduced TPV/ET ratio in PSGL-1
-/-
 female mice from 3 months of age consistent with the vessel wall 
thickening, suggesting that PSGL-1
-/-
 mice are susceptible to PAH at young age. 
Chronic hypoxia killed 40% of PSGL-1
-/-
 females during the first days of treatment, suggesting that 
some PSGL-1
-/-
 mice are unable to adapt to reduced O2 pressure. WT and surviving PSGL-1
-/- 
females 
showed an increased pulmonary artery pressure during the first week of hypoxia and both groups were 
able to partially compensate pulmonary artery pressure (increase PAT/ET ratio) during the next two 
weeks of exposure, although the recovery was slower for PSGL-1
-/-
 mice. However, WT and PSGL-1
-/-
 
littermates showed a similar Fulton index and loss of NO-dependent relaxation, indicating that some 
hypoxia changes are not additive to PSGL-1 absence after the 3-week exposure to low oxygen 
pressure. These data suggest that the endothelial dysfunction promoted by hypoxia in WT mice is 
already present in PSGL-1
-/-
 females. Importantly, and according with this hypothesis, we found that 
lung of aged PSGL-1
-/-
 females, in addition to having a lower expression of AT2R, showed increased 
AngII concentration and reduced NO production by ECs, which might explain the higher contractility 
and reduced relaxation capability of lung arteries at this age, ultimately leading to elevated flow 
resistance and hence to increased pulmonary pressure and reduced TPV/ET. 
In this context, pentraxin-3 (PTX3) is a soluble ligand of P-selectin that interferes with P-sel/PSGL-1 
interaction 
35, 36
. The administration of PTX3 to wild-type mice induced endothelial dysfunction and 
increased blood pressure 
36
. Interestingly, PTX3 circulating levels were elevated in patients with 
hypertension 
36
 and SSc 
37
. These data suggest that, after binding to PSGL-1, signals transduced by P-
selectin on endothelial cells may by implicated in the maintenance of the correct endothelial function 
and integrity. 
Molecular systems implicated in the control of the vascular tone, such as ET-1, AngII and NO, have 
been described to be altered in several animal models and in patients with PAH 
4, 9, 15
. Thus, hypoxic 
and MCT-treated rats showed increased AngII and AT1R levels 
13, 38, 39
, and patients with iPAH 
showed higher levels of pulmonary AngII due to increased activity of ACE, as well as increased 
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expression and signaling of AT1R, resulting in augmented vascular smooth muscle cell (VSMC) 
proliferation 
40
. Inhibitors of the RAAS have been proven to have an effect in reducing PAP and other 
PAH signs in some animal models and also in pilot studies with small patient cohorts, underscoring 
the role of RAAS in the pathology of PAH. For example, treatment with losartan (AT1R antagonist) or 
captopril (inhibitor of ACE) was able to reduce mean PAP, RV hypertrophy and lung vascular 
remodeling in rats exposed to hypobaric hypoxia for 14 days 
40, 41
. Furthermore, treatment with 
captopril showed a clear effect in reducing PAP in some studies, whereas in others captopril was 
unable to lower PAP 
9
.  
The increased levels of pulmonary AngII found in aged PSGL-1
-/-
 female mice might be explained by 
either an enhanced activity of ACE, which has been previously reported for patients with PAH and 
animal models 
40, 42
, or an overexpression/overactivity of chymase. Mast cell chymase, expressed 
mainly in kidney and heart tissue, is an enzyme that cleaves both Ang(1-12) and angiotensinogen into 
AngII 
43-45
. It can be released by mast cell degranulation, and might account for the elevated AngII 
levels not only in inflammatory conditions such as atherosclerosis but also in heart failure 
17
. 
Interestingly, the chymase-dependent increase of cardiac AngII is related to aging 
44
 and aged PSGL-1
-
/-
 mice are massively infiltrated by immune cells, as previously reported 
21
. 
NO is a critical regulator of vascular homeostasis, not only by modulating vascular tone, but also by 
controlling VSMC proliferation and migration as well as leukocyte adhesion to endothelium 
15, 46
. We 
found reduced NO production by PSGL-1
-/-
 lung endothelial cells, but similar expression levels of 
eNOS. However, differences in eNOS activity due to changes in the post-translational modifications 
could account for the reduced NO levels of PSGL-1
-/-
 lung endothelial cells 
47
.  Also, it has been 
reported that an increase in AngII could lead to eNOS uncoupling, which results in reduced NO 
production 
28
. In addition, several reports have highlighted the relevant role of inflammation and the 
immune system in endothelial dysfunction 
28, 31, 48
.  In this context, vascular dysfunction in aortic 
endothelial cells can be mediated by inflammatory monocytes and NK cells producing IFN-γ and IL-
12 in an AngII-dependent manner 
28, 48
. A similar mechanism could be operating in the pulmonary 
vasculature of female PSGL-1
-/-
 mice, in which aging increases IFN-γ production in macrophages, B 
cells and T cells, and AngII pulmonary levels that can account for the endothelial dysfunction and 
eNOS uncoupling with the ensuing reduction in the endothelial NO. 
Inflammation has emerged as a pivotal contributor to the development of PAH 
49-51
. Perivascular 
infiltration of mononuclear immune cells has been reported in almost all animal models, especially in 
rodents subjected to chronic hypoxia or MCT administration, and in IL-6 knock-in transgenic mice 
31
. 
Additionally, the upregulation of chemokines (CCL-2, CCL-5, RANTES, fractalkine) and 
proinflammatory cytokines (IL-6, IL-1, IFN-γ) has been described in patients with severe PAH 4, 52-56. 
In the case of CTD-associated PAH, it has been proposed that autoantibodies (anti-U1-RNP and anti-
dsDNA) forming immune complexes could trigger the upregulation of endothelial ligands for 
leukocytes, such as ICAM-1 or E-selectin, initiating or contributing to lung vasculopathology 
57
. 
Interestingly, PSGL-1
-/-
 mice showed increased expression of P-selectin and E-selectin in lung 
endothelial cells. The activation of the lung endothelium has been previously described for PAH 
patients. Plasma levels of soluble (s)P-selectin, sE-selectin, sICAM-1 and sVCAM-1 were reported to 
be higher in patients with PAH than in healthy controls 
51, 54, 58
. In another study, treatment with 
prostacyclin reduced the levels of sP-selectin in a cohort of mainly iPAH patients
59
. Similar results 
have been reported in MCT-induced PAH in rats, which present increased expression of pulmonary 
ICAM-1, VCAM-1 and E-selectin 
49
. Moreover, it has been demonstrated by immunohistochemistry 
that infusion of AngII was able to induce the expression of P-selectin, E-selectin, ICAM-1 and 
VCAM-1 in mesenteric arterioles and venules in rats 
16
.  
In the present study, we highlight the importance of leukocyte-endothelium interactions for the 
maintenance of vascular homeostasis and protection against PAH. Deficieny for leukocytic PSGL-1, 
which interacts with P-selectin and E-selectin on the surface of activated endothelium, induces AngII-
dependent endothelial dysfunction characterized by reduced vasodilation response due to impaired NO 
production. This impairment in endothelial function leads to vascular remodeling, PAH and, 
ultimately, to premature death in mice. Our work contributes to the identification of new pathways and 
10 
 
possible pharmaceutical targets for the treatment of PAH, which is crucial to improve the survival and 
the long-term prognosis of patients with this disease.  
 
Author Contributions 
AU conceived and supervised the study. RG-T and AU designed and interpreted the experiments and 
analyzed data. RG-T performed most of the experiments and wrote the manuscript. JS and MF-F 
performed ELISA and western blotting experiments. LJ J-B performed, analyzed and interpreted 
echocardiography experiments. AC, FP-V, DM-C and BB performed and analyzed the myography and 
cardiac morphometry experiments. EV-R SC, CG and LJ J-B gave clinical advice. CG analyzed and 
interpreted histological samples. SC provided reagents. All the authors contributed to discuss the data 
and revised the manuscript. 
 
Acknowledgments  
We thank the UAM and CNIC animal facilities for animal breeding and care. We are indebted to Ana 
Vanesa Alonso and Lorena Flores of the Vascular Imaging Unit at CNIC for the echocardiography 
performance. We also thank the Cytometry Unit and Statistical and Methodological Support Unit of 
the Hospital de la Princesa for technical support.  We thank Dr. Kenneth McCreath for manuscript 
editing and Juan M. Serrador for generously supplying the anti-eNOS antibody.  
 
Sources of Funding 
This work was supported by Spanish Ministry of Health and ISCIII (cofinanced by Fondos FEDER) 
(FIS-PI14-01698, FIS-PI12-01578, Proyecto Coordinado de Excelencia PIE13-00041) and the Spanish 
Ministry of Economy and Competitiveness (predoctoral FPI grant to D.M-C.; research grants 
SAF2011-28150 to F.P.V. and SAF 2014-55399 and SAF2016-77222-R to F.P.V. and A.C.). Rafael 
González-Tajuelo was supported by the Proyecto Coordinado de Excelencia PIE13/00041. 
 
Disclosures 
The authors have declared that non conflict of interest exists 
 
 
REFERENCES 
1. Farber H, Loscalzo J. Pulmonary Arterial Hypertension. N Engl J Med. 2004;351:1655-1665. 
2. Leopold JA, Maron BA. Molecular Mechanisms of Pulmonary Vascular Remodeling in 
Pulmonary Arterial Hypertension. Int J Mol Sci. 2016;17(761). 
3. Vonk Noordegraaf A, Westerhof B, Westerhof N. The Relationship Between the Right 
Ventricle and its Load in Pulmonary Hypertension. J Am Coll Cardiol. 2017;69(2):236-243. 
4. Montani D, Günther S, Dorfmüller P, Perros F, Girerd B, Garcia G, Jaïs X, Savale L, Artaud-
Macari E, Price LC, Humbert M, Simonneau G, Sitbon O. Pulmonary arterial hypertension. 
Orphanet Journal of Rare Diseases. 2013;8(97). 
5. Derrett-Smith EC, Dooley A, Gilbane AJ, Trinder SL, Khan K, Baliga R, Holmes AM, Hobbs 
AJ, Abraham D, Denton CP. Endothelial Injury in a Transforming Growth Factor β–
Dependent Mouse Model of Scleroderma Induces Pulmonary Arterial Hypertension. Arthritis 
Rheumatol. 2013;65(11):2928–2939. 
6. Rhee RL, Gabler NB, Praestgaard A, Merkel PA, Kawut SM. Adverse Events in Connective 
Tissue Disease–Associated Pulmonary Arterial Hypertension. Arthritis Rheumatol. 
2015;67(9):2457–2465. 
11 
 
7. Zuckerbraun BS, George P, Gladwin MT. Nitrite in pulmonary arterial hypertension: 
therapeutic avenues in the setting of dysregulated arginine/nitric oxide synthase signalling. 
Cardiovascular Research. 2011;89:542–552. 
8. Gaddam RR, Chambers S, Bhatia M. ACE and ACE2 in Inflammation: A Tale of Two 
Enzymes. Inflammation & Allergy - Drug Targets. 2014;13:224-234. 
9. Maron BA, Leopold JA. The role of the renin-angiotensin-aldosterone system in the 
pathobiology of pulmonary arterial hypertension Pulm Circ. 2014;4(2):200-210. 
10. Liu S-S, Wang H-Y, Tang J-M, Zhou X-M. Hypoxia-Induced Collagen Synthesis of Human 
Lung Fibroblasts by Activating the Angiotensin System. Int J Mol Sci. 2013;14:24029-24045. 
11. Santos RA, Ferreira AJ, Simoes E. Recent advances in the angiotensin-converting enzyme 2-
angiotensin(1-7)-Mas axis. Exp Physiol. 2008;93(5):519-527. 
12. Bruce E, Shenoy V, Rathinasabapathy A, Espejo A, Horowitz A, Oswalt A, Francis J, Nair A, 
Unger T, Raizada MK, Steckelings UM, Sumners C, Katovich MJ. Selective activation of 
angiotensin AT2 receptors attenuates progression of pulmonary hypertension and inhibits 
cardiopulmonary fibrosis. British Journal of Pharmacology 2015;172:2219–2231. 
13. Yuan Y-M, Luo L, Guo Z, Yang M, Ye R-S, Luo C. Activation of renin–angiotensin–
aldosterone system (RAAS) in the lung of smoking-induced pulmonary arterial hypertension 
(PAH) rats. Journal of the Renin-Angiotensin-Aldosterone System. 2015;16(2):249-253. 
14. Maron BA, Loscalzo J. Pulmonary Hypertension: Pathophysiology and Signaling Pathways. 
In: Marc Humbert, Evgenov OV, Stasch J-P, eds. Pharmacotherapy of Pulmonary 
Hypertension. Heidelberg: Springer; 2013. 
15. Rabinovitch M. Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest. 
2012;122(12):4306-4313. 
16. Álvarez Á, Cerdá-Nicolás M, Nabah YNA, Mata M, Issekutz AC, Panés J, Lobb RR, Sanz M-
J. Direct evidence of leukocyte adhesion in arterioles by angiotensin II. Blood. 2004;104:402-
407. 
17. Company C, Piqueras L, Nabah YNA, Escudero P, Blanes JI, Jose PJ, Morcillo EJ, Sanz M-J. 
Contributions of ACE and mast cell chymase to endogenous angiotensin II generation and 
leucocyte recruitment in vivo. Cardiovascular Research. 2011;92:48-56. 
18. Zarbock A, Ley K, McEver RP, Hidalgo A. Leukocyte ligands for endothelial selectins: 
specialized glycoconjugates that mediate rolling and signaling under flow. Blood. 
2011;118:6743-6751. 
19. Urzainqui A, Serrador JM, Viedma F, Yáñez-Mó M, Rodríguez A, Corbí AL, Alonso-Lebrero 
JL, Luque A, Deckert M, Vázquez J, Sánchez-Madrid F. ITAM-Based Interaction of ERM 
Proteins with Syk Mediates Signaling by the Leukocyte Adhesion Receptor PSGL-1. 
Immunity. 2002;17:401–412. 
20. Urzainqui A, Hoyo GMd, Lamana A, Fuente Hdl, Barreiro O, Olazabal I, Martin P, Wild M, 
Vestweber D, González-Amaro R, Sánchez-Madrid F. Functional role of P-selectin 
glycoprotein ligand 1/P-selectin interaction in the generation of tolerogenic dendritic cells. J 
Immunol. 2007;179(11):7457-7465. 
21. Pérez-Frías A, González-Tajuelo R, Núñez-Andrade N, Tejedor R, García-Blanco M, Vicente-
Rabaneda E, Castañeda S, Gamallo C, Silván J, Esteban-Villafruela A, Cubero-Rueda L, 
García-García C, Muñoz-Calleja C, García-Diez A, Urzainqui A. Development of an 
autoimmune syndrome affecting the skin and internal organs in P-selectin glycoprotein ligand 
1 leukocyte receptor-deficient mice. Arthritis Rheumatol. 2014;66(11):3178-3189. 
22. Nuñez-Andrade N, Lamana A, Sancho D, Gisbert J, Gonzalez-Amaro R, Sanchez-Madrid F, 
Urzainqui A. P-selectin glycoprotein ligand-1 modulates immune inflammatory responses in 
the enteric lamina propria. J Pathol. 2011;224(2):212-221. 
23. He X, Schoeb TR, Panoskaltsis-Mortari A, Zinn KR, Kesterson RA, Zhang J, Samuel S, Hicks 
MJ, Hickey MJ, Bullard DC. Deficiency of P-Selectin or P-Selectin Glycoprotein Ligand-1 
Leads to Accelerated Development of Glomerulonephritis and Increased Expression of CC 
Chemokine Ligand 2 in Lupus-Prone Mice. J Immunol. 2006;177:8748-8756. 
24. Rivera-Nieves J, Burcin T, Olson T, Morris M, McDuffie M, Cominelli F, Ley K. Critical role 
of endothelial P-selectin glycoprotein ligand 1 in chronic murine ileitis. J Exp Med. 
2006;203(4):907-917. 
25. Angiari S, Rossi B, Piccio L, Zinselmeyer BH, Budui S, Zenaro E, Bianca VD, Bach SD, 
Scarpini E, Bolomini-Vittori M, Piacentino G, Dusi S, Laudanna C, Cross AH, Miller MJ, 
12 
 
Constantin G. Regulatory T Cells Suppress the Late Phase of the Immune Response in Lymph 
Nodes through P-Selectin Glycoprotein Ligand-1. J Immunol. 2013;191:5489–5500. 
26. Thibault H, Kurtz B, Raher M, Shaik R, Waxman A, Derumeaux G, Halpern E, Bloch K, 
Scherrer-Crosbie M. Noninvasive assessment of murine pulmonary arterial pressure: 
validation and application to models of pulmonary hypertension. Circ Cardiovasc Imaging. 
2010 3(2):157-163. 
27. Urboniene D, Haber I, Fang Y, Thenappan T, Archer S. Validation of high-resolution 
echocardiography and magnetic resonance imaging vs. high-fidelity catheterization in 
experimental pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2010;299:401-
412. 
28. Kossmann S, Hu H, Steven S, Schönfelder T, Fraccarollo D, Mikhed Y, Brähler M, Knorr M, 
Brandt M, Karbach SH, Becker C, Oelze M, Bauersachs J, Widder J, Münzel T, Daiber A, 
Wenzel P. Inflammatory Monocytes Determine Endothelial Nitric-oxide Synthase Uncoupling 
and Nitro-oxidative Stress Induced by Angiotensin II. J Biol Chem. 2014;289(40):27540–
27550. 
29. Morales-Cano D, Menendez C, Moreno E, Moral-Sanz J, Barreira B, Galindo P, Pandolfi R, 
Jimenez R, Moreno L, Cogolludo A, Duarte J, Perez-Vizcaino F. The Flavonoid Quercetin 
Reverses Pulmonary Hypertension in Rats. PLoS ONE. 2014;9(12). 
30. Cogolludo A, Frazziano G, Briones A, Cobeño L, Moreno L, Lodi F, Salaices M, Tamargo J, 
Perez-Vizcaino F. The dietary flavonoid quercetin activates BKCa currents in coronary 
arteries via production of H2O2. Role in vasodilatation. Cardiovasc Res. 2007 73(2):424-431. 
31. Stenmark K, Meyrick B, Galie N, Mooi WJ, McMurtry IF. Animal models of pulmonary 
arterial hypertension: the hope for etiological discovery and pharmacological cure. Am J 
Physiol Lung Cell Mol Physiol. 2009;297:L1013-L1032. 
32. Bleeker GB, Steendijk P, Holman ER, Yu C-M, Breithardt OA, Kaandorp TAM, Schalij MJ, 
Wall EEvd, Nihoyannopoulos P, Bax JJ. Assessing right ventricular function: the role of 
echocardiography and complementary technologies. Heart. 2006;92:i19-i26. 
33. Brittain E, Penner NL, West J, Hemnes A. Echocardiographic Assessment of the Right Heart 
in Mice. J Vis Exp. 2013;81:e50912. 
34. Chen G, Li Y, Tian J, Zhang L, Jean-Charles P, Gobara N, Nan C, Jin J, Huang XP. 
Application of Echocardiography on TransgenicMice with Cardiomyopathies. Biochemistry 
Research International. 2012. 
35. Deban L, Russo R, Sironi M, Moalli F, Scanziani M, Zambelli V, Cuccovillo I, Bastone A, 
Gobbi M, Valentino S, Doni A, Garlanda C, Danese S, Salvatori G, Sassano M, Evangelista 
V, Rossi B, Zenaro E, Constantin G, Laudanna C, Bottazzi B, Mantovani A. Regulation of 
leukocyte recruitment by the long pentraxin PTX3. Nat Immunol. 2010;11(4):328-334. 
36. Carrizzo A, Lenzi P, Procaccini C, Damato A, Biagioni F, Ambrosio M, Amodio G, 
Remondelli P, Giudice CD, Izzo R, Malovini A, Formisano L, Gigantino V, Madonna M, 
Puca AA, Trimarco B, Matarese G, Fornai F, Vecchione C. Pentraxin 3 Induces Vascular 
Endothelial Dysfunction Through a P-selectin/Matrix Metalloproteinase-1 Pathway. 
Circulation. 2015;131:1495-1505. 
37. Ílgen U, Yayla M, Düzgün N. Low serum fibroblast growth factor 2 levels not accompanied 
by increased serum pentraxin 3 levels in patients with systemic sclerosis. Clin Rheumatol. 
2017;36(2):367-372. 
38. Becker MO, Kill A, Kutsche M, Guenther J, Rose A, Tabeling C, Witzenrath M, Kühl AA, 
Heidecke H, Ghofrani HA, Tiede H, Schermuly RT, Nickel N, Hoeper MM, Lukitsch I, 
Gollasch M, Kuebler WM, Bock S, Burmester GR, Dragun D, Riemekasten G. Vascular 
receptor autoantibodies in pulmonary arterial hypertension associated with systemic sclerosis. 
Am J Respir Crit Care Med. 2014;190(7):808-817. 
39. Li G, Liu Y, Zhu Y, Liu A, Xu Y, Li X, Li Z, Su J, Sun L. ACE2 Activation Confers 
Endothelial Protection and Attenuates Neointimal Lesions in Prevention of Severe Pulmonary 
Arterial Hypertension in Rats. Lung. 2013;191:327-336. 
40. Man FSd, Tu L, Handoko ML, Rain S, Ruiter G, François C, Schalij I, Dorfmüller P, 
Simonneau G, Fadel E, Perros F, Boonstra A, Postmus PE, Velden Jvd, Vonk-Noordegraaf A, 
Humbert M, Eddahibi S, Guignabert C. Dysregulated Renin–Angiotensin–Aldosterone 
System Contributes to Pulmonary Arterial Hypertension. Am J Respir Crit Care Med. 
2012;186(8):780–789. 
13 
 
41. Morrell N, Morris K, Stenmark K. Role of angiotensin-converting enzyme and angiotensin II 
in development of hypoxic pulmonary hypertension. Am J Physiol 1995;269(4):1186-1894. 
42. Shenoy V, Qi Y, Katovich MJ, Raizada MK. ACE2, a Promising Therapeutic Target for 
Pulmonary Hypertension. Curr Opin Pharmacol. 2011;11(2):150–155. 
43. Ahmad S, Varagic J, VonCannon JL, Groban L, Collawn JF, Dell'Italia LJ, Ferrario CM. 
Primacy of cardiac chymase over angiotensin converting enzyme as an angiotensin-(1-12) 
metabolizing enzyme. Biochem Biophys Res Commun. 2016;478(2):559–564. 
44. Froogh G, Pinto JT, Le Y, Kandhi S, Aleligne Y, Huang A, Sun D. Chymase-dependent 
production of angiotensin II: an old enzyme in old hearts. Am J Physiol Heart Circ Physiol. 
2016. 
45. Jessup JA, Trask AJ, Chappell MC, Nagata S, Kato J, Kitamura K, Ferrario CM. Localization 
of the novel angiotensin peptide, angiotensin-(1-12), in heart and kidney of hypertensive and 
normotensive rats Am J Physiol Heart Circ Physiol. 2008;294(6):H2614–H2618. 
46. Martinelli R, Gegg M, Longbottom R, Adamson P, Turowski P, Greenwood J. ICAM-1–
mediated Endothelial Nitric Oxide Synthase Activation via Calcium and AMP-activated 
Protein Kinase Is Required for Transendothelial Lymphocyte Migration Mol Biol Cell. 2009 
20(3):995–1005. 
47. Siragusa M, Fleming I. The eNOS signalosome and its link to endothelial dysfunction. Eur J 
Physiol. 2016;468:1125–1137. 
48. Kossmann S, Schwenk M, Hausding M, Karbach SH, Schmidgen MI, Brandt M, Knorr M, Hu 
H, Kröller-Schön S, Schönfelder T, Grabbe S, Oelze M, Daiber A, Münzel T, Becker C, 
Wenzel P. Angiotensin II–Induced Vascular Dysfunction Depends on Interferon-γ–Driven 
Immune Cell Recruitment and Mutual Activation of Monocytes and NK-Cells. Arterioscler 
Thromb Vasc Biol. 2013;33:1313-1319. 
49. Zhao H, Xue Y, Guoa Y, Sun Y, Liu D, Wang X. Inhibition of endocan attenuates 
monocrotaline-induced connective tissue disease related pulmonary arterial hypertension. 
International Immunopharmacology. 2017;42: 115–121. 
50. Steiner MK, Syrkina OL, Kolliputi N, Mark EJ, Hales CA, Waxman AB. Interleukin-6 
Overexpression Induces Pulmonary Hypertension. Circ Res. 2009;104:236-244. 
51. Dorfmüller P, Perros F, Balabanian K, Humbert M. Inflammation in pulmonary arterial 
hypertension. Eur Respir J. 2003;22:358–363. 
52. Savai R, Pullamsetti SS, Kolbe J, Bieniek E, Voswinckel R, Fink L, Scheed A, Ritter C, Dahal 
BK, Vater A, Klussmann S, Ghofrani HA, Weissmann N, Klepetko W, Banat GA, Seeger W, 
Grimminger F, Schermuly RT. Immune and Inflammatory Cell Involvement in the Pathology 
of Idiopathic Pulmonary Arterial Hypertension. Am J Respir Crit Care Med. 2012;186(9):897-
908. 
53. Humbert M, Monti G, Brenot F, Sitbon O, Portier A, Grangeot-Keros L, Duroux P, Galanaud 
P, Simonneau G, Emilie D. Increased interleukin-1 and interleukin-6 serum concentrations in 
severe primary pulmonary hypertension. Am J Respir Crit Care Med. 1995;151:1628–1631. 
54. Balabanian K, Foussat A, Dorfmüller P, Durand-Gasselin I, Capel F, Bouchet-Delbos L, 
Portier A, Marfaing-Koka A, Krzysiek R, Rimaniol A, Simonneau G, Emilie D, Humbert M. 
CX(3)C chemokine fractalkine in pulmonary arterial hypertension. Am J Respir Crit Care 
Med. 2002;165:1419–1425. 
55. Dorfmüller P, Zarka V, Durand-Gasselin I, Monti G, Balabanian K, Garcia G, Capron F, 
Coulomb-Lherminé A, Marfaing-Koka A, Simonneau G, Emilie D, Humbert M. Chemokine 
RANTES in severe pulmonary arterial hypertension. Am J Respir Crit Care Med. 
2002;165:534–539. 
56. Sanchez O, Marcos E, Perros F, Fadel E, Tu L, Humbert M, Dartevelle P, Simonneau G, 
Adnot S, Eddahibi S. Role of endothelium-derived cc chemokine ligand 2 in idiopathic 
pulmonary arterial hypertension. Am J Respir Crit Care Med. 2007;176:1041–1047. 
57. Okawa-Takatsuji M, Aotsuka S, Fujinami M, Uwatoko S, Kinoshita M, Sumiya M. Up-
regulation of intercellular adhesion molecule-1 (ICAM-1), endothelial leucocyte adhesion 
molecule-1 (ELAM-1) and class II MHC molecules on pulmonary artery endothelial cells by 
antibodies against U1-ribonucleoprotein. Clin Exp Immunol. 1999;116(1):174-180. 
58. Iannone F, Riccardi MT, Guiducci S, Bizzoca R, Cinelli M, Matucci-Cerinic M, Lapadula G. 
Bosentan regulates the expression of adhesion molecules on circulating T cells and serum 
14 
 
soluble adhesion molecules in systemic sclerosis-associated pulmonary arterial hypertension. 
Ann Rheum Dis. 2008;67:1121-1126. 
59. Sakamaki F, Kyotani S, Nagaya N, Sato N, Oya H, Satoh T, Nakanishi N. Increased plasma P-
selectin and decreased thrombomodulin in pulmonary arterial hypertension were improved by 
continuous prostacyclin therapy. Circulation. 2000;102(22):2720–2725. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
15 
 
TABLES 
Table 1 
Antibody Origin Dilution Reference Manufacturer 
Anti-ACE Rabbit 1/1000 LS-C291661/61036 LifeSpan BioSciences 
Anti-ACE2 Rabbit 1/1000 NBP1-76614 Novus Biologicals 
Anti-AT1R Rabbit 1/1000 NBP1-77078 Novus Biologicals 
Anti-AT2R Rabbit 1/1000 NBP1-77368 Novus Biologicals 
Anti-ETA Rabbit 1/1000 NBP1-87467 Novus Biologicals 
Anti-ETB Rabbit 1/1000 NBP2-16334 Novus Biologicals 
Anti-β-actin Rabbit 1/5000 V4505-100UL Sigma Aldrich 
Anti-Vinculin Rabbit 1/2000 A5316-100UL Sigma Aldrich 
Anti-eNOS Mouse 1/1000 610297 BD Pharmingen 
Table 1. Antibodies used for immunoblotting 
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FIGURES 
 
Fig.1 
 
Figure 1. Vascular remodeling in pulmonary small vessels of PSGL-1
-/- 
mice. (A) Representative 
microphotographs of anti-αSMA-immunostained lung sections of 1.5, 12 and >20-month-old mice (n 
= 5– (B) Percentage of vessel wall area in <50 µm-diameter 
pulmonary blood vessels at 1.5, 12 and >20 months of age (>150 vessels analyzed for each group of 
age). Data are expressed as the mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.005, by 2-tailed Student’s 
t test. 
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Fig.2 
 
 Figure 2. RV echocardiographic parameters of PAH in PSGL-1
-/- 
mice. (A) Upper panel: B-Mode 
showing the echocardiographic plane used for Doppler pulmonary flow acquisition. PV=pulmonary 
valve; PA=pulmonary artery; AA=ascending aorta. Lower panels: representative Doppler pulmonary 
artery flow of female WT and PSGL-1
-/-
 mice. (B and C) Longitudinal study of PAT/ET (B) and RV 
wall thickness (C) in male and female WT and PSGL-1
-/-
 mice at 14, 18 and 22 months of age (n = 5 
mice per group). (D and E) Longitudinal study of PAT/ET (D) and body weight (E) between 1.5 and 
18 months of age in WT mice (n = 4), surviving PSGL-1
-/-
 mice (n = 6) and PSGL-1
-/-
 mice dying 
prematurely (n = 3). (F) Fulton index (RV/LV+S) measured in WT and surviving PSGL-1
-/-
 mice. 
Data are expressed as the mean ± SD. * WT vs surviving PSGL-1
-/-
; # WT vs dead PSGL-1
-/-
; $ 
surviving PSGL-1
-/-
 vs dead PSGL-1
-/-
 mice, by one-way ANOVA with Bonferroni post hoc test. 
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Fig.3 
 
 
Figure 3. Vascular response to vasoconstrictor and vasodilator agents and quantification of NO 
production by lung endothelial cells. (A and B) Contractile response to KCl (A) and serotonin (B) in 
pulmonary arterial rings obtained from 18-month-old female WT and PSGL-1
-/-
 mice. A.E.P: Active 
Effective Pressure. (C and D) Vasodilating response to acetylcholine (C) and sodium nitroprusside (D) 
in pulmonary arterial rings obtained from 18-month-old female WT and PSGL-1
-/-
 mice. (E and F) 
Vascular response of mesenteric arterial rings to KCl (E) and acetylcholine (F) obtained from 18-
month-old female WT and PSGL-1
-/-
 mice. (G and H) Percentage of lung endothelial cells producing 
moderate (G) or high (H) amounts of NO measured in 3 and >18-month-old female WT and PSGL-1
-/-
 
mice. (I) Fold change of medium fluorescence intensity (M.F.I.) for the NO-sensing probe DAR-4M 
AM measured in lung endothelial cells of 3 and >18-month-old female WT and PSGL-1
-/-
 mice. (J) 
Western blot showing eNOS expression in the lungs of female WT (n = 4) and PSGL-1
-/-
 (n = 4) 
(upper panels) mice and densitometry quantification (lower panel). Vinculin was used as loading 
control.   Data are expressed as the mean ± SD. (A-I) *P < 0.05, **P < 0.01 by 2-tailed Student’s t 
test. (J) Non significant (n.s.) differences were found by Mann-Whitney’s U test. 
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Fig.4 
 
Figure 4. Effects of 24-day exposure to 10% O2 on WT and PSGL-1
-/-
 mice. (A) PAT/ET measures 
from basal to day 22 of hypoxia in female WT (n = 4) and surviving PSGL-1
-/-
 (n = 5) mice. Shown in 
red is the percentage of dead PSGL-1
-/-
 mice before day 10. (B) Fulton index calculated at day 24 for 
WT (n = 4) and surviving PSGL-1
-/-
 (n = 5) mice exposed to hypoxia. (C) Contractile response to 
serotonin of pulmonary arterial rings obtained from female WT (n = 4) and surviving PSGL-1
-/-
 (n = 5) 
mice exposed to hypoxia. (D and E) Vasodilating response to acetylcholine (D) and sodium 
nitroprusside (E) of pulmonary arterial rings obtained from female WT (n = 4) and surviving PSGL-1
-
/-
 (n = 5) mice exposed to hypoxia. Data are expressed as the mean ± SD. *P < 0.05 by 2-tailed 
Student’s t test. 
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Fig.5 
 
Figure 5. Endothelin-1, ENDRA and ENDRB expression in lungs of WT and PSGL-1
-/-
 mice. (A) 
ET-1 concentration in lung lysates of WT (n = 4) and PSGL-1
-/-
 (n = 4) mice. (B) Western blot 
showing ENDRA and ENDRB (left panels) expression in the lungs of female WT (n = 4) and PSGL-1
-
/-
 (n = 4) mice and densitometry quantification (right panels). β-actin and vinculin were used as 
loading controls.  Data are expressed as the mean ± SD. *P < 0.05 by Mann-Whitney’s U test. 
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Fig.6 
 
Figure 6. Angiotensin II pathway analysis in the lung of WT and PSGL-1
-/-
 mice. (A) AngII 
concentration in lung lysates of WT (n = 4) and PSGL-1
-/-
 (n = 4) mice. (B) Immunoblots showing 
ACE, ACE2, AT2R and AT1R (left panels) expression in the lungs of female WT (n = 4) and PSGL-1
-
/-
 (n = 5) mice and densitometric quantification (right panels). β-actin and vinculin were used as 
loading controls.  Data are expressed as the mean ± SD. *P < 0.05 by Mann-Whitney’s U test. n.s. not 
significant.  
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Fig.7 
 
Figure 7. Immune system analysis and expression of endothelial P-selectin and E-selectin in lung 
of WT and PSGL-1
-/-
 mice. (A) Percentage of T lymphocytes producing IL-10, IFN-γ, IL-17 in 3 and 
>18-month-old WT and PSGL-1
-/-
 mice. (B) Percentage of B lymphocytes producing IL-10, IFN-γ, IL-
17 in 3 and >18-month-old WT and PSGL-1
-/-
 mice. (C) Percentage of macrophages and dendritic 
cells producing IFN-γ in 3 and >18-month-old WT and PSGL-1-/- mice. AM: alveolar macrophages; 
DC: dendritic cells; MФ: interstitial macrophages. (D and E) Percentage of endothelial cells 
expressing P-selectin (D) or E-selectin (E). *P < 0.05, **P < 0.01 by 2-tailed Student’s t test. 
 
 
